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An acute bout of moderate-intensity dynamic exercise results in a sustained rise in
skeletal muscle blood flow from that of pre-exercise levels. This postexercise skeletal
muscle hyperemia is mediated by two histamine receptors (subtypes, HI and H2).
Skeletal muscle glucose uptake is also enhanced, in an insulin-independent manner,
following moderate-intensity dynamic exercise. The impact of skeletal muscle
hyperemia on glucose regulation following exercise has yet to be examined. Therefore,
the purpose of this dissertation was to determine if postexercise skeletal muscle
hyperemia plays a substantial role in glucose regulation in humans. In Chapter III I
tested my ability to block local H1- and Hyreceptors located in the vastus lateralis muscle
in humans. The results demonstrate that I was able to successfully block the increase in
local blood flow evoked by compound 48-80 with the combination of the HI-receptor
antagonist pyrilamine and the H2-receptor antagonist cimetidine, administered via
skeletal muscle microdialysis. In Chapter IV I sought to determine the effect of local
vcombined H j - and Hrreceptor blockade, administered via skeletal muscle microdialysis,
on postexercise interstitial glucose concentrations. My findings indicate postexercise
delivery of glucose to the interstitial space of the previously active skeletal muscle is
mediated, in part, by local H1- and H2-receptors. In Chapter V I examined the effect of
oral administration ofH j - and Hrreceptor antagonists on glucose regulation following a
postexercise oral glucose load. The results showed that the glycemic and insulin
responses to postexercise oral glucose load were more sustained with H1- and Hrreceptor
blockade versus control, suggesting a histaminergic effect on postexercise glucose
regulation.
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1CHAPTER I
INTRODUCTION
Statement of the Problem
An acute bout of moderate-intensity dynamic exercise results in a sustained rise in
skeletal muscle blood flow from that of pre-exercise levels (Halliwill, 2001; Pricher et
al., 2004). This skeletal muscle hyperemia is found in both men and women (Senitko et
al., 2002) and in both sedentary and endurance exercise trained individuals (Lockwood et
al., 2005b; McCord et al., 2006; McCord & Halliwill, 2006). Recent evidence suggests
this postexercise skeletal muscle hyperemia is mediated by two (HI and H2) histamine
receptor subtypes (Lockwood et al., 2005b; McCord et al., 2006; McCord & Halliwill,
2006). The function, however, of this histamine-receptor-mediated hyperemia found after
an acute bout of dynamic exercise has yet to be elucidated.
It is well established that skeletal muscle glucose uptake is enhanced, in an
insulin-independent manner, during the first 90 minutes postexercise (Wasserman &
Halseth, 1998; Richter et al., 2001a; Henriksen, 2002). Much research has focused on the
role of glucose transporters, primarily the GLUT4 isoform found in skeletal muscle, on
glucose uptake during and immediately following exercise (Kennedy et al., 1999; Thorell
et al., 1999). However, while the mechanisms surrounding both postexercise skeletal
muscle hyperemia and postexercise glucose regulation have bee? explored, the
2relationship between these factors, as well as the implications of this relationship,
remains poorly understood.
The purpose of the work described in this dissertation was to determine if
postexercise skeletal muscle hyperemia plays a substantial role in glucose regulation in
humans. More specifically, these studies were designed to determine the effect of
combined local and oral Hj- and Hrreceptor blockade on interstitial and blood glucose
concentrations following a bout of dynamic exercise. The studies described in Chapter
III were conducted to test our ability to both measure and block increases in regional
blood flow by local Hj- and H2-receptor blockade administered via skeletal muscle
microdialysis. The study described in Chapter IV was designed to determine the effect of
blocking both local Hj- and H2 receptors in the skeletal muscle on postexercise interstitial
glucose concentrations. Finally, in conducting the experiment described in Chapter V, we
sought to determine the effect of blunting postexercise hyperemia by comparing blood
glucose and plasma insulin concentrations in response to postexercise oral glucose
tolerance tests (OGTT) in combined oral Hj and Hrreceptor blockade versus control
conditions.
Significance
The findings from the work described in this dissertation, via their mechanistic
and clinical relevance, have the potential to make an impact on a variety of populations,
ranging from the apparently healthy to those suffering from cardiovascular and metabolic
disease.
3First of all, this research expands our understanding ofthe relationship between
cardiovascular and metabolic regulation. It provides evidence that postexercise
hyperemia plays a significant role in skeletal muscle glucose delivery and therefore
uncovers a potential mechanism of both glucose uptake and maintenance of systemic
glucose levels following exertion.
Furthermore, the apparent effects of postexercise hyperemia on glucose delivery
may have implications on our understanding of recovery following dynamic exercise.
Elevated blood flow to the previously active muscles may be imperative for timely
postexercise glycogen repletion, as well as for optimal performance during subsequent
bouts of exercise.
Perhaps most importantly, these findings have revealed potential clinical
implications of common medications for those who depend on exercise to regulate their
blood glucose levels. This may be particularly relevant to populations which have
reduced skeletal muscle perfusion, such as the aged, obese individuals and those suffering
from diabetes. For example, it is possible that by increasing glucose delivery,
postexercise hyperemia may be an important mechanism by which to circumvent insulin
resistance in diabetes. Furthermore, these findings have highlighted some potentially
problematic effects on blood glucose regulation of commonly used medications, such as
those that alleviate allergy symptoms via blockade of histamine-l receptors. These effects
may confound exercise as a "treatment" for both the healthy population and those
suffering from various diseases. This research is important, therefore, not only to
4enhance our understanding of glucose regulation, but also because of its potential wide-
ranging clinical implications.
Review of the Literature
Regional changes in vascular conductance following exercise
Following a bout of dynamic exercise, humans experience a sustained drop in
systemic vascular resistance (Kenney & Seals, 1993; Halliwill, 2001; MacDonald, 2002).
Postexercise reductions have been found in calf vascular resistance (Hara & Floras, 1992;
Halliwill et al., 1996a; Halliwill et al., 2000) and forearm vascular resistance in both
healthy individuals (Coats et al., 1989) and those with mild to moderate hypertension
(Cleroux et al., 1992). These findings indicate vasodilation is found in both previously
active and inactive regions following dynamic exercise.
Pricher et al. found that both postexercise splanchnic and renal vascular
conductance was not different from preexercise levels, indicating that these vascular beds
do not contribute significantly to elevated systemic vascular conductance following
exercise (Pricher et al., 2004). Interestingly, in the same investigation they found an
increase in leg vascular conductance from preexercise levels that lasted 100 minutes and
was virtually parallel to the increase in systemic vascular conductance. A companion
study examined the role of cutaneous vascular conductance in changes in systemic
vascular conductance and mean arterial blood pressure following 60 minutes of moderate
exercise (60% ofV02peak) on a cycle ergometer. Despite an elevation in core body
temperature that persisted for 90 minutes postexercise, cutaneous vascular conductance,
as measured in four sites, quickly returned to the level prior to the exercise bout (Wilkins
5et al., 2004b). A recent investigation examining the relationship between regional
cerebral blood flow and mean arterial blood pressure following exercise found reduced
blood flow to some regions of the cerebral cortex (e.g., insular cortex) that could playa
role in postexercise hypotension (Williamson et aI., 2004). Thus, it does not appear that
vasodilation of the cerebral, renal, splanchnic, or cutaneous vasculature contributes to the
rise in systemic vascular conductance following dynamic exercise. Rather, the primary
contributors to increases in postexercise systemic vascular conductance seem to be
elevations in blood flow to previously exercised and non-exercised skeletal muscles
(skeletal muscle hyperemia).
Mechanisms ofincreased systemic vascular conductance postexercise
Previous research indicates that both neural and vascular factors mediate
sustained vasodilation in humans following dynamic exercise (Halliwill et al., 1996a).
Neural factors refer to reduced sympathetic nerve activity to skeletal muscle vascular
beds for given diastolic pressures, whereas the vascular factors refer to reduced
vasoconstrictor responses to given levels of sympathetic outflow and/or the effects of
local vasodilators on the vasculature following exercise (Hara & Floras, 1992; Halliwill
et aI., 1996a).
Role of the arterial baroreflex
The arterial baroreflex maintains tight regulation of arterial blood pressure under
resting conditions. Transient reductions in arterial pressure diminish the transmural
pressure exerted on carotid and aortic baroreceptors which results in decreased afferent
activity to the cardiovascular control center, thereby triggering increases in sympathetic
6outflow which act to raise arterial pressure. At the onset of exercise, central command
mediates an upward resetting of the baroreflex which results in an increase in mean
arterial pressure and redistribution ofblood flow via cardiac parasympathetic withdrawal
and augmented sympathetic outflow.
To assess baroreflex control of sympathetic nervous outflow following exercise,
Halliwill and coworkers infused vasoactive drugs (nitroprusside and phenylephrine)
while measuring muscle sympathetic nervous activity (microneurography) after 60
minutes of dynamic exercise and after 60 minutes of seated rest (sham). They discovered
that across the entire range of diastolic pressures, muscle sympathetic nervous activity
was blunted in the postexercise condition compared to the sham condition, indicating a
downward resetting of the baroreflex following exercise (Halliwill et at., 1996a). These
findings confirmed the presence of altered baroreflex control of sympathetic outflow
following exercise, as suspected by previous investigators who found reductions in
muscle sympathetic nervous activity in borderline hypertensive men following exercise,
accompanied by postexercise hypotension (Floras et at., 1989).
To evaluate postexercise baroreflex control of heart rate, Halliwill and colleagues
employed sequential neck pressure and neck suction before and after 60 minutes of
moderate intensity aerobic exercise. They found that baroreflex heart rate gain was
augmented postexercise, indicating that baroreflex control of heart rate opposes rather
than contributes to reductions in blood pressure following exercise (Halliwill et al.,
1996b). Furthermore, these results suggest postexercise baroreflex resetting probably
occurs at the level of the central nervous system, as opposed to the level of the
7baroreceptors themselves. Combined with the results from the aforementioned
investigations (Floras et aI., 1989; Hara & Floras, 1992; Halliwill et at., 1996a), these
findings suggest that changes in the alierial baroreflex, via reductions in systemic
sympathetic nervous activity, playa role in elevations in systemic vascular conductance
following exercise.
Blunted transduction of sympathetic nervous activity
As previously noted, in addition to a downward resetting of the baroreflex
following exercise, local vascular factors have also been cited as potential contributors to
elevated postexercise systemic vascular conductance. Halliwill et al. examined the
relationship between muscle sympathetic nerve activity and calf vascular resistance in
response to sympatho-excitation induced by isometric handgrip exercise (held to fatigue)
after 60 minutes of dynamic exercise and non-exercise sham (Halliwill et at., 1996a).
They found for a given level of muscle sympathetic nerve activity, calf vascular
resistance was attenuated postexercise compared to post-sham, demonstrating a blunted
transduction of sympathetic nerve activity to vasoconstriction following exercise
(Halliwill et at., 1996a). This blunted transduction of sympathetic outflow into
vasoconstriction may be the result of an inhibition ofpre-synaptic neurotransmitter
release, hypo-responsive post-synaptic alpha receptors, or active vasodilation via
circulating or local factors (Kenney & Seals, 1993; Halliwill, 2001; MacDonald, 2002).
Pre-synaptic inhibition
Sympathetic neurons release norepinephrine which, when bound to a-adrenergic
receptors on vascular smooth muscle of alierioles, leads to vasoconstriction. It is
8possible that the release of norepinephrine from these pre-synaptic neurons may be
blunted following exercise. If so, less vasoconstriction would occur for a given level of
sympathetic outflow, contributing to elevated postexercise vascular conductance.
Previous research indicates that plasma ~-endorphin levels are elevated in humans
following dynamic exercise (Farrell et aI., 1982; Goldfarb et aI., 1987). Animal research
has shown that opioids may inhibit sympathetic transmission (Konishi et aI., 1979) by
acting on the central nervous system (Thoren et aI., 1990), leading to the hypothesis that
opioids playa role in altered postexercise hemodynamics. Hara and Floras administered
the opioid receptor antagonist naloxone or vehicle to normotensives (Hara & Floras,
1992, 1995) and young hypertensives (Hara & Floras, 1995) prior to moderate intensity
treadmill exercise. Interestingly, although naloxone had no effect on muscle sympathetic
nerve activity and postexercise hypotension, it did attenuate the reduction in calf and total
peripheral resistance in normotensives but not in hypertensives (Hara & Floras, 1992,
1995). Thus it seems that although opioid receptor activation is not crucial to reductions
in blood pressure following exercise, it may mediate postexercise vasodilation in healthy
adults via peripheral, as opposed to central mechanisms.
In addition to opioids, there are other substances or receptors that may mediate
pre-synaptic inhibition. It is well established that adenosine can produce vasodilation in a
variety of vascular beds (Nowak et aI., 1987; Edlund et aI., 1990). Furthermore, it
appears adenosine 5' -triphosphate (ATP) and norepinephrine are co-released from
sympathetic nerves (Bumstock & Sneddon, 1985), prior to the prompt conversion of ATP
to adenosine within the synaptic cleft. Research by Rongen and colleagues indicates
9adenosine inhibits the release of norepinephrine from sympathetic nerves during
sympatho-excitation (Rongen et al., 1996). Moreover, recent animal research suggests
this norepinephrine inhibition is mediated by adenosine-2 and adenosine-3 receptors
located on pre-synaptic nerve terminals (Donoso et al., 2006).. Although these studies
present compelling evidence that adenosine is involved in inhibition of norepinephrine
release, it has yet to be determined if this process mediates increased vascular
conductance after exercise.
Since first being discovered in the rat cerebral cortex (Arrang et aI., 1983),
histamine-3 receptors have been found on autonomic nerve tenninals in guinea pigs
(Ishikawa & Sperelakis, 1987) and sympathetic nerve terminals in the human heart
(Imamura et aI., 1995). Moreover, in vitro investigations have shown that histamine-3
receptor activation attenuates norepinephrine exocytosis (Molderings et aI., 1992; Silver
et aI., 2002; Seyedi et aI., 2005), so it is feasible that histamine-3 receptors contribute to
postexercise hyperemia via pre-synaptic inhibition of norepinephrine release. However,
with no histamine-3 receptor antagonist approved for use in humans, it is not currently
possible to test this theory in humans.
Hypo-responsive post-synaptic alpha receptors
Transduction of sympathetic outflow into vasoconstriction could be blunted if
post-synaptic alpha-adrenergic receptors are hypo-responsive to sympathetic stimulation,
so a given degree of norepinephrine binding would result in less vasoconstriction
following exercise. When the aI-adrenergic receptor agonist phenylephrine was infused
locally in rabbits (Howard & DiCarlo, 1992) and rats (Patil et al., 1993; Rao et aI., 2002),
10
it produced substantially less vasoconstriction in the postexercise versus sham condition.
Thus in the animal model it appears that aI-adrenergic receptors are hypo-responsive
following exercise (Howard & DiCarlo, 1992; Patil et al., 1993; Rao et al., 2002) and
nitric oxide appears to mediate part of this postexercise attenuated aI-adrenergic receptor
response (Patil et al., 1993; Rao et a!., 2002).
In a study performed on dogs, Buckwalter and colleagues discovered that even
during mild exercise a2-adrenergic receptor responsiveness was reduced, whereas heavy
exercise was required to reduce the responsiveness of aI-adrenergic receptors
(Buckwalter et al., 2001). Furthermore, Dinenno et al. concluded that a2-adrenergic
receptors contribute more than a I-adrenergic receptors to resting vascular tone in
humans, suggesting differential responsiveness of the two a-receptor sub-types (Dinenno
et al., 2002). The question remained, however, if hypo-responsiveness of either al- or a2-
adrenergic receptors contributed to the postexercise hyperemia in humans. To address
this question, Halliwill et a!. used intraarterial infusions of a I-agonist phenylephrine and··
a2-agonist clonidine before and 30 minutes after moderate cycling exercise. They found
that vasoconstrictor responses following exercise were intact in both the forearm and the
leg, demonstrating that blunted alpha-adrenergic receptor responsiveness does not
contribute to enhanced postexercise vascular conductance (Halliwill et al., 2003).
Possible vasodilators
It is feasible that one or more vasodilator substances - released either systemically ""
or locally - may contribute to postexercise hyperemia. Several substances have been
suspected to contribute to enhanced vascular conductance following exercise, most
11
notably nitric oxide, epinephrine, adenosine, atrial natriuretic peptide, and prostaglandins
(Kenney & Seals, 1993; Halliwill, 2001; MacDonald, 2002). The vasodilator substance
could be a circulating honnone or locally released substance (Kenney & Seals, 1993)
capable of competing with vasoconstrictor substances at the arteriole smooth muscle
(Halliwill, 2001).
Dynamic exercise results in increased blood flow and vascular sheer stress, which
has been shown to facilitate nitric oxide fonnation from vascular endothelial cells (Cooke
et a!., 1991; Miller & Burnett, 1992). Along these lines, Jungersten et a!. measured
elevated plasma nitrate, an index of overall fonnation of nitric oxide, in healthy humans
following dynamic exercise (Jungersten et al., 1997). As previously noted, nitric oxide
has also been implicated as a mediator of reduced vascular responsiveness to adrenergic
receptor stimulation in animal models (Patil et a!', 1993; Rao et a!', 2002). It seems
reasonable, therefore, to predict nitric oxide plays a role in postexercise hyperemia in
humans. However, systemic nitric oxide synthase inhibition failed to abolish
postexercise peripheral vasodilation in healthy humans, which suggests that postexercise
hyperemia is not dependent upon enhanced nitric oxide production (Halliwill et a!',
2000).
Epinephrine released during exercise binds to pz-adrenergic receptors on
arterioles, resulting in moderate vasodilation. In a study conducted on men with primary
hypertension, Wilcox and colleagues found postexercise hypotension after p-adrenergic
receptor antagonism with epanolo1 and atenolol (Wilcox et al., 1987). Although
postexercise foreann blood flow was only reported during distal body sub-atmospheric
12
pressure, this postexercise hypotension, combined with the fact that plasma epinephrine
quickly returns to pre-exercise levels in hypertensives (Wilcox et al., 1987; MacDonald
et al., 2002) and normotensive men and women (Perrault et al., 1989; Horton et a!.,
2006), argues against epinephrine and/or ~2-adrenergic receptor-mediated vasodilation
following exercise.
Evidence suggests adenosine inhibits pre-synaptic release of norepinephrine (see
Pre-synaptic inhibition, above), but it is possible it also contributes to postexercise
hyperemia via postsynaptic inhibition of a-adrenergic mediated vasoconstriction. When
compared with equipotent doses of the vasodilator sodium nitroprusside, brachial arterial
infusions of adenosine attenuated the increase in forearm vascular resistance induced by
local infusions of both norepinephrine and tyramine, which stimulates endogenous
release of norepinephrine (Smits et a!., 1991b). Similar attenuation of vasoconstrictor
responsiveness to lower body negative pressure (Smits et a!., 1991b) and cold pressor test
(Smits et a!., 1991a) was found with adenosine versus sodium nitroprusside infusions,
despite similar levels of forearm production of norepinephrine (Smits et al., 1991 a; Smits
et al., 1991 b). These results suggest a post-synaptic inhibition of a-adrenergic
vasoconstriction, although whether this is a factor in postexercise hyperemia remains
unknown.
DUling dynamic exercise, enhanced venous return leads to increased atrial filling.
The resulting distention of the atria stimulates the secretion of atrial natriuretic peptide
(Ledsome et a!., 1985; Perrault et a!., 1989), which is known to cause profound
vasodilation (Cody et al., 1986). It appears that atrial natriuretic peptide is not
13
accountable for postexercise hyperemia, however, as reductions in calf vascular
resistance actually correspond with reductions in atIia1 natriuretic peptide concentrations
following exercise in humans (Hara & Floras, 1992, 1995).
The arteriolar sheer stress that accompanies dynamic exercise elicits the release of
prostaglandins, leading to vasodilation (Koller & Kaley, 1990). Cowley and colleagues
measured calf and forearm blood flow before and immediately after treadmill exercise on
control and cyclooxygenase inhibition (aspirin) days. They found aspirin, which inhibits
prostaglandin synthesis, attenuated the increase in forearm and calf blood flow
immediately following exercise (Cowley et ai., 1984; Cowley et ai., 1985). To detelmine
if prostaglandin-dependent vasodilation is responsible for the long lasting reductions in
systemic vascular conductance underlying postexercise hypotension, Lockwood et ai.
measured changes in vascular conductance before and through 90 minutes following an
hour of moderate intensity cycling after cyclooxygenase inhibition via ibuprofen. They
found cyclooxygenase inhibition had no effect on either femoral or systemic vascular
conductance following exercise, which suggests prostaglandin-mediated vasodilation is
not responsible for the extended hyperemia following exercise (Lockwood et ai., 2005a).
Our understanding of the mechanisms underlying postexercise hyperemia was
recently advanced by the discovery that ingestion of the HI-receptor antagonist
fexofenadine hydrochloride attenuates the elevated femoral vascular conductance
following exercise (Lockwood et ai., 2005b). The effects of H I-receptor blockade on
hemodynamics were most pronounced during the first 30 minutes following exercise.
This observation, combined with the previous findings indicating similar vasodi1atory but
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different time-course effects of H1 - and H2-receptors (Black et aI., 1975; Chipman &
Glover, 1976), led to an investigation into the role ofH2 -receptors in postexercise
vasodilation (McCord et al., 2006). H2-receptor antagonist ranitidine blunted the
increases in femoral and brachial vascular conductance following exercise, with the effect
most pronounced from 60 -90 minutes postexercise (McCord et aI., 2006). Subsequently,
when combined H 1- and H2 -receptor antagonists were ingested by both sedentary and
endurance trained individuals, the hyperemia seen through 90 minutes postexercise in the
control condition was reduced by 80% (McCord & Halliwill, 2006). Thus it has become
clear H 1- and H2-receptors playa role in mediating postexercise hyperemia in both
trained and untrained men and women.
The question remains, however, whether histamine is the active vasodilator which
contributes to postexercise hyperemia. Elevated histamine concentrations have been
found in whole blood of humans both during (Campos et al., 1999) and after (Harries et
aI., 1979) dynamic exercise. It has been suggested that stimuli such as vibration and heat
elicit histamine release from mast cells (Atkinson TP, 1992), which implies that exercise
could be a stimulus for elevations in blood histamine concentrations. Furthermore it
appears that sympathetic withdrawal can evoke histamine release (Powell & Brody,
1976) and, as discussed previously, sympathetic withdrawal plays a role in postexercise
hyperemia (Floras et al., 1989; Halliwill et al., 1996a).
Thus, it seems likely that HI- and H2-receptors are bound by histamine to
contribute to postexercise hyperemia. However, recent findings from our lab indicate
interstitial histamine concentrations in the biceps brachii, as determined via muscle
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microdialysis, were unaffected by 60 minutes of moderate intensity cycling (unpublished
observations). It is plausible that histamine release sufficient to cause measurable
increases in the interstitium, may be confined to previously active skeletal muscles.
Another feasible explanation is exercise could increase the sensitivity of the Hj- and H2_
receptors, so a given level of histamine would induce greater vasodilation following
exercise than produced prior to exercise. Along these lines, reductions in pH, which can
accompany moderate to high intensity exercise, have been found to increase the
sensitivity of HI-receptors to histamine (Gannellin & Parsons, 1982). Although the
specific effect of histamine has yet to be elucidated, it is evident that both H j- and H2-
receptors, along with the aforementioned neural and vascular factors, mediate
postexercise hyperemia in humans.
Function o.fpostexercise hyperemia
While strides have been made in understanding the mediators of postexercise
hyperemia, it is unclear what purpose this increased blood flow might serve. Recently,
Williams et at. investigated the relationship between leg blood flow and oxygen uptake
following 60 minutes of moderate-intensity exercise. They found the time course ofleg
blood flow recovery did not match that of oxygen uptake, suggesting the skeletal muscle
hyperemia does not subserve oxygen delivery to the previously exercised muscle
(Williams et at., 2005).
Previous research indicates that, following exercise, elevations in glucose uptake
and glycogen repletion follow a similar time-course as that of skeletal muscle blood flow.
It is plausible postexercise hyperemia functions to enhance glucose delivery and
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subsequent glycogen repletion to previously exercised muscle. The remainder of this
dissertation will address the relationship between elevated blood flow and glucose
regulation following dynamic exercise.
Glucose regulation following exercise
It is well known that during dynamic exercise there is an increase in glucose
uptake from the circulation to the working muscles. While glucose oxidation
predominates during exercise, the glucose taken up following exercise contributes to
glycogen repletion in healthy individuals (Richter et al., 1989; Casey et al., 2000) and
diabetics (Maehlum et al., 1977, 1978).
Glucose uptake
Glucose uptake by skeletal muscle is a complex process, with three general rate-
limiting steps: glucose supply to skeletal muscle cells, glucose transport into skeletal
muscle cells, and subsequent intracellular metabolic flux (Rose & Richter, 2005).
Glucose delivery from the blood to the interstitium is determined by a combination of
skeletal muscle blood flow, blood glucose concentration, and endothelial permeability to
glucose. Transport of glucose into the cells is determined by the presence of a glucose
gradient, as well as by the number and activity of glucose transporters in the sarcolemma.
Finally, intracellular metabolism is determined by substrate flux and concentration of
hexokinase in the skeletal muscle (Wasserman & Halseth, 1998; Rose & Richter, 2005;
Wasserman & Ayala, 2005). Once glucose enters the cell, it is quickly converted by
hexokinase to glucose-6-phosphate, which insures low intracellular free glucose stores,
thereby maintaining a concentration gradient that favors transport of glucose into the cell
17
(Ivy, 1991). Subsequently, glucose-6-phosphate is a substrate for subsequent metabolic
reactions (O'Doherty et al., 1994; Wasserman & Ayala, 2005).
The rate-limiting step in skeletal muscle glucose uptake can vary depending on
the specific conditions, such as subject activity (rest, exercise, postexercise) and
nutritional (fasted vs fed) status. For instance, by studying transgenic mice with
overexpression of either GLUT4 transporters or hexokinase II, investigators have
concluded that glucose transport is the principal barrier to muscle glucose uptake under
basal conditions but phosphorylation of glucose is more of a rate-limiting factor during
physiological hyperinsulemia (Fueger et al., 2005; Wasserman & Ayala, 2005).
Moreover, this model has been used to pinpoint the sites where interventions such as high
fat diet and exercise training alter glucose uptake and metabolism (Kim et al., 2000). An
over-arching theme generated by this line of research is that resistance to muscle glucose
uptake is generally distributed among multiple sites and that this distribution changes in
response to different physiological conditions.
Following exercise, there is a well-documented increase of insulin action on
skeletal muscle glucose uptake (Mikines et af., 1988; Richter et af., 1989). This
enhanced insulin sensitivity has been found to persist up to 48 hours following 60
minutes of moderate-intensity exercise (Mikines et af., 1988). Increased insulin
sensitivity and resulting skeletal muscle glucose uptake following exercise is known to be
mediated, in part, by translocation of GLUT4 glucose transporters to the plasma
membrane (Hansen et al., 1998), although GLUT4 activity is increased during and
directly after exercise, even in the absence of insulin. Studies utilizing muscle biopsies of
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the vastus lateralis have shown increases in skeletal muscle plasma membrane GLUT4
protein following moderate intensity cycling exercise in healthy humans and non-insulin
dependent diabetics (Kennedy et aI., 1999; Thorell et al., 1999). In fact, exercise induces
GLUT4 translocation equivalent to that evoked by euglycemic-hyperinsulinemic clamp
(Thorell et al., 1999). Moreover, the increases in plasma membrane GLUT4 glucose
transporter after exercise are comparable between diabetics and non-diabetics (Kennedy
et aI., 1999), indicating a mechanism of GLUT4 translocation capable of circumventing
insulin resistance.
Glycogen synthesis
Once glucose is transported into skeletal muscle cells after exercise, glycogenesis,
mediated by the enzYme glycogen synthase, insures repletion of glycogen stores.
Glycogen synthase activity is known to be increased following dynamic exercise (Garetto
et aI., 1984; Mikines et aI., 1988), an effect which can be amplified when glycogen stores
are low (Maehlum et al., 1977; Maehlum & Hermansen, 1978; Wojtaszewski et al.,
2001). Thus the rate of glycogen synthesis is typically highest the first 30 minutes
following exercise (Price et al., 1994) and, given adequate glucose availability,
restoration of glycogen stores is usually complete within 24 hours (Bergstrom &
Hultman, 1966; Ivy, 1991; Casey et al., 1995). As illustrated by studies involving
electrical stimulation of the rat hindlimb (Richter et al., 1984) and single-legged exercise
in humans (Bergstrom & Hultman, 1966; Richter et al., 1989), glucose uptake and
glycogen repletion occurs preferentially in the previously exercised skeletal muscle.
Moreover, postexercise glycogen synthesis is augmented by glycogen depletion,
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especially when accompanied by carbohydrate and/or protein ingestion (Fell et at., 1982;
Carrithers et al., 2000; Wojtaszewski et at., 2001).
Maehlum found that insulin-dependent diabetics, despite being deprived of their
insulin, had similar glycogen synthesis rates in the first hour following exercise as their
non-diabetic counterparts (Maehlum, 1978). When postexercise glycogen recovery time
was extended, investigators found glycogen repletion in response to postexercise feeding
to be similar in diabetics with and without insulin during the first four hours after
exercise. However, only in the diabetics receiving insulin did muscle glycogen
concentration continue to rise over the next eight hours, reaching 95% ofpre-exercise
values by 12 hours postexercise (Maehlum et al., 1978). These results suggested
diabetics experienced biphasic glycogen recovery following exercise, with the first phase
being insulin-independent and the latter phase requiring insulin. Researchers confirmed
an early insulin-independent phase of glycogen synthesis in an animal model, finding
enhanced glycogen repletion in rats following hind-limb electrical stimulation (Richter et
al., 1984) and treadmill rmming (Garetto et al., 1984) despite the absence of insulin.
Price and colleagues used an elegant approach to ascertain if the biphasic
postexercise glycogen resynthesis found in rats and insulin-dependent diabetics existed in
healthy humans. They infused somatostatin intravenously to inhibit endogenous insulin
secretion following different degrees of gastrocnemius glycogen depletion induced by toe
raises (Price et at., 1994). Using natural abundance 13C-nuclear magnetic resonance
spectroscopy, they discovered somatostatin infusion had no effect on early intramuscular
glycogen repletion in response to glucose infusion. In contrast, there was a plateau in
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intramuscular glycogen concentration approximately 90 minutes postexercise with
somatostatin infusion, while glycogen levels continued to rise in the control condition
(Price et aI., 1994). These findings confirmed an early insulin-independent phase of
rapid glycogen resynthesis in healthy humans after glycogen-depleting exercise, which is
followed by a prolonged period of glycogen synthesis characterized by increased insulin
sensitivity.
Effect ofenhanced bloodflow on glucose uptake
Impact of exogenous vasodilators
Given the insulin-independent nature of early postexercise glucose uptake and
glycogen resynthesis, as well as their similar time course with postexercise skeletal
muscle hyperemia, it is intuitive to suspect this hyperemia plays a role in enhanced
glucose uptake following exercise. The plausibility of this idea has been bolstered by
numerous studies which have suggested blood flow as a rate-limiting factor in glucose
regulation. For example, early animal research found glucose uptake was enhanced with
increases in isolated rat hindlimb perfusion, even when blood glucose and insulin
concentrations were maintained (Grubb, 1977; Schultz, 1977).·
Turning to the human model, Baron et al. employed hyperinsulinemic euglycemic
clamp and leg glucose balance techniques to examine the effect of enhanced leg
perfusion, evoked by intrafemoral arterial infusions of the endothelium-dependent
vasodilator methacholine hydrochloride, on leg glucose uptake. They discovered both
leg blood flow and leg glucose uptake were substantially greater in the combined insulin
and methacholine trials versus the insulin only trials, indicating skeletal muscle perfusion
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can independently impact insulin-mediated glucose uptake in humans (Baron et aI.,
1994). Subsequently, Durham and coworkers infused the nitric oxide donor sodium
nitroprusside into the femoral arteries of young, healthy subjects while measuring
arteriovenous glucose differences and leg blood flow. They measured profound increases
in leg glucose uptake in response to exogenous nitric oxide-mediated increases in leg
blood flow (Durham et aI., 2003). It is worth noting that this enhanced glucose uptake
was found in the absence of insulin stimulation, indicating either the increased blood flow
itself or some other effect of nitric oxide mediated the increased glucose uptake.
Examinations of interstitial glucose
Investigations utilizing skeletal muscle microdialysis have enabled researchers to
examine glucose regulation from a unique perspective, as the glucose in the interstitium
is at the crossroads of glucose delivery from the blood and glucose transport to the
muscle cells (Wasserman & Ayala, 2005). As such, interstitial glucose concentrations
give a good indication of nutritive blood flow - that is flow through blood vessels
supplying muscle cells so that nutrient exchange may occur (Newman et aI., 2002).
Healthy, young males had muscle microdialysis probes inserted into their vastus lateralis
muscles prior to performing progressive single leg knee extensions. Interstitial glucose
concentrations rose almost 30% upon the initiation of exercise in these subjects,
suggesting a flow-limitation for glucose uptake at rest (MacLean et ai., 1999). In
response to heating and perfusion of a local vasodilator Hickner and coworkers saw a rise
in dialysate glucose levels that was negatively correlated with the ethanol outflow-inflow
ratio, which suggests the increase in local blood flow mediated glucose delivery to the
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interstitial space (Hickner et a!., 1992). Henriksson and Knol inserted muscle
microdialysis probes in each leg of healthy subjects who had just completed two hours of
one-legged cycling (Henriksson & Knol, 2005). They tracked interstitial glucose
concentrations and local leg blood flow in each leg over the next eight hours and
observed interstitial glucose levels in the previously exercised leg to be appreciably
reduced compared to the control leg through five and a half hours postexercise. In
addition, local blood flow, as estimated by ethanol outflow-to-inflow ratio, had stabilized
by this time. Taken together, these results imply that the notable reduction in interstitial
glucose concentrations after prolonged exercise may limit skeletal muscle glucose uptake
when blood flow is no longer elevated.
Role of insulin delivery
In addition to its well established effects on skeletal muscle glucose uptake,
insulin is known to induce significant effects on the vasculature (Laakso et a!., 1990;
Baron, 1994). Along these lines, there is considerable evidence physiological
concentrations of insulin evoke increased limb blood flow in both rats (Rattigan et a!.,
1997) and humans (Laakso et aI., 1990). Work by Steinberg and colleagues suggests
insulin-mediated vasodilation is dependent upon nitric oxide (Steinberg et a!., 1994).
Moreover, they found inhibition of nitric oxide synthase blunted skeletal muscle insulin-
mediated glucose uptake by approximately 25% (Steinberg eta!', 1994).
Investigations using both the rat (Vincent et a!', 2004) and human model (Coggins
et aI., 2001) have shown insulin increases capillary recruitment. It appears the
mechanism behind insulin-mediated capillary recruitment involves insulin signaling to
23
endothelial cells which, in tum, produce nitric oxide to induce vasodilation (Rattigan et
al., 2005). Insulin binds primarily to insulin-like growth factor- I receptors and insulin
receptors in the vascular endothelium to initiate this process (Wang et a!., 2006).
Vincent et al. measured microvascular recruitment in the rat hindlimb using both
metabolism of exogenously infused I-methylxanthine and contrast-enhanced ultrasound.
They found nitric oxide synthase inhibition attenuated microvascular recruitment and
limb glucose uptake, as measured by arterial-venous concentration differences, in
response to insulin infusion (Vincent et a!., 2003). It makes sense that capillary
recruitment would enhance muscle glucose uptake, as it functions to both increase the
surface area and decrease the distance for diffusion to the skeletal muscle cells. Thus, as
previously suggested, it seems insulin is not only a mediator of its own delivery (Vincent
et al., 2005), but it appears both insulin-mediated vasodilation and capillary recruitment
are key regulators of muscle glucose uptake. Moreover, as indicated by research
conducted on lean versus obese Zucker rats, attenuations in insulin-mediated limb blood
flow and capillary recruitment are components of insulin resistance (Wallis et al., 2002),
but may be circumvented via skeletal muscle contractions (Wheatley et a!., 2004).
In order for insulin to aid in glucose delivery, it must move from the central
circulation to the skeletal muscle microvasculature and subsequently to the interstitium;
therefore anything that can facilitate insulin transport to the interstitium is likely to
expedite muscle glucose uptake. Insulin concentrations within the skeletal muscle
interstitial space have typically been found tobe approximately 50% of that in the
plasma, so there is a large gradient for diffusion into the interstitium (Vincent et al.,
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2005). Plasma insulin concentrations can change quickly, whereas interstitial insulin
concentrations change rather slowly (Miles et al., 1995). Moreover, skeletal muscle
glucose uptake tracks the timeframe of interstitial insulin levels better than plasma insulin
levels, which suggests insulin delivery to the interstitium is crucial in timely muscle
glucose uptake (Miles et al., 1995; Vincent et aI., 2005). This notion is supported by a
recent study by Chiu and coworkers who found intramuscular injection of insulin resulted
in an immediate rise in hindlimb glucose uptake in dogs (Chiu et al., 200~)
Evidence suggests insulin-mediated capillary recruitment occurs quickly, while
insulin-mediated increases in limb blood flow are slower, and delayed relative to muscle
glucose uptake (Vincent et aI., 2004). Along these lines, research on dogs indicates
approximately 30% of capillaries are perfused at rest (Honig et al., 1982), which implies
a flow limitation to skeletal muscle insulin and/or glucose delivery under resting
conditions (Vincent et al., 2005), as opposed to conditions in which capillary recruitment
is increased, such as exercise. It has been suggested, in fact, in situations where skeletal
muscle glucose uptake is elevated, increases in limb blood flow will increase insulin
delivery to facilitate further glucose delivery, especially when capillary recruitment is
augmented (Clark et aI., 2003; Clerk et al., 2004). In other words, since insulin mediates
glucose uptake via metabolic and vasculature actions, postexercise skeletal muscle
hyperemia likely "mediates the mediator" by enhancing delivery of insulin to the
microvasculature when the stimulus for glucose uptake is high.
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Impact on glucose effectiveness
Glucose effectiveness refers to the ability of glucose to mediate glucose disposal
independent of the influence of circulating insulin (Bergman et a!., 1979). The effect of
acute exercise on glucose effectiveness and insulin sensitivity was examined by Brun et
al. by administering an intravenous glucose tolerance test 25 minutes after a 15 minute
bout of cycling exercise. They found both glucose effectiveness and insulin sensitivity
were greater in the postexercise versus non-exercise control condition (Brun et a!., 1995).
Subsequently, Sakamoto and colleagues conducted a similar investigation, but used 60
minutes of cycling at lactate threshold intensity as their exercise stimulus and measured
leg blood flow via venous occlusion plethysmography. They also measured a substantial
increase in glucose effectiveness following exercise that corresponded to elevated leg
blood flow, implying postexercise hyperemia promotes glucose effectiveness (Sakamoto
et al., 1999).
Role of vascular and metabolic training adaptations
Postexercise glycogen resynthesis and glycogen repletion rates are greater in
trained versus untrained individuals (Rickner et a!., 1997). Furthermore, Greiwe and
colleagues found both postexercise muscle glycogen content and glycogen accumulation
rates to be markedly increased after 10 weeks of endurance training (Greiwe et a!., 1999),
which indicates faster glycogen repletion is a result of training per se, as opposed to being
a purely genetic phenomenon. Furthermore, an increase in GLUT4 glucose transporter
protein and glycogen synthase activity appear to be adaptations to endurance training that
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facilitates this augmented glycogen repletion (Hickner et aI., 1997; Greiwe et al., 1999;
Richter et aI., 2001b).
It is worth mentioning that increased skeletal muscle capillary density is also a
well-documented adaptation to endurance training (Andersen & Henriksson, 1977). In
context of the aforementioned importance of insulin delivery to the skeletal muscle
microvasculature and interstitial space, it is reasonable to suggest greater training-
induced capillary density also functions to improve skeletal muscle glucose uptake. This
notion falls in line with idea of postexercise skeletal muscle hyperemia sub-serving
glucose uptake, as increased perfusion, combined with an increased capacity of the
microvasculature, would likely result in enhanced skeletal muscle glucose uptake and
subsequent glycogen repletion following dynamic exercise.
Specific Aims
The studies discussed in Chapters III through V were designed to address the following
specific aims:
1. The study entitled "Local H j- and Hrreceptor blockade, administered via muscle
microdia1ysis, abolishes the increase in local blood flow evoked by compound 48-
80" (Chapter III) was designed to test our ability to block local H j- and H2-
receptors located in the vastus 1ateralis muscle in humans. Specifically, we
sought to determine the dosages of the Hj-receptor antagonist pyrilamine and the
H2-receptor antagonist cimetidine required to block the increase in local blood
flow evoked by compound 48-80.
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2. The study entitled "Local H j - and H2-receptor blockade blunts postexercise
interstitial glucose concentrations in the vastus lateralis" (Chapter IV) was
designed to determine the effect oflocal H j- and Hrreceptor blockade,
administered via skeletal muscle microdialysis, on postexercise interstitial glucose
concentrations.
3. The study entitled "H j - and H2-histamine receptor blockade augments the
glycemic response to postexercise oral glucose load" (Chapter V) was designed to
detennine if postexercise skeletal muscle hyperemia influences glucose regulation
via enhanced glucose delivery following a bout of exercise.
Hypotheses
The studies discussed in this dissertation tested the following hypotheses:
1. In Chapter III, we tested the hypothesis that local H j - and H2-receptor blockade,
administered via muscle microdialysis, would abolish the increase in local blood
flow evoked by compound 48-80.
2. In Chapter IV, we tested the hypothesis that postexercise interstitial glucose
concentrations, as determined by muscle microdialysis, would be higher in the
control versus the combined H j and H2histamine receptor antagonist sites.
3. In Chapter V, we tested the hypothesis that the glycemic response to an oral
glucose load (OGTT) following exercise would be more sustained with H j - and
Hrreceptor blockade versus control.
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CHAPTER II
OVERVIEW OF THE METHODOLOGIES
Subject characterization
All study protocols described in this dissertation were approved by the
Institutional Review Board ofthe University of Oregon (Protocols #C2-ll6-08F, #C2-
294-08F-3, #A548-07F) and were conducted in accordance with the guidelines set forth
by the Office for Protection of Human Subjects of the University of Oregon. Each
subject gave his or her written consent prior to participation in the study.
Data from 44 subjects (29 men: 15 women, age 20-35 years) who volunteered to
participate in the three protocols described are included in this dissertation. Subjects
were healthy, normotensive, non-smokers, ranging in fitness from sedentary to
moderately aerobically trained, and taking no medications with the exception of oral
contraceptives. For all visits, subjects reported to the laboratory at least three hours post-
prandial, having refrained from alcohol consumption and exercise for 24 hours and
consumption of caffeine for 12 hours. Female subjects had a negative pregnancy test on
the screening visit. In addition, female subjects were studied during the early follicular
phase oftheir menstrual cycle or during the placebo phase of the oral contraceptive cycle
to minimize the potential effects of reproductive hormones on cardiovascular and/or
metabolic regulation.
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Peak aerobic power test
Subjects participating in exercise protocols initially visited the laboratory to
perform a peak aerobic power test on a cycle ergometer, in addition to self-repOliing
activity levels on two questionnaires. Subjects performed an incremental cycle exercise
test to exhaustion to determine peak oxygen uptake (VOz peak), measured via a mixing
chamber integrated with a mass spectrometry system. A similar computerized system has
been validated versus traditional Douglas bag method, at rest and during graded exercise
testing (Bassett et aI., 2001). Peak aerobic power was determined to aid in quantifying
the proper intensity of exercise for the subsequent exercise days, as well as to use for
subject charactellzation.
Moderate intensity cycling exercise
After a brief rest (~ 5 min), subjects returned to the cycle ergometer to determine
the workload con"esponding to a steady-state oxygen consumption of 60% ofVOzpeak.
This workload was used on the exercise study day(s) for the 60-minute exercise bout.
Exercise of this intensity and duration has proven to evoke sustained (~100 minutes)
postexercise skeletal muscle hyperemia (Pricher et aI., 2004), which was crucial in the
undertaking of the studies discussed in Chapters IV and V of this dissertation.
Heart rate
Heart rate was monitored throughout all protocols via 5-lead electrocardiogram
(Quinton Instruments, Bothell, WA), as a safety measure, as well as to assess
hemodynamic changes throughout the protocols.
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Arterial pressure
Arterial pressure was measured with an automated oscillometric device (Dinamap
Pro100 vital signs monitor, Critikon Inc, Tampa, FL) during resting conditions. Arterial
pressure readings from a similar unit are highly correlated with intra-arterial
measurements, which are established as the "gold standard" in arterial pressure
evaluation (Hossack et at., 1982). Arterial pressure during exercise was determined via
manual auscultometry. Mean arterial pressure was calculated as:
MAP = diastolic BP + [(systolic BP - diastolic BP)/3]
Limb and skeletal muscle blood flow
There are numerous methods to measure both limb and skeletal muscle blood
flow in humans. The proper technique to use depends on a number of factors, including
technical requirements, cost, level of invasiveness, and validity of the technique. The
most commonly used methods appropriate for use in research on humans are reviewed
below, with special emphasis placed on the methods employed in the protocols discussed
in this dissertation.
Limb bloodflow
For the protocol described in Chapter V of this dissertation, Doppler ultrasound
was used to measure leg blood flow, as calculated using mean blood velocities and
diameters of subjects' femoral arteries. Doppler ultrasound measurements are derived
from changes in frequency (Doppler shift) produced via the scattering oftransmitted
sound waves by red blood cells (Gill, 1985). The direction and velocity of red blood cell
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movement is determined by this frequency change, as detected by the ultrasound
transducer (Bums & Jaffe, 1985).
In order to obtain an accurate full parabolic blood velocity profile, it is crucial the
Doppler sampling volume spans the entire vessel lumen (Bums & Jaffe, 1985; Gill, 1985;
Radegran, 1999). Moreover, imaging with a consistent angle of insonation, preferably :s
60°, insures flow estimate errors are minimized (Gill, 1985; Hoskins, 1990). Finally,
since flow rate is the product of mean blood velocity and lumen cross-sectional area,
accurate measurement of vessel lumen diameter is essential for valid determination of
blood flow (Gill, 1985; Hoskins, 1990).
There are a number of advantages to using Doppler ultrasound for measurement
oflimb blood flow. It is a non-invasive method to obtain continuous blood flow
measurements under a variety of conditions (Radegran, 1999). As demonstrated by
Radegran (1997), Doppler ultrasound blood flow measurements were strongly correlated
with those simultaneously obtained by thermodilution. This held true during resting
conditions, as well as during intense dynamic knee extension exercise, during which time
Doppler ultrasound detected blood flow changes with a high temporal resolution
(Radegran, 1997). Furthermore, although the equipment is expensive and the method is
tec1mically advanced, once trained, researchers can acquire reproducible mean blood
velocity and vessel diameter measurements under both resting and exercising conditions
(Shoemaker et at., 1996).
Several indicator methods have been used to measure blood flow in humans,
thermodilution and indo-cyanine green dye being two of the most common techniques.
32
The thennodilution technique is used to detennine blood flow by measuring temperature
changes within a vein during infusion of saline cooled to a known temperature (Ganz et
al., 1964; Andersen & Saltin, 1985). A thennistor inserted into the vein allows
temperature measurement of the blood both before and after being mixed with the saline.
The temperature change resulting from the saline infusion, along with the known saline
and blood temperatures and rate of saline infusion, allow for calculation of blood flow
(Ganz et al., 1964; Radegran, 1999). Ideally used in steady state conditions, in vitro
experiments have indicated the technique, when carefully controlled, can accurately
measure blood flow from resting conditions and during dynamic exercise (Ganz et al.,
1964; Andersen & Saltin, 1985), although frequency and volume of saline infusion must
be maintained such that tissue cooling does not occur (Radegran, 1999). Although
relatively inexpensive to implement and conduct studies with thennodilution, it is an
invasive procedure.
The indo-cyanine green dye technique entails the infusion of a known
concentration of dye into a blood vessel and subsequent sampling ofblood downstream
from the infusion rate, which enables investigators to measure the concentration of the
dye once it has thoroughly mixed with the blood (Wahren & Jorfeldt, 1973). Under
steady state conditions, if the infusion rate and sample concentrations are known, blood
flow may be calculated (Wahren & Jorfeldt, 1973; Radegran, 1999; Pricher et al., 2004).
Dye infusion techniques allow investigators to obtain reliable blood flow measurements
at rest and during steady state exercise (Wahren & Jorfeldt, 1973), but the method is
invasive and conducting experiments can be expensive (Radegran, 1999).
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Venous occlusion plethysmography involves the use of a strain-gauge to detect
changes in limb girth when arterial inflow is allowed but venous outflow is prevented
(Conrad & Green, 1961; Bygdeman et al., 1971). Thus while the venous outflow is
arrested, the rate oflimb swelling is used to assess arterial inflow rate. In order to obtain
accurate results, venous occlusion must be complete and arterial inflow must be
maintained (Conrad & Green, 1961). Advantages of venous occlusion plethysmography
include its low cost, relative ease of use and non-invasiveness (Radegran, 1999), but due
to problems with motion artifacts (Benj amin et al., 1995), it is only suitable for resting
measurements.
For the protocol described in Chapter V, mean blood velocities and diameters of
the common femoral artery were measured using a linear ultrasound probe (lOMHz
linear-array vascular probe, GE Vingmed System 5, Horton, Norway) placed distal to the
inguinal ligament, approximately 2-3 cm proximal to the bifurcation. The entire width of
the artery was insonated with an angle of 60 degrees and velocity measurements were
taken immediately before diameter measurements. Leg blood flow was calculated as
artery cross-sectional area multiplied by femoral mean blood velocity, doubled to
represent both legs, and reported as ml . min-I. Leg vascular conductance was calculated
as flow for both legs/mean arterial pressure and expressed as ml . min-I. mmHg-1•
Muscle bloodflow
For the protocols described in Chapter III and IV of this dissertation,
microdialysis ethanol outflow-inflow ratio was used to measure local blood flow in the
vastus lateralis. This technique requires the inseliion of a microdialysis probe into
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skeletal muscle. A portion of the microdialysis probe is composed of a semi-permeable
membrane, which is positioned in the muscle belly. The microdialysis probe is then
perfused, at a steady rate, with a physiological perfusion medium (perfusate) containing a
known concentration of ethanol. Ethanol readily diffuses through the semi-permeable
membrane and is not metabolized by the muscle tissue (Lieber, 1977). Therefore as local
capillary blood flow increases, more ethanol is removed from the interstitial space, the
ethanol concentration gradient in the vicinity of the probe increases, and less ethanol is
collected as out-flowing dialysate (Hickner et ai., 1991, 1992). Thus the ethanol outflow-
inflow ratio is regarded as an inverse surrogate oflocal blood flow.
Efforts to quantify local blood flow using the ethanol removal technique have
been made, based on studies conducted with cats (Hickner et ai., 1995; Wallgren et ai.,
1995) and humans (Hickner et ai., 1994). Hickner and colleagues have found the ethanol
clearance technique to be strongly correlated with Xenon-133 (133Xe) clearance (Hickner
et ai., 1994), although there has been concern that 133Xe clearance is non-linear and
underestimates blood flow (Cerretelli et ai., 1984; Radegran, 1999). Subsequently, on a
study conducted in cats, they found when blood flow was held constant at various flow
rates, ethanol outflow-inflow ratios and flow rates were negatively and linearly correlated
in a flow range of 4 - ~45 ml . 100 g -I . min -I, although the ethanol removal technique
was less sensitive at higher flow rates (Hickner et ai., 1995). In a companion study, a
mathematical model for measuring local blood flow was derived using the
aforementioned ethanol outflow-inflow ratios (Wallgren et ai., 1995). Although the
model-based blood flow predictions tracked relatively well with the known blood flows,
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these results were applicable only when specific probes were used (Wallgren et al.,
1995). An additional concern exists regarding the effect of muscle contractions, per se,
on ethanol outflow-inflow ratio measures, independent of changes in blood flow
(Radegran et al., 1998). Nevertheless, in the absence of skeletal muscle contractions,
when local blood flow rates are low to moderate, the ethanol removal technique can
supply investigators with valuable infonnation regarding the relative effect of various
interventions on local blood flow.
Another traditional method of estimating local blood flow is the isotope clearance
technique, which is based on the assumption that clearance of an inert isotope is
dependent upon local blood flow (Kety, 1951; Lassen et al., 1964). The isotope, usually
133Xe, is injected directly into the muscle and its disappearance rate is tracked externally
(Lassen et al., 1964; Cerretelli et al., 1984). The slope of the resulting wash-out curve is
used to calculate flow, as the steeper the slope, the greater the local blood flow (Lassen et
al., 1964). Although it may be used to measure local blood flow during exercise, when
compared against direct venous outflow and microsphere trapping flow, the isotope
clearance technique was found to drastically underestimate local blood flow in canine
muscles (Cerretelli et al., 1984). Combined with the requisite radioactive exposure, as
well as the expense associated with the technique, isotope clearance is a less than ideal
method of measuring local blood flow in humans.
Positron emission tomography (PET), combined with the intravenous infusion of
a tracer substance labeled with a positron-emitting isotope, can be also used to measure
muscle blood flow (Raitakari et al., 1996). In order to obtain accurate blood flow results,
36
it is important that the tracer (e.g., ISO-labelled water) used is inert and able to diffuse
from the blood and surrounding tissues (Raitakari et al., 1996). High resolution PET
scanners are able to track the distribution of the tracer, as well as quantify its distribution
temporally, which is an advantage of using positron emission tomography (Radegran,
1999). However, this method necessitates that positron-emitting isotopes be injected into
the subject. Moreover, the equipment required and expense involved in this procedure, in
addition to the logistical barriers for use during exercise, make positron emission
tomography an impractical method of muscle blood flow measurement for most
investigators (Radegran, 1999).
Near-infrared Spectroscopy (NIRS) is a relatively new tool that can be used to
measure tissue oxygenation, muscle metabolism and blood flow in the microcirculation
(Boushel et al., 1998; Kalliokoski et al., 2006). It is a noninvasive method based on the
absorption oflight at wavelengths in the near-infrared range, which enables
determination of oxygenated and deoxygenated hemoglobin. An advantage ofNIRS is
that it can be used during exercise. NIRS can be used in conjunction with a light-
absorbing tracer to quantify blood flow in discrete areas ofthe microcirculation, however,
it has a limited capacity for discriminating between numerous, closely arranged micro-
vessels (Kalliokoski et al., 2006).
Muscle microdialysis
In order to determine glucose concentrations in the interstitial space, as well as
measure local blood flow (see previous section) and deliver drugs of interest to the
interstitium, I employed muscle microdialysis. First developed to study the animal brain
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(Delgado et aI., 1972; Ungerstedt & Pycock, 1974), microdialysis is a unique technique
in that it pennits scientists to monitor dynamic changes in concentrations of various
substances within the interstitium (Hickner, 2000). Whereas the classic muscle biopsy
technique (Bergstroem et aI., 1965; Hultman, 1967) allows investigators to evaluate
muscle composition (e.g., glycogen) under various conditions, its invasive nature limits
this method to a few samples per study, thus disallowing continuous monitoring of the
muscle tissue.
Administered SUbstances
in perfusate
o 0
Skin surface
Recovered substances
in dialysate
•
Illustration 1. Skeletal muscle microdialysis schematic. The open circles represent
perfusate being delivered through the probe. The filled circles represent the dialysate
collected from the probe. The dashed line represents the semi-permeable membrane that
allows the concentration-dependent exchange of molecules between the probe and the
interstitium.
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Microdialysis, on the other hand, entails the continuous delivery of perfusion fluid
through a probe at a constant rate, as well as continuous collection and subsequent
analysis of the outflowing dialysate (Plock & Kloft, 2005). The composition of the
dialysate is dictated by concentration gradients of various substances around the
microdialysis probe's semi-permeable membrane. In other words, depending on the size
of the pores in the semi-permeable membrane, substances with a small enough molecular
weight will either diffuse out of or into the perfusion fluid based on the relative
concentrations of those substances within both the probe and the interstitial space
(Rickner, 2000; Plock & Kloft, 2005)
Muscle microdialysis is an invasive technique, so great care must be taken to
minimize tissue trauma and risk of infection (Plock & Kloft, 2005). In addition,
microdialysis probes are quite fragile, so using this technique during exercise increases
the risk of probe kinking or breaking, although researchers have addressed this by
constructing reinforced probes (MacLean et al., 2000). Although commercially available
microdialysis probes can be rather expensive (~$150.00 per probe) (Rickner, 2000),
researchers can be circumvent this problem by assembling and sterilizing their own
probes.
For the protocols described in Chapter III and IV of this dissertation,
microdialysis probes were constructed in our laboratory. The membranes used in the
microdialysis probes were obtained from artificial dialysis kidney (GFS 18) with a
molecular mass cutoff of 3 KD and an inner diameter of 0.20 llllll. Each end of the
membranes were advanced approximately 1 ern into hollow polyimide tubing with an
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inner diameter of 0.36 mm and glued in place. The length of exposed membrane in each
fiber used was precisely 4 cm. The proximal end of the polyimide tubing was then
advanced approximately 2 cm into polyethylene tubing and glued in place. Subsequently
a luer tip adapter stub was attached to the proximal end of the polyethyline tubing in
order to accommodate a perfusate-filled syringe during the microdialysis procedure.
Each probe was tested by attaching an empty syringe to the luer tip adapter stub with the
distal tip of the microdialysis probe submerged in a beaker of dionized water. If gentle
advancement of the syringe plunge did not produce a steady stream of bubbles, the probe
was discarded. Microdialysis probes that were deemed operational were then gas
sterilized (Anprolene AN74i) for 12 hours prior to use.
Four microdialysis probes were inserted approximately 2-3 cm apart in the vastus
lateralis muscle of each subject's right leg. Prior to insertion, a sterile field was
established and the entire lateral thigh region was cleansed with an alcohol-based
antiseptic (ChloraPrep). The skin and subcutaneous tissue at both the probe insertion and
exit sites were then anesthetized via local administration of approximately 1 m12%
lidocaine (20 mg/ml) plus epinephrine 1:100,000 (1 0 ~g1ml) and sodium bicarbonate per
site. The epinephrine produced a local cutaneous vasoconstriction to minimize bleeding
and the sodium bicarbonate stabilized the pH to minimize subject discomfort during
lidocaine administration. Care was taken to not to introduce the lidocaine solution into
the muscle itself, thereby avoiding any alterations in the intramuscular environment. The
microdialysis probes were inserted in the vastus lateralis, in a direction parallel to muscle
fiber orientation, via a 20-gauge cannula. The probe insertion and exit sites were
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approximately 9 cm apart. Immediately after needle insertion, a sterilized microdialysis
probe was threaded through the needle lumen. The needle was then removed, leaving
only the microdialysis probe in place.
Following placement, each microdialysis probe was attached to a perfusion pump
(CMA 102 Microdialysis pump, CMA, North Chelmsford, MA) and perfused at a rate of
5JlL/min with a Ringer's solution containing 3.0 mM glucose, 0.5 mM lactate and 5.0
mM ethanol. Due to its similar composition of interstitial fluid, this perfusate served as
the control solution in each experiment, thus minimizing the potential draining of the
interstitial space (Lonnroth et al., 1987). For the protocol described in Chapter IV of this
dissertation, [6}H] glucose (2000 dpm/10 Jll) was included in the perfusate to serve as an
internal reference marker for recovery of glucose (Scheller & Kolb, 1991; MacLean et
aI., 2001) (see Assessment a.!probe recovery below). In addition, for protocols described
in both Chapters III and IV, additional drugs were included to the perfusate to either
evoke or antagonize increases in local blood flow (see Drugs administered via muscle
microdialysis below). Throughout the protocols described in Chapters III and IV of this
dissertation, the distal tips of the microdialysis probes were placed in microcentrifuge
tubes for dialysate collection. Non-porous tape was placed over the top of the
microcentrifuge tubes to prevent evaporation of ethanol. The tubes were weighed before
and after dialysate collection to verify fluid balance across the microdialysis probe
membrane. Microcentrifuge tubes were sealed, placed in a refrigerator, and dialysate was
analyzed within 48 hours of collection.
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Heated hand vein
In order to obtain "arterialized" blood samples, in lieu of placing more invasive
arterial cannulas, a heated hand vein method was used (Morris et aI., 1997). An
intravenous catheter was inserted retrogradely in the dorsal vein of the left hcimd, which
was then placed in a custom-made heating chamber ("hot-box"), which was flushed with
air at 55° C. Actual skin temperature was raised to approximately 42° C, which is below
the temperature that evokes sensations of pain. Heating the hand in this way induces the
opening of arterial-venous anastomoses in the hand circulation, thereby allowing
investigators to sample "arterialized" venous blood with higher and less variable oxygen
saturations and higher glucose concentrations compared to non-arterialized blood
samples (Morris et al., 1997).
Arterialized venous blood samples
Arterialization of venous blood samples was confirmed by immediate
measurement of oxygen saturation in duplicate by a co-oximeter (Radiometer
Copenhagen). Glucose concentrations of arterialized venous blood were measured in
duplicate with a clinical glucose analyzer (YSI 2300 Stat Plus Glucose and Lactate
Analyzer, YSI Life Sciences). Blood samples were promptly placed on ice, centrifuged
at 4° C, separated, and stored at -80° C until analyzed.
Insulin sensitivity and glucose tolerance tests
Researchers and clinicians have used numerous approaches to quantify insulin
sensitivity and glucose uptake in humans (Monzillo & Hamdy, 2003; Cobelli et al.,
2007). The approach taken is usually dictated by the specific objectives of the study, as
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well as by the resources available to those conducting the investigation. What follows is
a brief review of the most common methods used to assess insulin sensitivity and glucose
uptake, with special emphasis placed on the oral glucose tolerance test (OOTT), which
was employed in the protocols discussed in Chapters IV and V of this dissertation.
Elaboration regarding models and formulas used in conjunction with the OOTT is
included below in the section entitled "Estimation of glucose uptake and insulin
sensitivity".
Developed by Defronzo and colleagues, the hyperinsulinemic euglycemic glucose
clamp technique is considered the "gold standard" in the assessment of tissue insulin
sensitivity (DeFronzo et a!., 1979). During this procedure insulin is intravenously
infused at a constant rate in order to maintain a steady state insulin level greater than that
of fasting baseline. This hyperinsulinemic state evokes a marked increase in skeletal
muscle glucose uptake, while presumably suppressing hepatic glucose production.
Intravenously administered dextrose ensures maintenance of normal (euglycemic) blood
glucose concentration. Over the course of hours of insulin infusion, steady state blood
glucose, plasma insulin, and glucose infusion rate can be obtained. Thus, assuming
complete suppression of endogenous glucose production, glucose infusion rate and rate of
glucose uptake under these conditions must be equal (DeFronzo et a!., 1979; Muniyappa
et ai., 2008). This information can then be used to compute insulin sensitivity in a
precise and highly reproducible manner (DeFronzo et ai., 1979; Muniyappa et a!., 2008).
However, the glucose clamp technique is costly, time consuming, and requires constant
careful subject monitoring, which deems it impractical for use in many settings.
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The frequently sampled intravenous glucose tolerance test (FSIVGT), in
conjunction with Bergman's minimal model (Bergman et al., 1979), is another method
that has been utilized to assess insulin sensitivity and glucose effectiveness in humans.
This procedure consists of an intravenous bolus of glucose of 0.3 g/kg body weight and
measurement of plasma insulin and glucose at 31 time points through three hours post-
infusion. The glucose and insulin data are then analyzed via the minimal model program
to produce an insulin sensitivity index, which is defined as the glucose clearance rate per
change in plasma insulin concentration (Bergman et al., 1979; Monzillo & Hamdy, 2003;
Muniyappa et al., 2008). Some investigators have used a modified version of the
FSIVGT, adding either insulin (Finegood et ai., 1990) or tolbutamide infusion (Beard et
ai., 1986) 20 minutes after the glucose infusion, as this method has produced better
correlation of insulin sensitivity index with the hyperinsu1inemic eug1ycemic glucose
clamp technique. A reduced version of the FSIVGT has also been used, which has
shown strong correlation with, but slightly weaker reproducibility than the standard
version, while requiring less than half the number ofblood draws (Duysinx et ai., 1994;
Steil et al., 1994).
Although the FSIVGT has been a valuable tool in determining insulin sensitivity
and glucose effectiveness, there are a few drawbacks to this method. In comparison to
oral administration of glucose, the FSIVGT is a less physiological stimulus. Moreover,
the FSIVGT has been found to consistently underestimate insulin sensitivity and
overestimate glucose effectiveness (Quon et ai., 1994; Cobelli et ai., 1998), which has
been attributed to the relatively short exposure of peripheral tissues to hyperinsulinemia,
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as well as the oversimplification ofthe physiology by the minimal model. The concel11
over the oversimplification of the model is based on the model utilizing one compartment
to assess glucose dynamics, as well as its combination of the effects of insulin to elevate
glucose uptake and quell hepatic glucose production (Muniyappa et a!', 2008). Finally,
the FSIVGT is both invasive and labor intensive, due its duration and high number of
blood draws.
The oral glucose tolerance test (OGTT) has been widely used to assess glucose
tolerance, defined as the ability of the body to dispose of glucose following a glucose
load, in a variety of populations (Cobelli et a!., 2007). When combined with various
indices of insulin sensitivity and/or modeling techniques, the OGTT can be used to
determine ~-cell function and insulin sensitivity in humans. The method entails the
administration of an oral glucose tolerance beverage (usually containing 75 g glucose),
followed by blood draws for subsequent determination of glucose, insulin, and sometimes
c-peptide concentrations. The number and distribution of blood draws has varied across
investigations, depending on the primary objective of the investigation, as well as the
particular formula or model employed. The OGTT glucose and C-peptide minimal
models have been validated against tracer protocols (Dalla Man et a!., 2004) and the
euglycemic hyperinsulinemic clamp technique (Dalla Man et a!., 2005b). Recently,
Dalla Man and colleagues discovered a two-hour seven sample oral glucose tolerance test
protocol resulted in comparable minimal model assessment of ~-cell responsiveness and
insulin sensitivity to that oflonger versions requiring more blood samples (Dalla Man et
al.,2005a).
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Several factors associated with the OGTT have the potential to affect its
reproducibility. Chief among these are variations in glucose absorption, neuro-hormonal
interactions, splanchnic glucose uptake, and possible effects on incretin hormones, which
are known to stimulate insulin secretion in response to glucose ingestion (Muniyappa et
al., 2008). However, significant advantages of OGTT include its more physiological
delivery of glucose, relative ease of use, and reduced invasiveness, relative to the
FSIVGT and euglycemic hyperinsulinemic clamp.
In the protocol described in Chapter V, each subject consumed 0.1 oz per kg body
weight (up to 10 oz maximum) Oral Glucose Tolerance Beverage (Trutoll00, NERL
Diagnostics, East Providence, RI), which contained 109 of glucose per oz. Therefore,
subjects received an oral glucose dose of 1 g per kg body weight up to 100 g maximum.
Drug administration
Drugs were administered orally in the protocol described in Chapter V of this
dissertation. In the protocols described in Chapters III and IV, several drugs were
administered via muscle microdialysis.
Orally administered drugs
HI-receptor antagonism was produced at the onset of randomized study days via
oral administration of 540 mg fexofenadine hydrochloride (Allegra; Aventis
Pharmaceuticals Inc, Kansas City, MO). This oral dose of fexofenadine adequately and
selectively blocks HI-receptors, with a half-life of approximately 12 hours and a time to
peak concentration between 0.83 - 1.33 hours (Russell et aI., 1998). Fexofenadine is
non-sedating, does not appear to cross the blood-brain barrier or have anti-muscarinic
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effects (Hardman JG, 2001). Oral HI-receptor antagonism via 540 mg fexofenadine has
been shown to attenuate elevations in postexercise femoral vascular conductance in
humans (Lockwood et aI., 2005b).
Hz-receptor antagonism was produced at the onset of randomized study days via
oral administration of 300 mg ranitidine hydrochloride (Zantac; Pfizer Consumer
Healthcare, Morris Plains, NJ). This oral dose ofranitidine adequately and selectively
blocks Hz-receptors, with a half-life of 2.6 hours and a time to peak concentration of 2.2
hours (Garg et aI., 1985). Ranitidine is non-sedating, does not appear to cross the blood-
brain barrier or have any cardiovascular effects (Hardman JG, 2001). Oral Hz-receptor
antagonism via 300 mg ranitidine has been shown to attenuate elevations in postexercise
femoral vascular conductance in humans (McCord et aI., 2006).
Drugs administered via muscle microdialysis
In the protocol described in Chapter III of this dissertation 10mM compound 48-
80 (Sigma-Aldrich, St. Louis, MO) was administered, via skeletal muscle microdialysis,
to induce local histamine-mediated vasodilation. Compound 48-80 degranulates mast
cells, resulting in their release of histamine (Diamant & Dahlquist, 1970). This
compound 48-80-induced vasodilation was used to verify blockade oflocal H1- and Hz-
receptors.
In the protocols described in Chapters III and IV of this dissertation, local H1-
receptor antagonism was achieved with 1 mM pyrilamine maleate and local Hz - receptor
antagonism was achieved with 3 mM cimetidine, both administered via muscle
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microdialysis. These doses were titrated from those used previously to achieve H l - and
H2 -receptor blockade in the skin (Wilkins et al., 2004a; Wong et al., 2004).
Dialysate analysis
Ethanol assay
Ethanol analysis was performed in duplicate using a modified version of the
enzymatic analysis described by Hickner et al. (Hickner et al., 1992). The assay uses
alcohol dehydrogenase to break down ethanol (EtOH) per the following reaction:
EtOH + NAD+ ~ ADH ---* Acetylaldehyde + NADH
Briefly, 1 ml Glycine-Hydrazine Buffer with NAD, 50 fll Alcohol Dehydrogenase
Solution, and 5 fll dialysate were combined in test tubes, covered, and incubated in a
25°C bath for 75 minutes. Immediately following incubation, the contents of each test
tube was transferred to a cuvette and read by a digital filter fluorometer (Barnstead-
Turner Quantech) against a standard curve. Ethanol concentrations in the dialysate and
perfusate were used to determine the ethanol outflow-inflow ratio, which is an inverse-
surrogate to local blood flow, as discussed in the above section entitled Muscle blood
flow.
Glucose analysis ofdialysate
Dialysate glucose concentrations were determined, in duplicate, using a clinical
glucose analyzer (YSI 2300 Stat Plus Glucose & Lactate Analyzer, YSI Life Sciences).
Subsequently, dialysate glucose concentrations, coupled with probe recovery values (see
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Assessment o.fprobe recovery below) were used to detennine interstitial glucose
concentrations.
Assessment o.fprobe recovery
[6}H] glucose was included in the microdialysis perfusate to serve as an internal
reference for probe glucose recovery (Scheller & Kolb, 1991; MacLean et ai., 2001). 10
III samples of perfusate or dialysate were pipetted into a 5 ml scintillation vial, then
combined with 3 ml of scintillation fluid (Ultima Gold, Shelton, CT). Scintillation vials
were then vortexed and read by a scintillation counter (Beckman LS 6800). Probe
recovery, per the internal reference method, was calculated as:
Recovery (%) = (Perfusate activity (dpm) - Dialysate activity (dpm»/Perfusate activity (dpm)
Assessment o.finterstitial glucose concentrations
Interstitial glucose concentrations were detennined using the glucose
concentrations from the perfusate and dialysate, as well as the probe recovery, using the
internal reference method. The internal reference method has been validated against the
no-net flux method (MacLean et ai., 1999) and uses the following calculation to derive
interstitial glucose concentrations:
[Glucose] interstitial = (([glucose] dialysate - [glucose] perfusate)/recovery + [glucose] perfusate)
Blood hormone analysis
Analysis of insulin, glucagon and C-peptide was handled by the core lab at the
Oregon Clinical and Translational Research Institute (OCTRI) by standard methods.
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Estimation of glucose uptake and insulin sensitivity
Several indices to estimate insulin sensitivity and/or glucose uptake have been
developed for use with the oral glucose tolerance test (OGTT). This is a key
development, so the OGTT, as both a research and clinical tool, can be utilized t6 its full
capacity. Therefore, the most commonly used and well-validated indices are reviewed
below, with special emphasis on the MeR est and lSI est indices, developed by Stumvoll
and colleagues (2000).
The Matsuda insulin sensitivity index uses OGTT data to produce a composite
estimate of muscle and hepatic insulin sensitivity. The two components of this index
consider basal insulin sensitivity and insulin sensitivity following the glucose load. This
index is relatively easy to use and correlates well with the euglycemic hyperinsulinemic
clamp (Matsuda & DeFronzo, 1999). The formula used is:
lSI (Matsuda) = 10,000/'; [(G fasting X I fasting) X (G OGTTmean X I OGTTmean)]
The Gutt index (lSI 0,120) is a relatively simple model that uses basal plasma
glucose and insulin levels, as well as those at 120 minutes following OGTT to estimate
glucose uptake rate and insulin sensitivity. It correlates well with the euglycemic
hyperinsulinemic clamp (Gutt et al., 2000) and, when compared to other common
indices, was the best at predicting onset of type 2 diabetes (Hanley et at., 2003). The
ISI(O, 120) index is defined as:
lSI 0,120 = MCR/log MSI = mlMPG/log MSI
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where m (mg/min) is the glucose uptake rate in the peripheral tissues, based on the
formula:
m = [75,000 mg + (Glucose 0 - Glucose 120) x 0.19 x BW]/120 min
Mean plasma glucose (MPG) is the mean of the 0 and 120 min glucose values and mean
serum insulin (MSI) is the mean of the 0 and 120 min insulin values. Finally, the
metabolic clearance rate (MeR) = mIMPG, as this corrects for the potential influence of
different blood glucose levels on the rate of glucose uptake.
The MeR est and lSI est indices, developed by Stumvoll and coworkers use
results from the OGTT to estimate metabolic clearance rate of glucose and insulin
sensitivity. Using subject BMI, plasma glucose, and plasma insulin data, it has the
highest correlation (r = 0.80) with the euglycemic hyperinsulinemic clamp (Stumvoll et
aI., 2000) of all the established indices. It uses the following equations:
MeR est (OGTT) = 18.8 - 0.271 BMI - 0.0052 x I 120 - 0.27 x G 90
lSI est (OGTT) = 0.226 - 0.0032 x BMI - 0.0000645 x I 120 - 0.0037 x G 90
where BMI = body mass index, I 120 = plasma insulin at 120 min OGTT, and G 90 =
plasma glucose at 90 min OGTT.
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CHAPTER III
LOCAL H1- AND Hz-RECEPTOR BLOCKADE, ADMINISTERED VIA MUSCLE
MICRODIALYSIS, ABOLISHES THE INCREASE IN LOCAL BLOOD FLOW
EVOKED BY COMPOUND 48-80
Introduction
An acute bout of moderate-intensity dynamic exercise results in a sustained rise in
skeletal muscle blood flow from that of pre-exercise levels (Halliwill, 2001; Pricher et
ai.,2004). Recent evidence suggests this postexercise skeletal muscle hyperemia is
mediated by two (HI and Hz) histamine receptor subtypes (Lockwood et ai., 2005b;
McCord et ai., 2006; McCord & Halliwill, 2006). To date, this has only been
investigated using oral administration of HI- and Hz-receptor antagonists, which may
result in systemic effects. Circumventing this problem necessitates the isolated blockade
ofloca1 HI and Hz-receptors in the skeletal muscle.
Along these lines, skeletal muscle microdia1ysis is a unique tool that permits
researchers to deliver drugs of interest to the interstitial space, while simultaneously
monitoring concentrations of various substances within the interstitium (Hickner, 2000).
In order to determine if postexercise skeletal muscle hyperemia is mediated by local HI
and Hz-receptors, it is first necessary to confirm adequate receptor blockade. Thus, the
current investigation was designed to determine the dosages of the HI-receptor antagonist
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pyrilamine and the Hrreceptor antagonist cimetidine required to block local H j- and H2-
receptors located in the vastus lateralis muscle in humans. We tested the hypothesis that
local Hj- and H2-receptor blockade, administered via muscle microdialysis, would
abolish the increase in local blood flow evoked by compound 48-80.
Methods
This study was approved by the Institutional Review Board of the University of
Oregon and was conducted in accordance with the guidelines set forth by the Office for
Protection of Human Subjects of the University of Oregon. Each subject gave his or her
written consent plior to participation in the study.
Subjects
10 healthy, non-smoking, normotensive subjects (8 men; 2 women), between the
ages of20 and 26, participated in this study. Subjects reported to the laboratory at least
three hours post-prandial, having refrained from alcohol consumption and exercise for 24
hours and consumption of caffeine for 12 hours. Subjects were taking no medications
with the exception of oral contraceptives. In addition, female subjects were studied
during the early follicular phase of their menstrual cycle or during the placebo phase of
the oral contraceptive cycle to minimize the potential effects of reproductive hormones
on cardiovascular regulation.
Microdialysis probes
All microdialysis probes used in this study were constructed in our laboratory.
The membranes used in the probes were obtained from artificial dialysis kidney (GFS 18)
with a molecular mass cutoff of 3 KD and an inner diameter of 0.20 mm. Each end of the
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membranes was advanced approximately I cm into hollow polyimide tubing with an
inner diameter of 0.36 mm and glued in place. The length of exposed membrane in each
fiber used was precisely 4 cm. The proximal end of the polyimide tubing was then
advanced approximately 2 cm into polyethylene tubing and glued in place. Subsequently
a luer tip adapter stub was attached to the proximal end of the polyethyline tubing in
order to accommodate a perfusate-filled syringe during the microdialysis procedure.
Microdialysis probes were then gas sterilized (Anprolene AN74i) for 12 hours prior to
use.
Microdialysis probe insertion
Four microdialysis probes were inserted approximately 2-3 cm apart in the vastus
lateralis muscle of each subject's right leg. Prior to insertion, a sterile field was
established and the entire lateral thigh region was cleansed with an alcohol-based
antiseptic (ChloraPrep). The skin and subcutaneous tissue at both the probe insertion and
exit sites were then anesthetized via local administration of approximately 1 ml 2%
lidocaine (20 mg/ml) plus epinephrine I: 100,000 (10 flg/ml) and sodium bicarbonate per
site. The epinephrine produced a local cutaneous vasoconstriction to minimize bleeding
and the sodium bicarbonate stabilized the pH to minimize subject discomfort during
lidocaine administration. Care was taken not to introduce the lidocaine solution into the
muscle itself, thereby avoiding any alterations in the intramuscular environment. A
flexible 20-gauge needle was inserted in the vastus lateralis, in a direction parallel to
muscle fiber orientation. The insertion and exit sites were approximately 9 cm apart.
Immediately after needle insertion, a sterilized microdialysis probe was threaded through
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the needle lumen. The needle was then removed, leaving only the microdialysis probe in
place. Placement of all four probes was accomplished within 25 minutes of beginning
the procedure.
Experimental protocol
Following placement, each microdialysis probe was attached to a perfusion pump
(CMA 102 Microdialysis pump, CMA, North Chelmsford, MA) and perfused at a rate of
5J.lLlmin with a modified Ringer's solution containing 3.0 mM glucose and 0.5 mM
lactate. Concentrations of glucose and lactate in the perfusion solution were verified
using a clinical glucose analyzer (YSI 2300 Stat Plus Glucose & Lactate Analyzer, YSI
Life Sciences). By design, the perfusion solution had a composition similar to that of the
interstitial fluid, thereby minimizing osmotic differences across the probe membrane so
as to avoid net fluid movement between the interstitial space and the perfusion solution
within the probe (Lonnroth et al., 1987). In addition, all perfusate included 5 mM
ethanol. Ethanol readily diffuses through the semi-permeable membrane and is not
metabolized by the muscle tissue (Lieber, 1977). Therefore as local capillary blood flow
increases, more ethanol is removed from the interstitial space, the ethanol concentration
gradient in the vicinity of the probe increases, and less ethanol is collected as outflowing
dialysate (Rickner et al., 1991, 1992). Thus the ethanol outflow-inflow ratio was used as
an inverse surrogate to determine relative local blood flow.
In order to verify the stability of the ethanol outflow-inflow ratios over time, we
collected dialysate from one control probe through 120 minutes after probe insertion in
five subjects. For the remaining probes and subjects who participated in this protocol,
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probes were randomly assigned to be perfused with the control solution (no drug),
solution plus I mM HI-receptor antagonist pyrilamine maleate, solution plus 3 mM Hr
receptor antagonist cimetidine, or solution plus pyrilamine and cimetidine combined.
These doses were titrated from those used previously to achieve HI- and H2 -receptor
blockade in the skin (Wilkins et aI., 2004a; Wong et al., 2004). The distal tips of the
microdialysis probes were placed in microcentrifuge tubes for dialysate collection. Non-
porous tape was placed over the top of the microcentrifuge tubes to prevent evaporation
of ethanol.
For all subjects, the first collection of dialysate began 10 minutes following the
completion of insertion of all four probes, allowing time to verify probe function, set up
collection of dialysate, and flush out probe dead space. The microcentrifuge tubes were
replaced every 20 minutes, through 70 minutes following probe insertion, with the 70
minute collection serving as baseline for each probe. This equilibration period allowed
recovery from any cellular trauma induced by probe insertion and allowed for
equilibration of interstitial and dialysate fluxes and concentrations. Thus, baseline
collection periods were 10-30, 30-50, and 50-70 minutes following completion of probe
insertion.
As noted previously, we collected dialysate from one control probe through 120
minutes post probe insertion in five subjects. For the remaining subjects and probe sites,
following the baseline collection, the perfusion -solution for each probe was changed 70
minutes after completion ofprobe insertion. The new perfusion solution was identical to
that used during the equilibration period, except for the addition of 10mM compound 48-
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80 (Sigma-Aldrich, St. Louis, MO). Compound 48-80 degranulates mast cells, resulting
in their release of histamine (Diamant & Dahlquist, 1970), thereby evoking HI and H2 -
receptor mediated vasodilation. The change in perfusion solution was followed by three
more 15 minute collection periods (75-90, 90-105, and 105-120 min after completion of
probe insertion).
Analysis
All microcentrifuge tubes were weighed before and after dialysate collection to
verify fluid balance across the microdialysis probe membrane. Microcentrifuge tubes
were sealed, placed in a refrigerator, and dialysate was analyzed within 48 hours of
collection. Ethanol analysis was performed in duplicate using a modified version of the
enzymatic analysis described by Hickner et al. (Hickner et al., 1992). The assay uses
alcohol dehydrogenase (ADH) to break down ethanol (EtOH) per the following reaction:
EtOH + NAD+ +-- ADH ~ Acetylaldehyde + NADH
Briefly, 1 ml Glycine-Hydrazine Buffer with NAD, 50 III Alcohol Dehydrogenase
Solution, and 5 III dialysate were combined in test tubes, covered, and incubated in a 25
°C bath for 75 minutes. Immediately following incubation, the contents of each test tube
were transferred to a cuvette and read by a digital filter fluorometer (Barnstead-Turner
Quantech) against a standard curve. Ethanol concentrations in the dialysate and perfusate
were then used to determine the ethanol outflow-inflow ratio, thereby enabling
qualification oflocal blood flow.
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Statistics
The results were analyzed with a Two-Way Repeated Measures ANOVA (effect
of drug and time) with SigmaStat Version 2.0 (SPSS Inc.). Differences were considered
significant when P < 0.05. All values are reported as means ± SE unless otherwise noted.
Results
Muscle microdialysis control sites
Figure 1 illustrates the ethanol outflow-inflow ratios in the muscle microdialysis
control sites starting from 30 minutes through 120 minutes after completion of probe
insertion. There were no differences between the ethanol outflow-inflow ratio during the
30-50 minute collection period (0.555 ± 0.070) and ethanol outflow-inflow ratios at
subsequent dialysate collection periods (all P 2: 0.111).
Figure 1. Ethanol outflow-inflow ratios over time from muscle microdialysis
control probes inserted in the vastus lateralis. n = 5 subjects
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Verification oflocal Hr and Hrreceptor blockade
Figure 2 illustrates the effect of 10 mM Compound 48-80, delivered via skeletal
muscle microdialysis, on ethanol outflow-inflow ratio in control sites, as well as sites
with 1 mM pyrilamine, 3 mM cimetidine, or pyrilamine and cimetidine combined. There
were no statistically significant differences between the 70 minute baseline ethanol
outflow-inflow ratios at any of the sites (all P 2: 0.051). In the control site, ethanol
outflow-inflow ratio fell from 0..583 ± 0.022 at baseline to 0.497 ± 0.018 after the
addition of Compound 48-80 to the perfusate (P < 0.01). In the pyrilamine sites, ethanol
outflow-inflow ratio went from 0.609 ± 0.040 at baseline to 0.601 ± 0.051 with the
addition of Compound 48-80 (P = 0.636). In the cimetidine sites, ethanol outflow-inflow
ratio went from 0.531 ± 0.040 at baseline to 0.508 ± 0.036 with the addition of
Compound 48-80 (P = 0.049). In the combined H 1- and H2-receptor antagonist sites,
ethanol outflow-inflow ratio went from 0.574 ± 0.038 at baseline to 0.584 ± 0.057 with
the addition of Compound 48-80 (P = 0.552).
59
Figure 2. Ethanol outflow-inflow ratios in response to Compound 48-80 in control
and local histamine receptor blockade sites. n = 4-9 subjects, as indicated;
* p < 0.05 vs. baseline.
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The goal of this study was to test our ability to block local H j- and H2-receptors,
located in the vastus lateralis muscle in humans, via muscle microdialysis administration
of the Hj-receptor antagonist pyrilamine and the Hrreceptor antagonist cimetidine.
Furthermore, we wanted to explore the stability of the ethanol outflow-inflow ratios over
time following muscle microdialysis, in the absence of drugs. Our findings suggest a
combination oflocal H j- and H2-receptor blockade, administered via muscle
microdialysis, blocked the increase in local blood flow evoked by compound 48-80. In
addition, we found that under resting conditions, the ethanol outflow-inflow ratio
remained relatively stable from 30 to 120 minutes following insertion of muscle
microdialysis probes.
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This is the first investigation to demonstrate local blockade ofH j - and H2-
receptors in human skeletal muscle. As such, this finding presents a new approach in the
investigation of potential H t - and H2-receptor-mediated blood flow and metabolic
regulation, as previous investigations on this front have utilized oral administration ofR j -
and H2-receptor antagonists (Lockwood et ai., 2005b; McCord et ai., 2006; McCord &
Halliwill, 2006) which result in systemic blockade ofthe these receptors. The ability to
selectively block H j - and H2-receptors located in specific regions enables researchers to
better control for possible confounds associated with orally administered H[- and R2-
receptor antagonists. Moreover, it permits more integrative experimentation, as the
interstitial space is at the junction between cardiovascular and metabolic regulation in
humans (Rickner et ai., 1991; Rickner et ai., 1997; MacLean et ai., 1999; Newman et ai.,
2002).
It is worth noting that the microdialysis ethanol outflow-inflow ratio is not
considered a quantitative measure, per se, oflocal blood flow (Radegran, 1999). Factors
independent ofblood flow, such as capillary permeability and lymph flow, may affect
clearance of ethanol to some degree (Hickner et ai., 1995). In addition, initial trauma
caused by probe insertion may affect ethanol clearance. However, ethanol outflow-
inflow ratios have been shown to be sensitive to perturbations designed to increase and
decrease local blood flow (Hickner et ai., 1991, 1992; Hickner et ai., 1995). Moreover,
ethanol outflow-inflow ratios have been shown to be stable within 20 minutes of probe
insertion (Hickner et ai., 1994), which is consistent with our findings of stable ethanol
outflow-inflow ratios in the control sites, starting with the collection period from 30-50
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minutes after completion of probe insertion. Furthermore, this time frame is well before
the start of baseline dialysate collection in the compound 48-80 portion of the current
study. Thus, the ethanol outflow-inflow ratio appears to be a sound indicator of relative
changes in local blood flow, and has been found to be especially sensitive in the absence
of skeletal muscle contraction and during lower blood flow conditions (Hickner et al.,
1995).
In conclusion, our results demonstrate that we were able to block the increase in
local blood flow evoked by compound 48-80 with the combination of the Hj-receptor
antagonist pyrilamine and the Hz-receptor antagonist cimetidine, administered via
skeletal muscle microdialysis. Furthennore, we verified stability of the ethanol outflow-
inflow ratio under resting conditions, starting at the 30 minutes following the completion
of muscle microdialysis probe insertion. These findings set the stage for researchers to
explore how local H\- and Hz-receptors impact the intramuscular environment under a
variety of conditions.
In the study discussed in Chapter III, we verified our ability to block local H\- and
Hz-receptors in the vastus lateralis, using a combination ofthe H\-receptor antagonist
pyrilamine and the Hz-receptor antagonist cimetidine, administered via skeletal muscle
microdialysis. In addition, we confinned the stability of the ethanol outflow-inflow ratio
under resting conditions within 30 minutes following the completion of muscle
microdi'alysis probe insertion. These findings allowed us to proceed to the investigation
discussed in Chapter IV, during which we employed skeletal muscle microdialysis to
determine the effect oflocal H1- and Hrreceptor blockade on postexercise interstitial
glucose concentrations.
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CHAPTER IV
LOCAL HI- AND H2-RECEPTOR BLOCKADE BLUNTS POSTEXERCISE
INTERSTITIAL GLUCOSE CONCENTRATIONS IN THE VASTUS
LATERALIS
Introduction
Following 60 minutes of moderate intensity dynamic exercise, blood flow to
previously active skeletal muscle remains elevated above pre-exercise levels for
approximately 100 minutes (Halliwill, 2001; Pricher et al., 2004). This postexercise
skeletal muscle hyperemia is found in both men and women (Senitko et al., 2002) and in
both sedentary and endurance exercise trained individuals (Lockwood et al., 2005b;
McCord et aI., 2006; McCord & Halliwill, 2006). Recent studies employing oral
administration ofHj- and/or H2-receptor antagonists suggest this hyperemia is
histaminergic in nature (Lockwood et al., 2005b; McCord et al., 2006; McCord &
Halliwill, 2006). While strides have been made in understanding the mediators of
postexercise hyperemia, it is unclear what purpose this increased blood flow might serve.
Along these lines, Williams et al. investigated the relationship between leg blood flow
and oxygen uptake following 60 minutes of moderate-intensity exercise. They found the
time course of leg blood flow recovery did not match that of oxygen uptake, suggesting
skeletal muscle hyperemia does not subserve oxygen delivery to the previously exercised
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muscle (Williams et aI., 2005). The function, therefore, of this histamine-receptor-
mediated hyperemia found after an acute bout of dynamic exercise has yet to be
elucidated.
It is well established that skeletal muscle glucose uptake is enhanced, in an
insulin-independent manner, during the first 90 minutes postexercise (Wasserman &
Halseth, 1998; Richter et al., 2001a; Henriksen, 2002). The glucose taken up following
exercise contributes to glycogen repletion in humans (Richter et aI., 1989; Casey et al.,
2000) and the rate of glycogen synthesis is typically highest the first 30 minutes
following exercise (Price et al., 1994). Furthermore, as illustrated by studies involving
electrical stimulation of the rat hindlimb (Richter et aI., 1984) and single-legged exercise
in humans (Bergstrom & Hultman, 1966; Richter et al., 1989), glucose uptake and
glycogen repletion occurs preferentially in the previously exercised skeletal muscle.
This begs the question: Does postexercise skeletal muscle hyperemia serve to aid
glucose delivery to previously active skeletal muscles in humans? Numerous studies
have suggested blood flow as a rate-limiting factor in glucose regulation. Early animal
research found glucose uptake was enhanced with increases in isolated rat hindlimb
perfusion, even when blood glucose and insulin concentrations were maintained (Grubb,
1977; Schultz, 1977). Baron et al. discovered both leg blood flow and leg glucose uptake
were substantially greater in combined insulin and methacholine hydrochloride trials
versus the insulin only trials, indicating skeletal muscle perfusion can independently
impact insulin-mediated glucose uptake in humans (Baron et al., 1994). Subsequently,
Durham and coworkers measured substantial increases in leg glucose uptake in response
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to exogenous nitric oxide-mediated increases in leg blood flow (Durham et al., 2003). It
is worth noting that this enhanced glucose uptake was found in the absence of insulin
stimulation, indicating either the increased blood flow itself or some other effect of nitric
oxide mediated the increased glucose uptake.
Thus, it appears that elevations in blood flow can contribute to increased skeletal
muscle glucose uptake, in both animals and humans. Whether this relationship holds true
in the postexercise condition is not known. Moreover, while previous investigations have
employed orally administered H j - and Hrreceptor blockade, the effect ofblockade at the
level of the skeletal muscle has not been examined. Thus, while the mechanisms
surrounding both postexercise skeletal muscle hyperemia and postexercise glucose
regulation have been explored, the relationship between these factors remains poorly
understood. Therefore, the current investigation was designed to determine the effect of
local H j - and H2-receptor blockade, administered via skeletal muscle microdialysis, on
postexercise interstitial glucose concentrations. Skeletal muscle microdialysis is uniquely
suited to probe this relationship, as it allows delivery of drugs to the interstitial space, and
simultaneously monitors concentrations of various substances within the interstitium
(Hickner, 2000). We hypothesized that postexercise interstitial glucose concentrations,
as determined by muscle microdialysis, would be higher in the control versus the
combined H j - and Hrreceptor antagonist sites.
Methods
This study was approved by the Institutional Review Board of the University of
Oregon and was conducted in accordance with the guidelines set forth by the Office for
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Protection of Human Subjects of the University of Oregon. Each subject gave his or her
written consent prior to participation in the study.
Subjects
14 healthy, non-smoking, normotensive subjects (8 men; 6 women), between the
ages of20 and 27, participated in this study. Seven subjects (4 men; 3 women)
participated in an exercise protocol and seven subjects (4 men; 3 women) participated in
a sham (no exercise) protocol. For all study visits, subjects reported to the laboratory at
least three hours post-prandial, having refrained from alcohol consumption and exercise
for 24 hours and consumption of caffeine for 12 hours. Subjects were taking no
medications with the exception of oral contraceptives. In addition, female subjects were
studied during the early follicular phase of their menstrual cycle or during the placebo
phase of the oral contraceptive cycle, to minimize the potential effects ofreproductive
honnones on cardiovascular and metabolic regulation.
Screening visit
Subjects participating in the exercise protocol initially visited the laboratory to
perform a peak aerobic power test on a cycle ergometer, in addition to self-reporting
activity levels on two questionnaires. Subjects performed an incremental cycle exercise
test (Lode Excaliber, Groningen, The Netherlands) comprised of I-minute workload
increments to determine peak oxygen uptake (V02 peak). Specifically, after a 2-minute
warm-up period of easy cycling (20-30 watts), workload was increased by 20,25, or 30
watts every minute. Selection of the workload increment was based on self-reported
subject activity levels, with the goal of producing exhaustion within 8-12 minutes.
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Subjects were instructed to maintain 60-80 revolutions per minute to maximize muscular
efficiency. Whole body oxygen uptake was measured via a mixing chamber
(Parvomedics, Sandy, UT) integrated with a mass spectrometry system (Marquette MGA
11 00, MA TechServices, St. Louis, MO). Peak aerobic power was determined as either:
1) when subjects were unable to maintain 60 revolutions per minute, 2) had obtained a
respiratory exchange ratio of greater than 1.15, or 3) had reached subjective exhaustion
[rating of perceived exertion on the Borg (Borg, 1970) scale of 19-20] within the 8- to
12-minute period.
After resting for approximately-lO minutes, subjects returned to the cycle
ergometer to determine the workload corresponding to a steady-state oxygen
consumption of 60% ofV02 peak. The workload was titrated, as needed, to reach a steady
state oxygen consumption of 60% ofV02 peak, which was usually attained within five
minutes. This workload was used on the exercise study day for the 60-minute exercise
bout, as this intensity and duration of exercise has been shown to evoke sustained (~1 00
minutes) postexercise skeletal muscle hyperemia (Pricher et al., 2004).
Microdialysis probes
All microdialysis probes used in this study were constructed in our laboratory.
The membranes used in the probes were obtained from artificial dialysis kidney (GFS 18)
with a molecular mass cutoff of 3 KD and an inner diameter of 0.20 mm. Each end of the
membranes was advanced approximately 1 cm into hollow polyimide tubing with an
inner diameter of 0.36 mm and glued in place. The length of exposed membrane in each
fiber used was precisely 4 cm. The proximal end of the polyimide tubing was then
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advanced approximately 2 cm into polyethylene tubing and glued in place. Subsequently
a luer tip adapter stub was attached to the proximal end of the polyethyline tubing in
order to accommodate a perfusate-filled 'syringe during the microdialysis procedure.
Microdialysis probes were then gas sterilized (Anprolene AN74i) for 12 hours prior to
use.
Experimentalprotocol
On the study day, subjects were laid in the supine position for instrumentation.
Heart rate was monitored throughout the protocol via 5-lead electrocardiogram (Quinton
Instruments, Bothell, WA). Arterial pressure was measured with an automated
oscillometric device (Dinamap Pro100 vital signs monitor, Critikon Inc, Tampa, FL)
during pre-exercise resting conditions and 55, 75, 95, 115, and 135 minutes postexercise. -
Heated hand vein
In order to obtain "arterialized" blood samples, a heated hand vein method was
used (Morris et ai., 1997). An intravenous catheter was inserted retrogradely in the
dorsal vein of the left hand, which was then placed in a custom-made heating chamber
("hot-box"), which was flushed with air at 55° C. Actual skin temperature was raised to
approximately 42° C, which is below the temperature that evokes sensations of pain.
Heating the hand in this way induces the opening of arterial-venous anastomoses in the
hand circulation, thereby allowing investigators to sample "arterialized" venous blood
with higher and less variable oxygen saturations and higher glucose concentrations
compared to non-arterialized blood samples (Morris et ai., 1997). Arterialization of
venous blood samples was confirmed by immediate measurement of oxygen saturation in
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duplicate by a co-oximeter (Radiometer Copenhagen). Glucose concentrations of
arterialized venous blood were measured in duplicate with a clinical glucose analyzer
(YSI 2300 Stat Plus Glucose and Lactate Analyzer, YSI Life Sciences) pre-exercise, 30
minutes into the exercise bout, and 55, 75, 95, 115, and 135 minutes postexercise.
Preparation for microdialysis
In preparation for the postexercise insertion ofmuscle microdialysis fibers, a
sterile field was established and the entire lateral thigh region was cleansed with an
alcohol-based antiseptic (ChloraPrep). The skin and subcutaneous tissue at both the
probe insertion and exit sites were then anesthetized via local administration of
approximately 1 ml 2% lidocaine (20 mglml) plus epinephrine 1:100,000 (10 Ilglml) and
sodium bicarbonate per site. The epinephrine produced a local cutaneous
vasoconstriction to minimize bleeding and the sodium bicarbonate stabilized the pH to
minimize subject discomfort during lidocaine administration. Care was taken to not
introduce the lidocaine solution into the muscle itself, thereby avoiding any alterations in
the intramuscular environment.
Exercise
Subjects exercised upright on a stationary cycle at 60% ofV02 peak for 60 min.
Exercise of this intensity and duration produce sustained (~l 00 min) skeletal muscle
hyperemia (Pricher et al., 2004). During the 60 min of exercise, heart rate was measured
via 5-lead electrocardiogram (Quinton Instruments, Bothell, WA) and arterial pressure
was determined via manual auscultometry. Subjects drank 10 ml per kg body weight of
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water to offset volume loss during exercise. During the sham study, the 60 minutes of
cycling was replaced with 60 minutes of quiet rest.
Muscle microdialysis
Immediately following exercise, subjects were laid supine for insertion of muscle
microdialysis probes. Four microdialysis probes were inserted approximately 2-3 cm
apart in the vastus lateralis muscle of each subject's right leg. Prior to insertion, a sterile
field was established and the entire lateral thigh region was cleansed with an alcohol-
based antiseptic (ChloraPrep). A flexible 20-gauge needle was inserted in the vastus
lateralis, in a direction parallel to muscle fiber orientation. The insertion and exit sites
were approximately 9 cm apart. Immediately after needle insertion, a sterilized
microdialysis probe was threaded through the needle lumen. The needle was then
removed, leaving only the microdialysis probe in place. Placement of all microdialysis
probes was complete within 20 minutes from the end of the exercise bout.
Following placement, each microdialysis probe was attached to a perfusion pump
(CMA 102 Microdialysis pump, CMA, North Chelmsford, MA) and perfused at a rate of
5~Llminwith a modified Ringer's solution containing 3.0 mM glucose, 0.5 mM lactate, 5
mM ethanol, and [6-3H] glucose (2000 dpm/l 0 ~l). Concentrations of glucose and lactate
in the perfusion solution were verified using a clinical glucose analyzer (YSI 2300 Stat
Plus Glucose & Lactate Analyzer, YSI Life Sciences). Due to its similar composition of
interstitial fluid, this perfusate served as the control solution, thus minimizing osmotic
differences across the probe membrane and potential draining of the interstitial space
(Lonnroth et ai., 1987). [6)H] glucose (2000 dpm/lO ~l) was included in the perfusate to
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serve as an internal reference marker for recovery of glucose (Scheller & Kolb, 1991;
MacLean et a!., 2001). Ethanol readily diffuses through the semi-permeable membrane
and is not metabolized by the muscle tissue (Lieber, 1977). Therefore as local capillary
blood flow increases, more ethanol is removed from the interstitial space, the ethanol
concentration gradient in the vicinity of the probe increases, and less ethanol is collected
as out-flowing dialysate (Hickner et at., 1991, 1992). Thus the ethanol outflow-inflow
ratio was used as an inverse surrogate to determine relative local blood flow.
Two of the probes were perfused with the control solution plus combined 1 mM
Hj-receptor antagonist pyrilamine maleate, and 3 mM H2-receptor antagonist cimetidine,
to block local Hj- and H2-receptors. These doses were previously verified to produce Hj-
and H2 -receptor blockade in skeletal muscle via muscle microdialysis (see Chapter III).
Following the placement ofthe microdialysis probes, 15 minutes was allowed to verify
probe function, set up collection of dialysate, and flush out probe dead space, after which
time the distal tips ofthe microdialysis probes were placed in microcentrifuge tubes for
dialysate collection. Non-porous tape was placed over the top of the microcentrifuge
tubes to prevent evaporation of ethanol. The microcentrifuge tubes were replaced every
20 minutes, through 115 minutes following probe insertion, thus dialysate was collected
from 35-55, 55-75, 75-95, 95- 115, and 115-135 minutes postexercise. All
microcentrifuge tubes were weighed before and after dialysate collection to verify fluid
balance across the microdialysis probe membrane. Microcentrifuge tubes were sealed,
placed in a refrigerator, and dialysate was analyzed within 48 hours of collection.
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Oral glucose load
Forty minutes after microdialysis probe insertion, to induce an increase in blood
and interstitial glucose concentrations, each subject consumed 0.1 oz per kg body weight
(up to 10 oz maximum) Oral Glucose Tolerance Beverage (TrutollOO, NERL
Diagnostics, East Providence, RI), which contained 109 of glucose per oz. Therefore,
subjects received an oral glucose dose of 1 g per kg body weight up to 100 g maximum.
Analyses
Ethanol assay
Ethanol analysis was performed in duplicate using a modified version of the
enzymatic analysis described by Rickner et al. (Rickner et al., 1992). The assay uses
alcohol dehydrogenase to break down ethanol (EtOR) per the following reaction:
EtOH + NAD+ <- ADH ~ Acetylaldehyde + NADH
Briefly, 1 ml Glycine-Rydrazine Buffer with NAD, 50 fll Alcohol Dehydrogenase
Solution, and 5 ).ll dialysate were combined in test tubes, covered, and incubated in a 25
°C bath for 75 minutes. Immediately following incubation, the contents of each test tube
were transferred to a cuvette and read by a digital filter fluorometer (Barnstead-Turner
Quantech) against a standard curve. Ethanol concentrations in the dialysate and perfusate
were then used to determine the ethanol outflow-inflow ratio, thereby enabling
qualification of local blood flow.
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Probe recovery
[6}H] glucose was included in the microdialysis perfusate to serve as an internal
reference for probe glucose recovery (Scheller & Kolb, 1991; MacLean et aI., 2001). 10
III samples of perfusate or dialysate were pipetted into a 5 ml scintillation vial, then
combined with 3 ml of scintillation fluid (Ultima Gold, Shelton, CT). Scintillation vials
were then vortexed and read by a scintillation counter (Beckman LS 6800). Probe
recovery, per the internal reference method, was calculated as:
Recovery (%) = (Perfusate activity (cpm) - Dialysate activity (cpm))/Perfusate activity (cpm)
Assessment of interstitial glucose concentrations
Interstitial glucose concentrations were determined using the glucose
concentrations from the perfusate and dialysate, as well as the probe recovery, using the
internal reference method. The internal reference method uses the following calculation
to derive interstitial glucose concentrations:
[Glucose] interstitial = «([glucose] dialysate - [glucose] perfusate)/recovery + [glucose] perfusate)
Statistics
The results were analyzed with a Two-Way Repeated Measures ANOYA (effects
of drug and time) with SAS Proc Mixed (SAS v9.1, SAS Institute, Cary, NC).
Differences were considered significant when P:5 0.05. All values are reported as means
± SE unless otherwise noted.
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Results
Subject characteristics
Subject characteristics are presented in Table 1. VOZpeak values were within the
normal range for young, healthy subjects of sedentary to endurance trained status.
Table 1. Subject characteristics-Chapter IV.
Exercise protocol
n 7
Age (years) 23.1 ± 2.1
Height (cm) 176.3 ± 6.9
Weight (kg) 73.1 ± 9.7
Body mass index (kg m-z) 23.5 ± 2.5
VOzpeak (ml kg -I min -I) 54.3 ± 14.6
Workload at 60% ofV02peak (watts) 161.5 ± 31.8
Baecke sport index (arbitrary units) 12.7 ± 3.2
Index of physical activity (METhrwk) 163.5 ± 57.4
Sham protocol
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22.1 ± 2.3
173.8 ± 13.6
76.3 ± 19.1
24.8 ± 3.1
Values are means ± SD; V02 peak> peak oxygen consumption; MET, metabolic equivalents
Exercise
During the exercise protocol, the goal was to have each subject exercise for 60
min at 60% VOzpeak. The percentage of heart rate reserve (heart rate reserve is defined as
maximal heart rate achieved during V02 peak testing minus the resting supine heart rate)
attained during exercise (73.7 ± 1.6 %) was consistent with the target workload. Heart
rate increased from 53.5 ± 3.9 beats min- I during supine rest to 152.4 ± 1.6 beats min -I
during exercise (measured 30 min into exercise bout; P < 0.05). Mean arterial pressure
increased from 80.3 ± 1.8 mmHg during supine rest to 90.3 ± 1.9 mmHg during exercise
(P < 0.05). During the sham period, neither heart rate (P = 0.134) nor arterial pressure (P
= 0.319) changed from pre-sham supine rest.
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Hemodynamics
Mean arterial pressure reached a nadir 55 min following exercise (78.3 ± 1.9
mmHg; P < 0.05 vs preexercise), thereafter returning to values not different from
preexercise (all P 2: 0.15). Heart rate remained elevated above preexercise levels
throughout the postexercise period (P::S 0.013, all time points). During the sham
protocol, neither heart rate (all P 2: 0.134) nor mean arterial pressure (all P 2: 0.310)
changed from pre-sham baseline at any time point.
Blood glucose
Preexercise blood glucose concentrations, obtained from heated hand veins, were
4.33 ± 0.14 mM in the sham protocol and 4.41 ± 0.10 mM in the exercise protocol (P =
0.958 vs. sham). During the sham period, blood glucose concentration was 4.67 ± 0.14
mM, while during exercise blood glucose concentration was 4.35 ± 0.21 mM. In both
protocols, the oral glucose load induced a sharp increase in blood glucose levels, starting
95 minutes following sham or exercise (sham 5.80 ± 0.38 mM; exercise 5.67 ± 0.31 mM;
both P < 0.05 vs. preexercise baseline). In both protocols blood glucose concentrations
reached their peak 115 minutes following sham (7.44 ± 0.47 mM) or exercise (7.74 ±
0.46 mM).
Local bloodflow
As illustrated in Figure 3, local blood flow in the vastus lateralis in both the sham
and exerciseprotocol was assessed by ethanol outflow-inflow ratio, which is an inverse
surrogate to flow in the region surrounding the microdialysis probe (Hickner et a!., 1991,
1992). In the sham protocol, there were no differences in ethanol outflow-inflow ratio
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between the control and blockade sites at any time point (P 2': 0.389). In the postexercise
condition, however, ethanol outflow-inflow ratios were higher in the blockade sites at 55
minutes (0.481 ± 0.05 control vs. 0.538 ± 0.04 blockade; P = 0.030) and 75 minutes
(0.526 ± 0.05 control vs. 0.567 ± 0.05 blockade; P = 0.043) following exercise, but were
not significantly different at the subsequent time points (P 2': 0.168).
B0,70A
Figure 3. Ethanol outflow-inflow ratios following sham (A) and exercise (B). Open circles denote
control sites; filled circles denote combined blockade with pyrilamine and cimetidine. *P < 0.05 vs.
control at same time point; n = 7 for each group.
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Interstitial glucose concentrations
The interstitial glucose concentrations, in both the sham and exercise protocol, are
shown in Figure 4. In the sham protocol, there were no differences in interstitial glucose
concentrations between the control and blockade probes at any time point (all P 2': 0.507).
In contrast, postexercise interstitial glucose concentrations were higher in the control
probes at 55 minutes (control 3.99 ± 0.29 vs. blockade 3.56 ± 0.33 mM; P = 0.043), 95
minutes (control 4.76 ± 0.40 vs. blockade 4.08 ± 0.29 mM; P = 0.048) and 135 minutes
(control 8.66 ± 0.73 vs. blockade 7.10 ± 0.66 mM; P = 0.014) following exercise. On
average, interstitial glucose concentrations were 0.748 mM higher in the control versus
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the blockade sites. In both protocols, in the control and blockade sites, the oral glucose
load administered at 80 minutes postexercise evoked a marked rise in interstitial glucose
concentrations, starting 115 minutes following sham or exercise (both P :S 0.05).
Figure 4. Interstitial glucose concentrations following sham (A) and exercise (B). Open circles denote
control sites; filled circles denote combined blockade with pyrilamine and cimetidine. *P < 0.05 vs.
control at same time point; n = 7 for each group. *
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Ethanol ou~flow-il~flowvs. interstitial glucose concentrations
Figure 5 illustrates the relationship between postexercise ethanol outflow-inflow
ratios, expressed as the difference between blockade and control sites, and interstitial
glucose concentrations, expressed as the difference between control and blockade sites 55
minutes postexercise. Although there is no notable positive correlation between the
ethanol outflow-inflow and interstitial glucose concentrations, both the differences in
ethanol outflow-inflow ratios and the differences in interstitial glucose concentrations are
positive in all seven subjects. Moreover, it is interesting to note that, ifthe point
representing the greatest difference in ethanol outflow-inflow ratios were deleted, a
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moderate positive correlation (r = 0.605; P < 0.05) would exist between relative blood
flow and interstitial glucose concentrations.
Figure 5. Relationship between ethanol outflow-inflow ratio and interstitial glucose concentrations
following exercise. Outflow-inflow ratio expressed as blockade - control; Interstitial glucose
concentration expressed as control- blockade; n = 7; 55 min postexercise time point represented.
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Discussion"
The goal of this study was to determine the effect of combined local H j - and Hz-
receptor blockade, administered via skeletal muscle microdialysis, on postexercise
interstitial glucose concentrations. In agreement with our hypothesis, postexercise
interstitial glucose concentrations were higher in the control versus the combined H1- and
Hz-receptor antagonist sites. This finding suggests a histaminergic component of
postexercise interstitial glucose delivery in humans.
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This is the first study to investigate the effect of local administration of H\- and
. H2-receptor antagonists on muscle blood flow and glucose regulation following exercise.
Previous research has shown orally administered H\- and H2-receptor antagonists blunt
the sustained skeletal muscle hyperemia following dynamic exercise (Lockwood et ai.,
2005b; McCord et ai., 2006; McCord & Halliwill, 2006). However, this route of delivery
may evoke systemic effects and induce counter-regulatory hemodynamic responses that
could impact factors independent of blood flow. An advantage of using skeletal muscle
microdialysis for drug delivery lies in the ability of investigators to precisely target the
region of interest while simultaneously measuring substances within the interstitium.
While the results of the current investigation imply histaminergic skeletal muscle
hyperemia facilitates interstitial glucose delivery, there are a number of alternative
explanations for the reduced interstitial glucose concentrations in the face oflocal H\-
and H2-receptor blockade.
Potential histaminergic mechanisms
Results from previous studies utilizing skeletal muscle microdialysis have
consistently observed resting interstitial glucose concentrations to be on the order of 3.6-
3.8 mM (Maggs et ai., 1995; Muller et ai., 1995; MacLean et ai., 1999). These
interstitial glucose concentrations from prior investigations are in line with the resting
interstitial glucose concentrations we found in the sham protocol prior to administration
of the oral glucose load. Furthermore, in agreement with previous findings, we observed
notably higher plasma glucose concentrations, as derived from arterialized samples, than
those found in the interstitium (MacLean et al., 1999). The glucose concentration
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gradient that exists, between the arterial blood and both the interstitium and the venous
blood, aids in delivery of glucose to the skeletal muscle cells, an effect that is enhanced
when either arterial blood glucose is elevated and/or interstitial glucose concentrations
are reduced. Furthermore, the discovery that interstitial glucose concentrations rise at the
onset of exercise, despite elevated glucose uptake, lends support to the idea that glucose
delivery is limited at rest (MacLean et at., 1999). In fact, the aforementioned observation
is in accordance with the results from the current investigation.
There are at least four feasible mechanisms by which local H1- and Hz-receptors
may mediate glucose delivery to the interstitium following exercise. The first and most
likely means by which interstitial glucose delivery is enhanced is via a sustained
elevation in local blood flow. This concurs with our current findings that ethanol
outflow-inflow ratio, an inverse surrogate of muscle blood flow, was markedly increased
through 75 minutes postexercise in the microdia1ysis blockade sites, while there was no
difference in ethanol outflow-inflow ratios between control and blockade sites in the
sham protocol. The ethanol outflow-inflow ratio is considered to represent nutritive
blood flow - that is, flow through blood vessels supplying muscle cells to promote
nutrient exchange (J'Jewman et at., 2002). Indeed, we found notably greater interstitial
glucose concentrations in the control versus the blockade sites following exercise, both
before and after the administration of the oral glucose load. Previous investigations have
shown that rises in local blood flow induced by heating or pharmacological means, led to
increased dialysate glul;ose concentrations, while reductions in local blood flow elicited
the opposite effect (Hickner et at., 1991, 1992). Our results indicate the physiological
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elevation in postexercise blood flow has a similar effect on interstitial glucose
concentrations.
The second potential mechanism by which local HI- and H2-receptors may
mediate postexercise interstitial glucose delivery is by evoking changes in vascular
permeability. If capillaries demonstrate a postexercise histaminergic increase in
permeability, this would be expected to impact both clearance of ethanol and interstitial
delivery of glucose. Histamine is known to evoke a rapid and transient increase in
microvascular permeability (Majno & Palade, 1961; Killackey et al., 1986; Hill et al.,
1997; van Hinsbergh & van Nieuw Amerongen, 2002). This enhanced permeability is
mediated by HI-receptors and may be reversed by administration of HI-receptor
antagonists (Niimi et al., 1992). However, this effect has been found primarily in the
post-capillary venules (Hill et al., 1997; van Hinsbergh & van Nieuw Amerongen, 2002)
and in studies on cultured human umbilical vein endothelial cells (Niimi et al., 1992;
Ikeda et al., 1999), while evidence of HI-receptor mediated increases in penneability at
the level of the capillary is sparse. Moreover, there are notable differences in
permeability responses between arterial and venular vessels, as histamine has been shown
to evoke an H2-receptor mediated reduction in vascular penneability in cultured bovine
aortic endothelial cells (Ikeda et al., 1999). Thus, while it is plausible histaminergic
increases in capillary permeability playa role in glucose delivery to the interstitium
following exercise; there is a lack of evidence to support that explanation at this time.
A third way local HI- and Hrreceptors may promote postexercise interstitial
glucose delivery is by supporting enhanced insulin-mediated capillary recruitment and
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subsequent delivery of insulin to the interstitium. Studies using both the rat (Vincent et
aI., 2004) and human model (Coggins et al., 2001) have shown insulin increases capillary
recruitment. Insulin binds primarily to insulin-like growth factor-I and insulin receptors
in the vascular endothelium (Wang et al., 2006), which stimulates nitric oxide synthesis
to induce local vasodilation (Rattigan et al., 2005). Inhibition ofnitric oxide synthase has
been shown to attenuate microvascular recruitment and limb glucose uptake, as measured
by arterial-venous concentration differences, in response to insulin infusion (Vincent et
aI.,2003). Insulin-mediated capillary recruitment likely promotes muscle glucose uptake
via both an increase in surface area and a decrease in distance for diffusion to the skeletal
muscle cells. Along these lines, skeletal muscle glucose uptake has been found to track
the timefi'ame of interstitial insulin levels, which suggests insulin delivery to the
interstitium is crucial in timely muscle glucose uptake (Miles et al., 1995; Vincent et al.,
2005). This notion is supported by a recent study by Chiu and coworkers who found
intramuscular injection of insulin resultedin an immediate rise in hindlimb glucose
uptake in dogs (Chiu et al., 2008). Thus, glucose delivery and subsequent uptake is
reliant on delivery of insulin to the microvasculature, for promotion of capillary
recruitment and timely diffusion into the interstitial space. Local H\- and Hz-receptors
may affect this process, by mediating local blood flow or trans-capillary movement of
insulin to the interstitial space, thereby impacting skeletal muscle interstitial glucose
delivery.
A fourth possible explanation for the results of the current investigation is that
local administration ofH\- and Hz-receptor antagonists following exercise may enhance
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local glucose uptake by the skeletal muscle cells. If this were the case, even in the face of
comparable interstitial glucose delivery to the areas surrounding the control and blockade
sites, the interstitial glucose in the region surrounding the blockade probes could be
reduced. However, we were unable to find evidence to suggest either pyrilamine or
cimetidine enhances skeletal muscle glucose uptake or GLUT4 translocation.
Furthermore, ifthere was an effect of H j - and Hz-receptor blockade on glucose uptake by
the skeletal muscle cells, considering the fact that interstitial glucose concentrations were
- not different between control and blockade sites during the sham protocol, this effect
would be specific to the postexercise condition, which seems unlikely.
Afethodologicalconsiderations
The variability in the outflow-inflow ratios and interstitial glucose concentrations
in the current study are greater than we anticipated, resulting in some time points at
which there are no differences between control and blockade sites. This can largely be
attributed to a relatively small subject population, so if we were to increase the number of
subjects, we would likely see significant differences across a greater range of time points
in the exercise protocol. Nevertheless, the entire pattern of the relative responses to prior
exercise between the control and blockade sites indicates substantially reduced local
blood flow and interstitial glucose concentrations in the blockade versus control sites.
Moreover, as illustrated in Figure 5, 55 minutes after exercise, ethanol outflow-inflow
ratios were higher and interstitial glucose levels were lower in the blockade sites in every
subject, which suggests that decreased local blood flow has an adverse effect on
interstitial glucose delivery.
- --_._--------
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Microdialysis ethanol outflow-inflow ratio is not considered a quantitative
measure, per se, oflocal blood flow (Radegran, 1999). Factors independent of blood
flow, such as capillary penneability and lymph flow, may affect clearance of ethanol to
some degree (Hickner et al., 1995). In addition, initial trauma caused by probe insertion
may affect ethanol clearance and dialysate glucose concentrations. However, ethanol
outflow-inflow ratios have been shown to be sensitive to perturbations designed to
increase and decrease local blood flow (Hickner et al.,-199l, 1992; Hickner et-al., 1995).
Moreover, ethanol outflow-inflow ratios and dialysate glucose concentrations have been
shown to be stable within 20 minutes ofprobe insertion (Hickner et aI., 1994). Our first
dialysate collection period in the current study (35-55 min postexercise) started 15
minutes after probe insertion; therefore only one collection period was likely to be even
minimally affected by residual trauma response. Thus, skeletal muscle microdialysis is
an effective tool to assess relative changes in local blood flow, and has been found to be
especially sensitive in the absence of skeletal muscle contraction and during lower blood
flow conditions (Hickner et aI., 1995). Moreover, the current protocol was designed and
implemented to minimize potential methodological concerns.
Per~pectives
The current investigation provides evidence that postexercise skeletal muscle
hyperemia influences interstitial glucose delivery and this effect is blunted by local
administration ofH j - and Hz-receptor antagonists. This discovery may have implications
regarding our understanding of recoveryfollowing dynamic exercise. Elevated blood
flow to the previously active muscles may be crucial for timely postexercise glycogen
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repletion, which may affect performance during subsequent bouts of exercise. These
findings may also be relevant to populations which have reduced skeletal muscle
perfusion, such as the aged, obese individuals and those suffering from diabetes. For
instance, it is possible that by increasing glucose delivery, postexercise skeletal muscle
hyperemia may be a key mechanism by which to circumvent insulin resistance in
diabetes. These findings, therefore, have mechanistic and clinical relevance.
In conclusion, postexercise interstitial glucose concentrations, as determined by
skeletal muscle microdialysis, were greater in the control versus the combined HI- and·
H2-receptor antagonist sites. This finding suggests postexercise delivery of glucose to the
interstitial space of the previously active skeletal muscle is mediated, in part, by local HI-
and H2-receptors in humans.
In the study described in Chapter IV of this dissertation, we concluded
postexercise interstitial glucose concentrations, as determined by skeletal muscle
microdialysis, were greater in the control versus the combined H I- and H2-receptor
antagonist sites. This suggested glucose delivery to interstitial space was mediated, in
part, by local HI - and Hrreceptor-mediated skeletal muscle hyperemia. We then turned
our attention to systemic postexercise glucose levels in the face ofblockade, by
examining the effect of oral H I- and H2-receptor antagonists on the glycemic response to
an oral glucose load following exercise.
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CHAPTER V
Ht- AND Hz-HISTAMINE RECEPTOR BLOCKADE AUGMENTS THE
GLYCEMIC RESPONSE TO POSTEXERCISE ORAL GLUCOSE LOAD
Introduction
An acute bout of moderate-intensity dynamic exercise results in a sustained rise in
skeletal muscle blood flow from that ofpre-exercise levels (Halliwill, 2001; Pricher et
aI.,2004). This postexercise skeletal muscle hyperemia is found in both men and women
(Senitko et al., 2002) and in both sedentary and endurance exercise trained individuals
(Lockwood et aI., 2005b; McCord et aI., 2006; McCord & Halliwill, 2006). Recent
evidence suggests this postexercise skeletal muscle hyperemia is mediated by two (HI
and H2) histamine receptor subtypes (Lockwood et al., 2005b; McCord et al., 2006;
McCord & Halliwill, 2006). While the mechanisms ofpostexercise hyperemia are
becoming more apparent, it is unclear what purpose this increased blood flow might
serve. Along these lines, Williams et al. investigated the relationship between leg blood
flow and oxygen uptake following 60 minutes of moderate-intensity exercise. They
found the time course of leg blood flow recovery did not match that of oxygen uptake,
suggesting skeletal muscle hyperemia does not subserve oxygen delivery to the
previously exercised skeletal muscle (Williams et al., 2005). The function, therefore, of
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this histamine-receptor-mediated hyperemia found after an acute bout of dynamic
exercise has yet to be elucidated.
It is well established that skeletal muscle glucose uptake is enhanced, in an
insulin-independent manner, during the first 90 minutes postexercise (Wasserman &
Halseth, 1998; Richter et ai., 2001a; Henriksen, 2002). Much research has focused on
the role of glucose transporters, primarily the GLUT4 isoform found in skeletal muscle,
on glucose uptake during and immediately following exercise (Kennedy et ai., 1999;
Thorell et ai., 1999). In contrast, the impact of postexercise hyperemia on glucose
delivery has been sparsely explored. Several investigations in both animals (Grubb,
1977; Schultz, 1977) and humans (Hickner et ai., 1991; Baron et ai., 1994; Durham et ai.,
2003) suggest increased limb blood flow enhances skeletal muscle glucose uptake.
However, these prior studies have not examined the relationship between skeletal muscle
blood flow and glucose kinetics following exercise. Therefore, the current investigation
was designed to determine if postexercise skeletal muscle hyperemia influences glucose
regulation via enhanced glucose kinetics following a bout of dynamic exercise. We
tested the hypothesis that the glycemic response to an oral glucose load (OGTT)
following exercise would be higher and more sustained with H l - and H2-receptor
blockade versus control.
Methods
This study was approved by the Institutional Review Board of the University of
Oregon and was conducted in accordance with the guidelines set forth by the Office for
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Protection of Human Subjects ofthe University of Oregon. Each subject gave his or her
written consent p110r to participation in the study.
Subjects
Twenty healthy, non-smoking, normotensive subjects (13 men; 7 women),
between the ages of20 and 35, participated in this study. Twelve subjects (8 men; 4
women) participated in an exercise protocol and eight subjects (5 men; 3 women)
participated in a sham (no exercise) protocol. For all study visits, subjects reported to the
laboratory at least three hours post-prandial, having refrained from alcohol consumption
and exercise for 24 hours and consumption of caffeine for 12 hours. Subjects were taking
no medications with the exception of oral contraceptives. In addition, female subjects
were studied during the early follicular phase of their menstrual cycle or during the
placebo phase of the oral contraceptive cycle, to minimize the potential effects of
reproductive honnones on cardiovascular and metabolic regulation.
Screening visit
Subjects participating in the exercise protocol initially visited the laboratory to
perfonn a peak aerobic power test on a cycle ergometer, in addition to self-reporting
activity levels on two questionnaires. Subjects performed an incremental cycle exercise
test (Lode Excaliber, Groningen, The Netherlands) comprised of I-minute workload
increments to detennine peak oxygen uptake (VOzpeak). Specifically, after a 2-minute
warm-up period of easy cycling (20-30 watts), workload was increased by 20, 25, or 30
watts every minute. Selection of the workload increment was based on self-reported
subject activity levels, with the goal of producing exhaustion within 8-12 minutes.
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Subjects were instructed to maintain 60-80 revolutions per minute to maximize muscular
efficiency. Whole body oxygen uptake was measured via a mixing chamber
(Parvomedics, Sandy, UT) integrated with a mass spectrometry system (Marquette MGA
1100, MA Tech Services, St. Louis, MO). Peak aerobic power was determined as either
when subjects were unable to maintain 60 revolutions per minute, had obtained a
respiratory exchange ratio of greater than 1.15, and/or had reached subjective exhaustion
[rating of perceived exertion on the Borg (Borg, 1970) scale of 19-20] within the 8- to
12-minute period.
After resting for approximately 10 minutes, subjects returned to the cycle
ergometer to determine the workload corresponding to a steady-state oxygen
consumption of 60% of V02 peak. The workload was titrated, as needed, to reach a steady
state oxygen consumption of 60% ofV02 peak, which was usually attained within 5
minutes. This workload was used on the exercise study day for the 60-minute exercise
bout, as this intensity and duration of exercise has been shown to evoke sustained (~1 00
minutes) postexercise skeletal muscle hyperemia (Pricher et al., 2004).
Experimentalprotocol
For both the sham and exercise protocols, subjects reported for parallel
experiments on 2 separate days. The order of experiments was randomized between a
combined HI- and H2-receptor antagonist (fexofenadine and ranitidine) and a control day.
HI-receptor antagonism was produced via oral administration of 540 mg fexofenadine
hydrochloride (Allegra; Aventis Pharmaceuticals Inc, Kansas City, MO). This oral dose
offexofenadine adequately and selectively blocks HI-receptors, with a half-life of
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approximately 12 hours and a time to peak concentration between 0.83 - 1.33 hours
(Russell et al., 1998). Fexofenadine is non-sedating, does not appear to cross the blood-
brain barrier or have anti-muscarinic effects (Hardman JG, 2001). Oral HI-receptor
antagonism via 540 mg fexofenadine has been shown to attenuate elevations in
postexercise femoral vascular conductance in humans (Lockwood et al., 2005b).
Hrreceptor antagonism was produced via oral administration of 300 mg
ranitidine hydrochloride (Zantac; Pfizer Consumer Healthcare, Morris Plains, NJ). This
oral dose of ranitidine adequately and selectively blocks H2-receptors, with a half-life of
2.6 hours and a time to peak concentration of2.2 hours (Garg et al., 1985). Ranitidine is
non-sedating, does not appear to cross the blood-brain barrier or have any cardiovascular
effects (Hardman JG, 2001). Oral Hrreceptor antagonism via 300 mg ranitidine has
been shown to blunt elevations in postexercise femoral vascular conductance in humans
(McCord et al., 2006).
On each study day, subjects were laid in the supine position for instrumentation.
An intravenous catheter was inselied retrogradely in the dorsal vein of the left hand to
obtain blood samples. During the exercise protocol, subjects underwent a 60-min period
of seated upright cycling at 60% V02 peak. Exercise of this intensity and duration
produces a sustained (~100 min) postexercise skeletal muscle hyperemia (Pricher et al.,
2004). During exercise, subjects consumed 10 ml of water per kilogram of body weight
to offset volume loss during exercise. During the sham study, the 60 minutes of cycling
was replaced with 60 minutes of quiet rest. Immediately after exercise or sham, each
subject consumed 0.1 oz per kg body weight (up to 10 oz maximum) Oral Glucose
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Tolerance Beverage (Trutol 100, NERL Diagnostics, East Providence, RI), which
contained 109 of glucose per oz. Therefore, subjects received an oral glucose dose of 1
g per kg body weight up to 100 g maximum. Measurements were taken in the supine
position ptior to exercise or sham and through 120 minutes following the oral glucose
tolerance test (OGTT). Pre-exercise and postexercise measurements included heart rate,
arterial pressure, femoral blood flow, as well as collection ofblood samples for
detetmination of oxygen saturation and concentrations of glucose, insulin, C-peptide, and
glucagon. During exercise, blood pressure and heart rate were measured every 15
minutes.
Measurements
Heart rate and arterial pressure
Heart rate was monitored throughout both protocols via 5-lead electrocardiogram
(Quinton Instruments, Bothell, WA). Arterial pressure was measured with an automated
oscillometric device (Dinamap Pro100 vital signs monitor, Critikon Inc, Tampa, FL)
during resting conditions. Arterial pressure during exercise was determined via manual
auscultometry.
Leg blood flow
Mean blood velocities and diameters of the common femoral artery were
measured using a linear ultrasound probe (10MHz linear-array vascular probe, GE
Vingmed System 5, Horton, Norway) placed distal to the inguinal ligament,
approximately 2-3 cm proximal to the bifurcation. The entire width of the artery was
insonated with an angle of 60 degrees and velocity measurements were taken
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immediately before diameter measurements. Leg blood flow was calculated as artery
cross-sectional area multiplied by femoral mean blood velocity, doubled to represent both
legs, and reported as ml . min-I. Leg vascular conductance was calculated as flow for both
legs/mean arterial pressure and expressed as ml . min-I. mmHg- l .
Arterialized blood samples
"Arterialization" of venous blood samples was accomplished by placing each
subject's cannulated hand in a custom-made heating chamber ("hot-box"), which was
flushed with air at 55° C. Actual skin temperature was raised to approximately 42° C,
which is below the temperature that evokes sensations of pain. Heating the hand in this
way induces the opening of arterial-venous anastomoses in the hand circulation, thereby
allowing investigators to sample "arterialized" venous blood with higher and less variable
oxygen saturations and higher glucose concentrations compared to non-arterialized blood
samples (Morris et al., 1997). Arterialization of venous blood samples was confirmed by
immediate measurement of oxygen saturation in duplicate by a co-oximeter (Radiometer
Copenhagen). Glucose concentrations of arterialized venous blood were measured in
duplicate with a clinical glucose analyzer (YSI 2300 Stat Plus Glucose and Lactate
Analyzer, YSI Life Sciences). Blood samples were collected pre-exercise, half-way
through exercise, immediately postexercise, and 10, 20, 30, 45, 60, 90, and 120 minutes
following oral glucose load. Samples were promptly placed on ice, centrifuged at 4° C,
separated, and stored at -80° C until analyzed.
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Blood hormone analysis
Analysis of insulin, glucagon, and C-peptide was conducted by the core lab at the
Oregon Clinical and Translational Research Institute (OCTRI) by standard methods.
Estimation ofmetabolic clearance rate and insulin sensitivity
The MCR est and lSI est indices, developed by Stumvoll and co-workers (2000)
use results from the OGTT to estimate metabolic clearance rate of glucose and insulin
sensitivity. Using subject BMI, plasma glucose, and plasma insulin data, they have a
high correlation (r 2: 0.79) with the euglycemic hyperinsulinemic clamp (Stumvoll et al.,
2000). They use the following equations:
MeR est (OGTT) = 18.8 - 0.271 BMI - 0.0052 x I 120 - 0.27 x G 90
lSI est (OGTT) = 0.226 - 0.0032 x BMI - 0.0000645 x I 120 - 0.0037 x G 90
where BMI = body mass index, I 120 = plasma insulin at 120 min OGTT, and G 90 =
plasma glucose at 90 min OGTT.
Leg glucose delivery
Delivery of glucose to the legs was calculated as the product of arterialized
glucose concentrations, derived from heated hand vein samples, and femoral blood flow
per the following equation:
Leg glucose delivery (mg min-I) = ((Arterialized [glucose] (mg dL-I)1100) x Leg blood flow (ml min-I))
Statistics
The results were analyzed with a Two-Way Repeated Measures ANOVA (effects
of drug and time) with SAS Proc Mixed (SAS v9.l, SAS Institute, Cary, NC).
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Differences were considered significant when P ::; 0.05. All values are reported as means
± SE unless otherwise noted.
Results
Subject characteristics
Subject characteristics are presented in Table 2. V02peak values are within the
normal range for young, healthy subjects of sedentary to endurance trained status.
Table 2. Subject characteristics-Chapter V.
Exercise protocol
N 12
Age (years) 24.3 ± 3.6
Height (cm) 182.5 ± 12.1
Weight (kg) 77.9 ± 18.7
Body mass index (kg m-2) 23.1 ± 3.3
V02 peak (ml kg -I min -I) 54.0 ± 9.1
Workload at 60% ofV02peak (watts) 180.5 ± 54.9
Baecke sport index (arbitrary units) 12.3 ± 3.1
Index of physical activity (METhrwk) 168.7 ± 61.2
Sham protocol
8
24.2 ± 5.3
179.4 ± 10.2
79.3 ± 14.7
24.5 ± 3.5
Values are means ± SD; V02 peak> peak oxygen consumption; MET, metabolic equivalents
Exercise
During the exercise protocol, the goal was to have each subject exercise for 60
minutes at 60% V02peak. The percentage ofheart rate reserve (heart rate reserve is
defined as maximal heart rate achieved during V02 peak testing minus the resting supine
heart rate) attained during exercise (control 70.22 ± 1.7%; blockade 69.82 ± 2.3%; P =
0.78) was consistent with the target workload. Heart rate increased from 53.1 ± 2.0 beats
min- I during supine rest to 150.8 ± 2.1 beats min- I during exercise (measured 30 min into
exercise bout) on the control day and from 51.2 ± 2.1 beats min- I during rest to 149.4 ±
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2.9 beats min-] during exercise on the blockade day (P < 0.05 vs. rest on both days).
Mean arterial pressure increased from 79.1 ± 1.1 mmHg during supine rest to 91.2 ± 1.9
mmHg during exercise on the control day and from 77.8 ± 1.5 rnrnHg during supine rest
to 90.3 ± 1.7 mmHg during exercise on the blockade day (both P < 0.05 vs. rest on both
days). During the sham protocol, pre-sham resting heart rate (control 53.8 ± 3.1;
blockade 53.5 ± 3.6 beats min-!; P = 0.898) and mean arterial pressure (control 76.5 ±
2.0; blockade 74.9 ± 1.7 mmHg; P = 0.232) did not differ between control and blockade
days. Moreover, during the sham period on both study days, neither heart rate (control
53.3 ± 3.3; blockade 55.0 ± 3.6 beats min-I; bothP~ 0.391 vs. baseline) nor arterial
pressure (control 77.2 ± 2.7; blockade 76.2 ± 1.8; bothP~ 0.072 vs. baseline) changed
from pre-sham supine rest.
Hemodynamics
Table 3 shows the hemodynamic data derived from the exercise protocol. On
both the control and blockade days, mean arterial pressure reached a nadir 45 minutes
following exercise (control 71.9 ± 1.2; blockade 75.9 ± 1.6 mmHg; P < 0.05 vs. control).
Heart rate (P ~ 0.16) and femoral blood flow (P ~ 0.185) were not different between
control and blockade days at any time point. However, as illustrated by Figure 6, the
sustained elevation in femoral vascular conductance during the control trials, expressed
as percent change from pre-exercise, was significantly blunted in the blockade trials,
through 120 minutes postexercise (all P S. 0.016 vs. control). Furthermore, whereas
femoral vascular conductance in the control condition remained 34.0 ± 14.8% above pre-
exercise levels through 120 minutes postexercise (P S. 0.039), femoral vascular
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conductance in the blockade condition remained significantly elevated (24.5 ± 13.8%; P
= 0.027) only through 30 minutes postexercise. During the sham protocol, heart rate (P 2:
0.139) and mean arterial pressure (P 2: 0.088) did not differ between the control and
blockade days at any time point.
Table 3. Exercise protocol hemodynamics. n = 12 for heart rate and mean arterial pressure;
n = 8 for femoral blood flow; *p < 0.05 vs. control at same time point. Values are means ± SE.
Heart rate
(beats min ,I)
Mean arterial pressure
(mmHg)
Femoral blood flow
(ml min,l)
Time Control Blockade Control Blockade Control Blockade
Baseline
Exercise
Post-I5
Post-30
Post-45
Post-60
Post-75
Post-90
Post-I05
Post-120
53.1 ± 2.0 51.2 ± 2.1
150.8±2.1 149.4±2.9
71 ± 2.7 69.8 ± 2.6
64.6 ± 2.3 66.2 ± 2.7
62.9 ± 2.2 65.4 ± 2.8
62.4 ± 2.0 64.1 ± 2.6
60.8 ± 2.1 62.5 ± 2.6
61.5 ± 2.6 61.9 ± 2.5
61.0 ± 2.3 61.8 ± 2.4
61.3 ± 2.5 61.0 ± 2.7
79.1 ± 1.1 77.8 ± 1.5
91.2 ± 1.9 90.3 ± 1.7
79.7 ± 1.8 81.1 ± 1.9
75.5 ± 1.4 *78.2 ± 1.7
71.9 ± 1.2 *75.9 ± 1.6
72.5 ± 1.2 *76.0 ± 1.9
73.6 ± 1.0 76.0 ± 1.7
75.1 ± 1.2 76.5 ± 1.7
75.6 ± 1.5 77.2 ± 2.0
76.5 ± 1.4 77.2 ± 1.8
136.6 ± 32.2 142.1± 29.4
N/A N/A
208.1 ± 37.8 187.3 ± 26.9
192.5 ± 37.2 166.8 ± 27.3
180.9 ± 36.6 155.4 ± 29.4
179.9 ± 35.4 151.5 ± 29.1
180.9 ± 33.8 147.9 ± 27.3
169.3 ± 32.9 145.5 ± 28.9
164.3 ± 32.7 138.7 ± 30.5
159.2 ± 30.8 136.1 ± 29.2
Figure 6. Percent change in femoral vascular conductance from pre-exercise
baseline in response to 60 minutes of cycling at 60% of VOZpeak. Open circles
denote control day; filled circles denote H j - and Hrreceptor blockade (fexofenadine
and ranitidine) day. n = 8. *P < 0.05 vs. control at same time point. t P < 0.05 vs.
pre-exercise control; t P < 0.05 vs. pre-exercise blockade.
140120
* *
10080604020
t ;. t
t t -0- Control
--+- Blockade
t t
*
*
100
<l)
u 80c
Cll~~ <l)
u (J)
-6 .~ 60c Q>
0 X
<-) Q>I
.... Q>
Cll .... 40::;0...
u E(J)
Cll 0
>./:: 20(ij<l
o~
E~
0Q>
u.
-20
0
Time Postexercise (min)
97
Glycemic and insulin response to oral glucose load
During the sham protocol, baseline blood glucose concentrations were not
different between control (75.4 ± 1.7 mg dL'I) and blockade (78.2 ± 1.3 mg dL'I) days (P
= 0.255). Blood glucose concentration during the sham period was 77.2 ± 2.0 mg dL'1 on
the control day and 80.0 ± 1.4 mg dL'1 on the blockade day (P = 0.316 ys. control).
Figure 7 shows the glycemic and insulin response, expressed as change from immediate
post-sham baseline, to the oral glucose load during the sham protocol. Blood glucose
concentration immediately before glucose load was 77.1 ± 2.1 mg dL'1 on the control day
and 77.6 ± 1.0 mg dL'1 on the blockade day (P = 0.829 ys. control). During both the
control (.6. 67.2 ± 7.2 mg dL'I) and blockade (.6. 64.2 ± 7.2 mg dL'I; P = 0.751 ys. control)
days, blood glucose concentration peaked 45 minutes following the oral glucose load. At
no time point during the sham protocol did the glycemic response differ between the
control and blockade days (P 2': 0.271). During the sham protocol, baseline plasma
insulin concentrations were not different between control (4.49 ± 1.2 /lID mL'I) and
blockade (6.10 ± 1.5 /lID mL'I) days (P = 0.072). Plasma insulin concentration during
the sham period was 4.61 ± 1.2 /lID mL'1 on the control day and 5.91 ± 1.7 /lID mL'1 on
the blockade day (P = 0.239 YS. control). Plasma insulin concentration immediately
before glucose load was 3.90 ± 0.95 /lID mL'1 on the control day and 4.60 ± 1.3 /lID mL-1
on the blockade day (P = 0.190 YS. control). As shown in Figure 7B, on both the control
(.6. 21.1 ± 3.9 /lID mL'I) and blockade (.6. 19.1 ± 8.8 /lID mL'I; P= 0.830 YS. control)
days, plasma insulin concentration reached its peak 90 minutes following the glucose
98
load. At no time point during the sham protocol did the plasma insulin response to oral
glucose load differ between the control and blockade days (P ~ 0.160).
Figure 7. Sham protocol: change in (A) blood glucose and (B) plasma insulin
in response to oral glucose load. Open circles denote control day; filled circles denote
H 1- and Hrreceptor blockade (fexofenadine and ranitidine) day. n = 8.
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During the exercise protocol, pre-exercise blood glucose concentrations were not
different between control (80.6 ± 1.2 mg dL-1) and blockade (81.0 ± 1.6 mg dL-1) days (P
= 0.799). Blood glucose concentration during exercise was 76.6 ± 2.2 mg dL- I on the
control day and 75.0 ± 2.4 mg del on the blockade day (P = 0.282 vs. control). Figure 8
99
shows the glycemic and insulin response, expressed as change from immediate
postexercise baseline, to the oral glucose load during the exercise protocol. Blood
glucose concentration immediately before glucose load was 79.6 ± 2.7 mg dL-1 on the
control day and 76.6 ± 2.3 mg dL-1 on the blockade day (P = 0.167 vs. control). During
both the control (.6. 62.1 ± 6.7 mg dL-1) and blockade (.6. 65.7 ± 3.4 mg dL- 1; P= 0.517 vs.
control) days, change in blood glucose concentration was greatest 45 minutes following
glucose load. As illustrated by Figure 8A, 90 minutes following oral glucose load blood
glucose concentration remained more elevated on the blockade (.6. 46.9 ± 4.1 mg dL-1)
than on the control day (.6. 33.1 ± 6.8 mg dL- 1; P = 0.016 vs. blockade). During the
exercise protocol, pre-exercise plasma insulin concentrations were not different between
control (3.58 ± 0.5 JlIU mL-1) and blockade (3.84 ± 0.5 JlIU mL-1) days (P = 0.669).
Plasma insulin concentration during exercise was 1.82 ± 0.1 JlIU mL-1 on the control day
and 2.33 ± 0.3 JlIU mL- 1 on the blockade day (P = 0.139 vs. control). Plasma insulin
concentration immediately before glucose load was 3.59 ± 0.6 JlIU mL-1 on the control
day and 3.65 ± 0.5 JlIU mL-1 on the blockade day (P = 0.939 vs. control). As shown in
Figure 8B, on both the control (1'\ 13.2 ± 2.4 JlIU mL-1) and blockade (1'\ 17.6 ± 4.8 JlIU
mL-1; P = 0.299 vs. control) days, plasma insulin concentration peaked 30 minutes
following the glucose load. As shown in Figure 8B, 120 minutes following the glucose
load, plasma insulin concentration remained more elevated on the blockade day (.6. 11.5 ±
2.9 JlIU mL-1) than on the control day (.6. 5.6 ± 2.0 JlIU mL-1; P = 0.047 vs. blockade).
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Figure 8. Exercise protocol: change in (A) blood glucose and (B) plasma insulin
following postexercise oral glucose load. Open circles denote control day; filled
circles denote H I - and Hrreceptor blockade (fexofenadine and ranitidine) day. n = 12.
* p < 0.05 ys. control at same time point.
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Metabolic clearance rate and insulin sensitivity index
The estimated metabolic clearance rates of glucose and the insulin sensitivity
indices in response to oral glucose load following both sham and exercise are shown in
Figure 9. During the sham protocol, there was rio difference between the estimated
metabolic clearance rates on the control (14.17 ± 0.38 mg ki l min-I) and blockade days
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(14.04 ± 0.38 mg kg-I min-I; P = 0.453 vs. control). Likewise, during the exercise
protocol estimated metabolic clearance rates were not different between control (14.45 ±
0.26 mg kg-I min-I) and blockade days (14.3 ± 0.25 mg kg-I min-I; P = 0.132 vs. control).
The estimated insulin sensitivity during the sham protocol was not different
between the control (0.175 ± 0.005 ~mol kg- I min-I pM-I) and blockade trials (0.173 ±
0.005 ~mol kg- I min-I pM-I; p = 0.459 vs. control). There were also no differences in
estimated insulin sensitivity between the control (0.178 ± 0.003 ~mol kg-I min-I pM-I)
and blockade (0.176 ± 0.003 ~mol kg-I min- I pM-I; p = 0.182 vs. control) days during the
exercise protocol.
Leg glucose delivery
Estimated leg glucose delivery, both before and following postexercise oral
glucose load, is shown in Figure 10. There was no difference in leg glucose delivery
between the control (108.7 ± 26.4 mg min-I) and blockade (115.7 ± 27.6 mg min-I) days
prior to exercise (P = 0.556). There was a trend towards enhanced leg glucose delivery
on the control day at 30 minutes (control 264.4 ± 56.6 mg min-I; blockade 236.1 ± 46.8
mg min-I) and 60 min (control 225.7 ± 45.2 mg min-I; blockade 204.3 ± 37.7 mg min-I)
postexercise, although differences in these values were not statistically significant at
either time point (both P = 0.385). At 90 minutes postexercise, leg glucose delivery was
182.1 ± 43.9 mg min-Ion the control day and 183.9 ± 39.3 mg min-Ion the blockade day
(P = 0.933).
102
c=::J Control
_ Blockade
ExerciseSham
A
o -'-- .L----I_
20
15
OJ .....~
(.) I
C C
~ 'E
co
.!!2 "';" 10
(.) (J)
(.) ~
- (J)
.8£
co
Q5 5
E
-0
OJ
cu
E
~
w
Figure 9. Estimated (A) metabolic clearance rate of glucose and (B) Insulin sensitivity
index to oral glucose load following sham and exercise. Open bars denote control day; filled bars
denote HJ- and Hz-receptor blockade (fexofenadine and ranitidine) day. n = 8 for sham protocol; n = 12
for exercise protocol.
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Figure 10. Leg glucose delivery before and after postexercise oral glucose load.
Open circles denote control day; filled circles denote H j - and Hrreceptor blockade
(fexofenadine and ranitidine) day. n = 8.
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The goal of this study was to detennine the effect ofthe combination of orally
administered H j- and Hz-receptor antagonists on glucose regulation following a
postexercise oral glucose load. In agreement with our hypothesis, the glycemic response
to postexercise oral glucose load was more sustained on the H j- and Hz-receptor blockade
versus the control day, suggesting a histaminergic effect on postexercise glucose kinetics.
The finding that the glycemic response to an oral glucose load is prolonged during
Hj- and Hz-receptor antagonism suggests delivery of glucose to skeletal muscle cells is
blunted in the blockade condition. It has recently been established that combined oral
Hj- and Hz-receptor blockade attenuates postexercise hyperemia in previously active
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skeletal muscles by approximately 80% (McCord & Halliwill, 2006) which is in line with
the postexercise hyperemia found in the current study. While the current investigation
does not allow for direct measurement of glucose delivery to the skeletal muscle cells per
se, it implies glucose regulation is a function of skeletal muscle hyperemia following
dynamic exercise.
It is natural to consider the delivery of glucose itself as a potential key function of
postexercise hyperemia. However, perhaps equally crucial to the regulation of blood
glucose is the delivery of insulin to the microvasculature, where it can impose both its
hemodynamic and metabolic effects. Along these lines, physiological concentrations of
insulin have been shown to evoke increased limb blood flow (Laakso et ai., 1990) and
capillary recruitment (Coggins et ai., 2001) in humans. This insulin-mediated
vasodilation and capillary recruitment is dependent upon nitric oxide, as nitric oxide
synthase inhibition diminishes microvascular recruitment and, importantly, insulin-
mediated skeletal muscle glucose uptake (Steinberg et ai., 1994; Vincent et ai., 2003).
Movement of insulin from the central circulation to the skeletal muscle microvasculature
and subsequently to the interstitium is required to initiate this capillary recruitment,
therefore anything that aids insulin transport to the interstitium should accelerate muscle
glucose uptake. Skeletal muscle glucose uptake tracks the timeframe of interstitial
insulin levels better than plasma insulin levels, which suggests insulin delivery to the
interstitium is crucial in timely muscle glucose uptake (Miles et ai., 1995; Vincent et ai.,
2005). This notion is supported by a recent study by Chiu and coworkers who found
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intramuscular injection of insulin resulted in an immediate rise in hindlimb glucose
uptake in dogs (Chiu et al., 2008).
Evidence suggests insulin-mediated capillary recruitment occurs quickly, while
insulin-mediated increases in limb blood flow are slower, and delayed relative to muscle
glucose uptake (Vincent et al., 2004). Only about 30% of capillaries are perfused at rest
(Honig et al., 1982), which implies a flow limitation to skeletal muscle insulin and/or
glucose delivery under resting conditions (Vincent et a!., 2005), as opposed to conditions
in which capillary recruitment is increased. In fact, it has been suggested in situations
where skeletal muscle glucose uptake is elevated, increases in limb blood flow will
increase insulin delivery to facilitate further glucose delivery, especially when capillary
recruitment is augmented (Clark et al., 2003; Clerk et a!., 2004). Thus, as previously
suggested, it seems insulin is not only a mediator of its own delivery (Vincent et a!.,
2005) but it appears both insulin-mediated vasodilation and capillary recruitment are key
regulators of muscle glucose uptake. Therefore, since insulin mediates glucose uptake
via metabolic and vasculature actions, postexercise skeletal muscle hyperemia likely
facilitates this process by enhancing delivery of insulin to the microvasculature when the
stimulus for glucose uptake is high, such as following exercise. If this insulin delivery is
attenuated by H j - and H2-receptor antagonists, that could help explain the prolonged
glycemic response on the blockade days.
Another factor that may help explain the sustained glycemic response during H j -
and Hrreceptor blockade is the potential effect ofH j - and H2-receptor antagonists on
vascular permeability. If capillaries demonstrate a histaminergic increase in permeability
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following exercise, diffusion of glucose to the muscle cells would be expected to decline
during HI- and Hz-receptor blockade, resulting in greater recirculation of glucose.
Histamine evokes a rapid and transient increase in microvascular permeability (Majno &
Palade, 1961; Killackey et al., 1986; Hill et aI., 1997; van Hinsbergh & van Nieuw
Amerongen, 2002) that is mediated by HI-receptors and may be reversed by
administration of HI-receptor antagonists (Niimi et al., 1992). While this effect has been
typically observed in the post-capillary venules (Svensjo & Grega, 1986; van Hinsbergh
& van Nieuw Arnerongen, 2002) and in studies on cultured human umbilical vein
endothelial cells (Niimi et al., 1992; Ikeda et al., 1999), there is a dearth of evidence HI-
receptors mediate increases in permeability at the level of the capillary. Furthermore,
permeability responses to histamine differ between arterial and venular vessels, as
histamine has been shown to evoke an Hz-receptor mediated reduction in vascular
permeability in cultured bovine aortic endothelial cells (Ikeda et al., 1999). Therefore,
while histaminergic effects on capillary permeability may factor into the enhanced
glycemic response to postexercise oral glucose load during HI- and Hz-receptor blockade,
there is currently limited evidence to support this notion.
A fourth possible explanation for the results of the current investigation is that
orally administered HI- and Hz-receptor antagonists following exercise may inhibit the
transport of glucose into skeletal muscle cells. Blunted glucose transpoli would reduce
the concentration gradient between the capillaries and the interstitial space, reducing
diffusion of glucose and leading to the sustained elevation of blood glucose in response to
oral glucose load. However, although histamine has been shown to stimulate glucose
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transport in cultured cardiac endothelial cells in an Hj-receptor-dependent manner, this
result was attributed to effects on endothelial permeability, as opposed to factors such as
enhanced GLUT4 translocation (Thomas et al., 1995). Furthermore we were unable to
find compelling evidence of a histaminergic effect on skeletal muscle glucose transport or
GLUT4 activity, so we cannot determine if this is a mechanism that factors into the
results of our investigation.
If pancreatic insulin secretion were lessened by H j- and Hrreceptor antagonists,
this could help explain the prolonged elevation in blood glucose following postexercise
oral glucose load. However, insulin release in response to intravenous glucose
administration has been shown to be unaltered by Hj- and H2-receptor antagonists
(Pontiroli et al., 1982) and Hrreceptor blockade had no effect on insulin secretion
following oral glucose tolerance tests (Scarpignato et al., 1981). Moreover, in the current
investigation, the plasma insulin response to postexercise oral glucose load was equal or
greater on the blockade day, which argues against blunted insulin secretion due to Hj-
and H2-receptor blockade.
An effect ofH j- and Hrreceptor antagonism on hepatic glucose uptake or release
could contribute to the prolonged glycemic response to the postexercise oral glucose load
during Hj- and Hrreceptor blockade. However, we were unable to find evidence of
reduced hepatic glucose uptake or enhanced hepatic production during H j- and Hr
receptor blockade. Moreover, the combination of postexercise sympathetic withdrawal
(Halliwill et al., 1996a) and consumption of an oral glucose beverage should suppress
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glucogenesis, likely minimizing any impact of H1- and H2-receptor blockade in this
scenario.
Finally, an impact of H1- and H2-receptor blockade on gastric emptying could
help explain the sustained postexercise glycemic response in the current study. Previous
investigations on the effect of oral H2-receptor antagonists on gastric emptying have
yielded equivocal results, as H2-receptor blockade has been found to facilitate (Ohira et
al., 1993) and delay (Forrest et al., 1976) gastric emptying in humans. However, in the
current investigation, the sham protocol was undertaken to examine the effect of H1- and
H2-receptor blockade on the glycemic response to oral glucose load in the absence of
prior exercise. We found no difference in the glycemic or insulin response between the
control and blockade days during the sham protocol. Combined with the nearly
superimposable rise in blood glucose in response to the postexercise oral glucose load,
this indicates any effects of H1- and H2-receptor blockade on gastric emptying in our
study were minimal.
Afethodologicalconsiderations
Although the oral glucose tolerance test (OGTT) has been widely used to assess
glucose tolerance in a wide array of populations (Cobelli et al., 2007), numerous factors
associated with the OGTT may affect its reproducibility. These factors include variations
in glucose absorption, neuro-hormonal interactions, splanchnic glucose uptake, and
possible effects on incretin hormones, which are known to stimulate insulin secretion in
response to glucose ingestion (Muniyappa et al., 2008). However, when combined with
various indices of insulin sensitivity and/or modeling techniques, the OGTT can be used
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to estimate ~-cell function and insulin sensitivity in humans. Furthennore, significant
advantages of OGTT include its more physiological delivery of glucose, its relative ease
of use, and reduced invasiveness, relative to the FSIVGT and eug1ycemic
hyperinsulinemic clamp. Finally, as previously indicated, the results of our sham
protocol suggest the combined H1- and H2-receptor blockade had no discemable effect on
the glycemic response to OGTT in the absence of previous exercise.
As previously noted,~ oral administration of H1- and H2-receptor antagonists may
evoke systemic effects and induce counter-regulatory responses. However, given the
widespread use of fexofenadine and ranitidine to treat allergies and gastrointestinal
disorders, the relevance of using oral blockade in the current study outweighed potential
systemic effects.
An unexpected finding in the current investigation was the lack of difference in
the estimated metabolic clearance rates of glucose and insulin sensitivity indices between
the control and blockade days following postexercise oral glucose load. Given the
sustained postexercise glycemic response and the equal or greater insulin response on the
H1- and H2-receptor blockade day, we were anticipating that both the estimated metabolic
clearance rate of glucose and insulin sensitivity index would be higher on the control day.
Along these lines, although no statistically significant differences existed between the
control and blockade days, there was a trend for enhanced leg glucose delivery under the
control condition. However, the MeR est and lSI est indices, which are well correlated
(r 2: 0.79) with the euglycemic hyperinsulinemic clamp (Stumvoll et al., 2000) indicated
no differences in metabolic clearance rate of glucose or insulin sensitivity between the
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control and blockade trials. Therefore, to further investigate these parameters, we plan on
using recently analyzed C-peptide samples in conjunction with the minimal model
technique.
Perspectives
The results ofthe current investigation indicate commonly used medications may
impact normal glucose regulation following exercise. Although the current investigation
was conducted on healthy subjects, these findings reveal potential implications ofH j - and
H2-receptor antagonists for those who depend on exercise to regulate their blood glucose
levels. This may be particularly relevant to populations which have reduced skeletal
muscle perfusion, such as the aged, obese individuals and those suffering from diabetes.
For example, it is possible that by mediating glucose regulation, postexercise hyperemia
may be an important mechanism by which to circumvent insulin resistance in diabetes.
Furthermore, effects of these widespread medications may confound exercise as a
"treatment" for both the healthy population and those suffering from various diseases.
Further research is warranted to investigate the mechanisms behind this apparent
relationship between cardiovascular and metabolic regulation, including studies to
determine if these findings extend to those with disease, such as those suffering from
diabetes.
In conclusion, the glycemic response to postexercise oral glucose load was more
sustained on the H j - and H2-receptor blockade versus control day. This finding suggests a
histaminergic effect on postexercise glucose kinetics in humans.
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CHAPTER VI
CONCLUSIONS
Please note: This chapter has been written in the general fonnat of a brief, contemporary
review as an initial draft for future submission to Exercise and Sport Science Reviews.
Unlike reviews from Exercise and Sport Science Reviews however, I have cited
unpublished findings and have referred to figures included within this dissertation.
Introduction
Over the past several years, there have been substantial advances in our
understanding of blood flow regulation following dynamic exercise in humans. It has
become clear that acute exercise induces a sustained rise in blood flow, with the vast
majority of this blood being directed to skeletal muscle. The function of this skeletal
muscle hyperemia, however, has only recently been investigated. Current work in our
laboratory is focused on the relationship between skeletal muscle hyperemia and the well
established increase in skeletal muscle glucose uptake following acute exercise.
Therefore, the purpose of this review is to examine this emerging area of study, aimed at
detennining the impact of postexercise skeletal muscle hyperemia on glucose regulation
in humans.
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Regional changes in postexercise vascular conductance
Humans experience a sustained drop in systemic vascular resistance (Halliwill,
2001) following a bout of dynamic exercise. Postexercise reductions have been found in
calf(Hara & Floras, 1992; Halliwill et aI., 2000) and forearm vascular resistance in both
healthy individuals (Coats et aI., 1989) and those with mild to moderate hypertension
(Cleroux et al., 1992). Thus, vasodilation is found in both previously active and inactive
regions following dynamic exercise.
Pricher et aI. found that both postexercise splanchnic and renal vascular
conductance was not different from preexercise levels, but elevations in leg vascular
conductance were sustained for 100 minutes following exercise (Pricher et al., 2004).
In a companion study, Wilkins and colleagues found, despite an elevation in core body
temperature that persisted for 90 minutes postexercise, cutaneous vascular conductance
quickly returned to the level prior to the exercise bout (Wilkins et aI., 2004b). A recent
investigation found overall cerebral blood flow to be unchanged and blood flow to some
regions (e.g., insular cortex) to be reduced following exercise that evoked postexercise
hypotension (Williamson et al., 2004). Thus, it does not appear that vasodilation of the
renal, splanchnic, cerebral, or cutaneous vasculature contributes to the rise in systemic
vascular conductance following dynamic exercise. Rather, the primary contributors to
increases in postexercise systemic vascular conductance seem to be elevations in blood
flow to previously exercised and non-exercised skeletal muscles (skeletal muscle
hyperemia).
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Mechanisms of postexercise vasodilation
The sustained vasodilation observed in humans following dynamic exercise is
mediated by both neural and vascular factors (Halliwill et ai., 1996a). Following an
acute bout of dynamic exercise, there is a downward resetting of the arterial baroreflex,
so muscle sympathetic nervous activity is attenuated for a given diastolic blood pressure
(Halliwill et ai., 1996a). This resetting occurs at the level of the central nervous system,
as opposed to changes in baroreceptors sensitivity, per se (Halliwill et ai., 1996b).
Reduced vasoconstrictor responses to given levels of sympathetic outflow also
contribute to elevated vascular conductance following exercise (Halliwill et ai., 1996a).
This blunted transduction of sympathetic outflow into vasoconstriction most likely results
from inhibition of pre-synaptic neurotransmitter release, rather than the effects of local
vasodilators on the vasculature following exercise (Hara & Floras, 1992; Halliwill et ai.,
1996a; Halliwill et ai., 2003).
Recently it was discovered that ingestion of the H[-receptor antagonist
fexofenadine hydrochloride attenuates elevations in femoral vascular conductance
following exercise and the effect is most pronounced during the first 30 minutes
following exercise (Lockwood et al., 2005b). McCord and coworkers investigated the
role of Hz-receptors in postexercise vasodilation and found the Hz-receptor antagonist
ranitidine blunted increases in femoral and brachial vascular conductance following
exercise, with the effect most pronounced from 60-90 minutes postexercise (McCord et
ai.,2006). Subsequently, when combined H1- and Hz-receptor antagonists were ingested
by both sedentary and endurance trained individuals, the hyperemia seen through 90
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minutes postexercise in the control condition was reduced by 80% (McCord & Halliwill,
2006). Thus it has become clear H\- and H2 -receptors playa key role in mediating
postexercise hyperemia in both trained and untrained men and women.
Function of postexercise skeletal muscle hyperemia?
Although our understanding of the mechanisms underlying postexercise skeletal
muscle hyperemia has evolved over the last few years, the function of this sustained
elevation in blood flow has been elusive. In examining the relationship between leg
blood flow and oxygen uptake following exercise, Williams et al. found the time course
of leg blood flow recovery did not match that of oxygen uptake, suggesting the skeletal
muscle hyperemia does not subserve oxygen delivery to the previously exercised muscle
(Williams et ai., 2005).
It is possible that postexercise skeletal muscle hyperemia plays a role in glucose
regulation, as skeletal muscle glucose uptake is augmented, in an insulin-independent
manner, the first 90 minutes postexercise (Wasserman & Halseth, 1998). The glucose
taken up following exercise contributes to glycogen repletion in humans (Casey et ai.,
2000) and the rate of glycogen synthesis is typically highest the first 30 minutes
following exercise (Price et al., 1994). Furthermore, as illustrated by studies employing
single-legged exercise in humans (Bergstrom & Hultman, 1966; Richter et ai., 1989),
glucose uptake and glycogen repletion occur preferentially in the previously exercised
skeletal muscle. Investigations into the effect of blood flow manipulation on glucose
delivery have suggested increased limb blood flow enhances skeletal muscle glucose
uptake (Hickner et ai., 1991; Baron et ai., 1994; Durham et ai., 2003). However, while
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mechanisms surrounding both postexercise skeletal muscle hyperemia and postexercise
glucose regulation have been investigated, there is a dearth of information about the
relationship between these factors.
Effect of local Hr and Hrreceptor blockade on postexercise interstitial glucose
Recently, we set out to detennine the effect oflocal H j- and Hz-receptor
blockade, administered via skeletal muscle microdialysis, on postexercise interstitial
glucose concentrations (Chapter IV). Skeletal muscle microdialysis is an elegant
teclmique that allows continuous delivery of drugs to the interstitial space via a semi-
pemleable membrane, while simultaneously monitoring concentrations of various
substances within the interstitium (Hickner, 2000). In addition, whereas orally
administered H1- and Hz-receptor antagonists may evoke systemic effects and induce
counter-regulatory responses, muscle microdialysis allows targeted delivery of drugs and
the ability to isolate a specific region from which to sample.
We predicted postexercise interstitial glucose concentrations, as determined by
muscle microdialysis, would be higher in the control versus the combined Hj- and Hz-
receptor antagonist sites. Immediately following 60 minutes of moderate intensity
cycling exercise, subjects were placed supine and four muscle microdialysis fibers were
placed into the vastus lateralis. Two probes were randomly perfused with a physiological
control solution and two probes were perfused with the same solution with the addition of
a combination of 1 mM Hj-receptor antagonist pyrilamine maleate and 3 mM Hz-receptor
antagonist cimetidine, to block local Hj- and Hz-receptors. All four probes also
contained ethanol and tritiated glucose, which served as an internal reference marker to
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determine probe recovery. Ethanol readily diffuses through the probe membrane and is
not metabolized by the muscle, so the ratio of ethanol recovered in the outflowing
dialysate to the inf10wing perfusate (outflow-inflow ratio) is an inverse surrogate oflocal
blood flow.
Starting 15 minutes after probe insertion, dialysate was collected in
microcentrifuge tubes which were replaced every 20 minutes, through 135 minutes
postexercise (l00 minutes post fiber insertion) and subjects consumed an oral glucose
tolerance beverage half way through collection of dialysate. As illustrated in Chapter IV,
Figure 3B, the ethanol outflow-inflow ratio was lower at 55 and 75 minutes postexercise
in the control sites than in the blockade sites, indicating a greater relative local blood flow
in the control sites. As seen in Figure 4B, interstitial glucose concentrations were also
higher in the control sites at 55, 95 and 135 minutes postexercise. Taken together, these
results indicate postexercise delivery of glucose to the interstitial space of the previously
active skeletal muscle is mediated, in part, by local H\- and H2-receptors.
Effect of oral H1- and Hz-receptor blockade on postexercise glycemic response
In addition to studying glucose delivery at the level of the skeletal muscle, we
examined the effects ofH\- and H2-receptor antagonism on systemic glucose
concentrations following exercise (Chapter V). We tested the hypothesis that the
glycemic response to an oral glucose load following exercise would be more sustained
with oral H\- and Hrreceptor blockade versus control. Subjects underwent oral glucose
tolerance tests after 60 minutes of moderate intensity exercise on both a control and
blockade day, when they received a combination ofH\- and Hrreceptor antagonists
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(Allegra and Zantac). In agreement with previous research, the postexercise hyperemia,
as assessed by changes in femoral vascular conductance, was markedly reduced on the
blockade day. Moreover, on the blockade day the glycemic response to postexercise oral
glucose load was greater 90 minutes postexercise. This sustained glycemic response
during blockade suggests a histaminergic effect on postexercise glucose regulation.
Proposed interactions between postexercise hyperemia and glucose regulation
Illustration 2 shows the proposed relationship between blood flow and glucose
regulation following exercise. As shown in the illustration, when the HI- and Hz-receptor
antagonists (represented by the encircled b) bind to the HI-receptors, located on the
vascular endothelium or Hz-receptors, located on the vascular smooth muscle of the
resistance vessel, the normal histaminergic dilation (presumably mediated by histamine,
represented by the encircled h) is diminished. This results in reduced blood flow and thus
reduced glucose delivery to the capillaries, where diffusion of nuttients occurs. When
interpreting the results of the two previous studies, it is likely postexercise skeletal
muscle hyperemia plays a significant role in glucose delivery, as local blockade reduces
interstitial glucose concentration and oral blockade augments arterialized blood glucose
concentration.
It is intuitive to consider the delivery of glucose itself as a potential key purpose
of postexercise hyperemia. However, perhaps just as important to the regulation of blood
glucose is the delivery of insulin to the microvasculature, where it can impose both its
hemodynamic and metabolic effects. Along these lines, physiological concentrations of
insulin have been shown to evoke increased capillary recruitment in humans (Coggins et
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al.,2001). This insulin-mediated capillary recruitment is dependent upon nitric oxide, as
nittic oxide synthase inhibition attenuates microvascular recruitment and, importantly,
insulin-mediated skeletal muscle glucose uptake (Vincent et al., 2003). Transport of
insulin from the central circulation to the skeletal muscle microvasculature is required to
initiate this capillary recruitment; therefore anything that promotes insulin transport to the
interstitium should accelerate muscle glucose uptake. Skeletal muscle glucose uptake
tracks the timeframe of interstitial insulin levels better than plasma insulin levels, which
suggests insulin delivery to the interstitium is crucial in timely muscle glucose uptake
(Vincent et al., 2005). This notion is supported by a recent study by Chiu and coworkers
who found intramuscular injection of insulin resulted in an immediate rise in hindlimb
glucose uptake in dogs (Chiu et al., 2008).
Evidence suggests insulin-mediated capillary recruitment occurs quickly, while
insulin-mediated increases in limb blood flow are slower, and delayed relative to muscle
glucose uptake (Vincent et al., 2004). Only about 30% of capillaries are perfused at rest
(Honig et al., 1982), which implies a flow limitation to skeletal muscle insulin and/or
glucose delivery under resting conditions (Vincent et al., 2005), as opposed to conditions
in which capillary recruitment is increased. In fact, it has been suggested in situations
where skeletal muscle glucose uptake is elevated, increases in limb blood flow will
increase insulin delivery to facilitate further glucose delivery, especially when capillary
recruitment is augmented (Clerk et al., 2004). In Illustration 2 the dashed lines branching
off of the arteriole represent unrecruited capillmies, as a result of attenuated insulin
delivery to the microvasculature during H1- and Hz-receptor blockade.
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Illustration 2. Proposed interactions between postexercise hyperemia and glucose
regulation. The encircled b's represent H t - and Hrreceptor antagonists. The encircled
h represents histamine.
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In addition to reduced capillary recruitment, blunted insulin delivery will
adversely impact GLUT4 translocation to the skeletal muscle cell surface, thereby
inhibiting glucose transport into the myocyte. Thus, as previously suggested, it seems
insulin is not only a mediator of its own delivery (Vincent et aI., 2005) but it appears both
insulin-mediated vasodilation and capillary recruitment are key regulators of muscle
glucose uptake. Therefore, since insulin mediates glucose uptake via metabolic and
vasculature actions, postexercise skeletal muscle hyperemia likely facilitates this process
by enhancing delivery of insulin to the microvasculature when the stimulus for glucose
uptake is high, such as following exercise. If this insulin delivery is hindered by H 1- and
H2-receptor antagonists, that could help explain both the prolonged glycemic response
and the reduced interstitial glucose concentrations in the face of HI- and H2-receptor
blockade.
Another factor that may help explain both the sustained glycemic response during
oral HI- and H2-receptor blockade and the reduced interstitial glucose concentrations
during local HI- and H2-receptor blockade is the potential effect of HI- and H2-receptor
antagonists on vascular permeability. If capillaries demonstrate a histaminergic increase
in permeability following exercise, diffusion of glucose to the muscle cells would be
expected to decline during HI- and H2-receptor blockade, resulting in less delivery and
greater recirculation of glucose. Histamine evokes a rapid and transient increase in
microvascular permeability (van Hinsbergh & van Nieuw Amerongen, 2002) that is
mediated by HI-receptors and may be reversed by administration of HI-receptor
antagonists (Niimi et al., 1992). While this effect has been typically observed in the post-
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capillary venules (Svensjo & Grega, 1986) and in studies on cultured human umbilical
vein endothelial cells (Niimi et al., 1992; Ikeda et al., 1999), there is a lack of compelling
evidence H\-receptors mediate increases in permeability at the level of the capillary.
Furthermore, permeability responses to histamine differ between arterial and venular
vessels, as histamine has been shown to evoke an Hz-receptor mediated reduction in
vascular permeability in cultured bovine aortic endothelial cells (Ikeda et al., 1999).
Therefore, while histaminergic effects on capillary permeability may playa role in
postexercise glucose kinetics, there is currently limited evidence to lend credence to this
notion.
Future directions
Although the recent investigations discussed in this review have shed some light
on interactions between skeletal muscle hyperemia and glucose regulation following
exercise, there are still a myriad of questions to be answered. There is much to learn
about the events downstream of glucose transport, as studies utilizing muscle biopsy or
magnetic resonance spectroscopy to examine how postexercise skeletal muscle glycogen
concentrations are affected by H\- and Hz-receptor antagonists are warranted. Studies
utilizing the triple-tracer method or investigations measuring glucose uptake across the
leg following exercise will allow investigators to see the relationship between blood flow
and glucose regulation in a new light. Furthermore, studying how postexercise blood
flow and glucose regulation impacts fat metabolism is highly relevant, given the rise in
obesity in the United States.
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In addition to employing cutting-edge techniques to probe these questions,
varying interventions and populations may be studied. For example, how might different
durations and intensities or even modes of exercise, such as resistance training, affect the
relationship between postexercise blood flow and glucose regulation? Would this
relationship be different in trained versus untrained individuals or change in response to
chronic training? Moreover, how might this relationship change in those who may
already have compromised blood flow or glucose regulation, such as overweight
individuals, or those suffering from diabetes? This becomes a particularly compelling
question, given the nearly epidemic rise in the diagnoses of diabetes in the United States.
There seems to be no shortage of questions to ask and studies to conduct in this exciting
area of research.
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APPENDIX A
ETHANOL ASSAY PROCEDURES
This procedure is derived from Robert Hickner's original work on the Ethanol Perfusion
Technique for use with microdialysis and by correspondence with Hickner. It uses
alcohol dehydrogenase to break down ethanol (EtOH) by the chemical reaction:
EtOH + NAD+ +OADHO+ Acetylaldehyde + NADH
Preparation of Ethanol I Ringer's Perfusate for use with Microdialysis:
500 ml ofRinger's Solutions with ethanol, lactate, and glucose (3 mmolar dextrose, 0.5
mmolar lactate,S mmolar ethanol)
You will need the following:
Ringer's Injection, 500 ml (Solution) (Hypoxia Storage)
Lactated Ringer's Injection, 500 ml (Hypoxia Storage)
Ringer's Injection with 5% Dextrose, 500 ml (Hypoxia Storage)
Ethanol, 200 Proof, 1 Gallon Container (Flammables Cabinet)
1 - 1 ml Monoject Tuberculin Syringe wi Detachable Needle (IV Cart)
1 - 60 ml Monoject Sytinge (IV Cart)
1 - 20 ml Monoject Syringe (IV Cart)
2 - 10 ml Monoject Syringe (IV Cart)
3 - 16 Gauge x 38.1 mm (1 'ii inch) Needles (IV Cart)
1 - 25 Gauge x 50.8 mm (2 inch) Needle (IV Cart)
1 - Electronic Balance (reads to .0001 g)
-It is important that this solution remain sterile. Wear gloves and use only sterile
equipment.
-Find the appropriate amount of ethanol to add to the Ringer's Solution using the
equation:
Desired molar concentration EtOH (46.068 g 11 mole)*(1 L 11000 ml)*500.15 ml=
Desired # of grams EtOH per 500.15 ml of solution.
Example: 0.005 mole/L EtOH (46.068 g EtOH I 1 mole)*(1 L 11000 ml)*500.15 ml =
0.1152 g per 500.15 ml of solution
-Taking the Ringer's Injection draw out 24 ml using the 60 ml syringe and discard.
124
-Draw out 15 m1 of Lactated Ringer's Injection using the 20 m1 syringe and set aside.
-Draw out 9 ml of Ringer's Injection with 5% Dextrose using the 10 ml syringe and set
aside.
-Using the other 10 ml syringe wi 25 gauge needle draw up 1-2 ml of ethanol.
-Remove the needle from the 10 ml syringe.
-From the 10 ml syringe draw up approximately 0.1 ml of ethanol using the 1 ml
tuberculin syringe.
-Remove the air bubbles from the 1 ml syringe and push out the ethanol used to flush the
needle and syringe.
-Mass the flushed syringe and needle on the balance and tare.
-Draw approximately 0.14 ml of ethanol into the syringe and mass. You need 0.1152 g
of ethanol and 0.14 ml should be close to this. (For a 5 mmolar solution 500.15 ml in
volume you need 0.1152 g of ethanol and ethanol has a density of 0.789 glml so;
0.1152 g (1 m1 I 0.789 g) = 0.146 ml)
-Inject the ethanol into the Ringer's Injection then add the 15 ml of Lactated Ringer's
Injection and 9 ml of Ringer's Injection with 5% Dextrose.
-This solution is then ready for use.
Preparation of Ethanol Assay for use with Microdialysis:
140 ml ofG1ycine-Hydrazine Buffer w/NAD (G-H B wi NAD) @pH 9.0 (Glycine (22.0
mmo1ar), Sodium Pyrophosphate Decahydrate (74.6 mmo1ar), Hydrazine Sulfate (50.0
mmo1ar), and NAD (0.54 mmolar))
100 ml of Ammonium Sulfate Buffer (ASB) (Ammonium Sulfate (22 mmolar))
1 m1 Alcohol Dehydrogenase (ADH) Solution (ADS) (1 ml Ammonium Sulfate Buffer,
1.1 mg ADH)
You will need the following:
1 vial (50 mg) ~-nicotinamideadenine dinucleotide (NAD+) (Freezer)
4.6463 g Sodium Pyrophosphate Decahydrate (Na407 * 10 H20) (Chern.
Cabinet)
0.2306 g Glycine (C2HsN02) (Chern. Cabinet)
0.9084 g Hydrazine Sulfate (N2H4 * H2S04) (Chern. Cabinet)
0.2907 g Ammonium Sulfate ((NH4)2S04) (Chern. Cabinet)
0.0011 g Alcohol Dehydrogenase (lyophilized powder, 314 units/mg) (Sub
80 Freezer)
50 ml 25% w/v NaOH (prepare from 50 % w/v in the flammables cabinet)
250 ml Deionized Water
1 - 200 ml Beaker
1 - 150 ml Beaker
1 - 10 ml Screw Top Vial
1 - 200 ml Screw Top Glass Container
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1 - Rainin 1000 L Pipette
1 - Box Rainin 1000 L Pipette Tips
1 - Electronic Balance (reads to .0001 g)
1 - Stir Bar
2 - Magnetic Stirrers
1 - Electronic pH meter (preferably with a long probe)
1 - Ring Stand
1 - Ring Stand Clamp
For the G-H B wi NAD:
-Remember that you are handling chemicals that can splash and spill. Wear gloves and
goggles. Mind the warning labels on the chemicals used.
-Calibrate the pH meter that will be used to track the pH of this solution (refer to manual
for instructions).
-Add 100 ml ofDI water to a 200 ml beaker along with the stir bar.
-Set the 200 ml beaker on the stir plate and set up the pH probe in the ring stand clamp
such that it is submerged in the water but does not touch the stir bar or the beaker
surfaces.
-Set up the pH meter for continuous monitoring or begin by running a baseline reading to
make sure the probe is working properly and the pH of the water is around 7.
-Mass out the Glycine (0.2306 g), Hydrazine Sulfate (0.9084 g), and Sodium
Pyrophosphate (4.6464 g) using weigh boats and the electronic balance. Be cautious
when handling the Hydrazine Sulfate as it is toxic.
-Start the magnetic stirrer and add the chemicals.
-Add an additional 30 ml ofDI water to the 200 ml beaker. Check the pH.
-Add dropwise the 25% wlv NaOH while monitoring the pH. When the pH reaches a
value of 9.0 stop (Note: it may be necessary to use a higher % wlv NaOH solution to
achieve a pH of 9.0 without going over 140 ml).
-Fill the beaker with DI water to the 135 ml mark.
-Remove the stir bar from the 200 ml beaker as it takes up approximately 1.3 ml of
volume. Use a scoopula or stir rod for the final adjustments. (Note: the pH will change
very slowly here. Be sure to monitor constantly and stir well to ensure that you have not
gone over pH 9.0)
-Adjust the pH to 9.0 ifit is lower and then remove the pH probe. The pH should not
change significantly when filling the beaker with DI water to the 140 ml mark.
-Check the pH of the solution. It should be at or very near 9.0.
-If the solution is for immediate use, mass out and add the NAD. Check the pH again.
-If the solution is for later use do not add the NAD, wait until the solution is to be
used then add the NAD.
-Pour the contents of the beaker into the 200 ml screw top glass container.
-The prepared solution wi NAD has a shelf life of approximately 1 Yz -2 weeks under
refrigeration. Adjust the volume of the solution prepared to what is expected to be used
during this period.
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For ASB:
-Remember that you are handling chemicals that can splash and spill. Wear gloves and
goggles. Mind the warning labels on the chemicals used.
-Add 50 ml ofDI water to a 150 ml beaker along with the stir bar.
-Mass out the Ammonium Sulfate (0.2907 g).
-Tum on the magnetic stirrer and place the Ammonium Sulfate in the 150 ml beaker.
-After the solution is mixed add DI water to the 150 ml beaker to the 100 ml mark.
-Pour this solution into a storage vessel and place under refrigeration.
-The Ammonium Sulfate Buffer is stable at room temperature indefinitely and 100 ml
should be good for 100 enzyme preparations. Each enzyme preparation should then be
good for approximately 20 sample assays, so a 100 ml preparation of Ammonium Sulfate
Buffer should be enough for approximately 2000 sample assays.
For ADS:
-The solution should be made during or just before the ethanol assay procedure due
to its short shelf life.
-Weight out 1.1 mg of ADH (this amount is based on a total activity of approximately
332 units of ADH per 1 ml of solution and as lyophilized ADH activity of 314 units/mg)
into the small screw top vial (can also use a 1.5 ml microcentrifitge tube).
-Add 1 ml of the Ammonium Sulfate Buffer using the Rainin 1000 L Pipette to the vial.
-Mix by twisting the vial along the vertical axis. Do not shake or invert as this will cause
the ADH crystals to stick to the vial walls. The final product should be a slightly
discolored liquid.
-The ADS has a life of 90 minutes when stored between 0 and 25 degrees Celsius.
This vial is good for approximately 20 sample assays.
Ethanol Assay Procedure:
You will need the following:
Dialysate Samples
Glycine-Hydrazine Buffer wi NAD (G-H B wi NAD)
Alcohol Dehydrogenase Solution (ADS)
Plastic Test Tubes wi Stoppers (glass tubes may be used)
Plastic 1.5 ml Fluorometer Cuvettes (clear on all sides)
1 Box Rainin 1000 L Pipette Tips (blue box)
1 Box Rainin 200 L Pipette Tips (green box)
1 Box Rainin 20 L Pipette Tips (red box)
1 Rainin 1000 L Pipette
1 Rainin 200 L Pipette
1 Rainin 20 L Pipette
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1 Rectangular, Heat-Safe Container wi at least 1000 ml capacity
1 Hot Plate wi Magnetic Stirrer
1 Magnetic Stirrer
1 Thermometer, Centigrade
1 Ring Stand
1 Ring Stand Clamp
1 Test Tube Rack
1 Fluorometer (or a spectrometer capable of reading absorbance at 340 nm)
1 Sharpie Marker
-Remember that you are handling chemicals that can splash and spill. Wear gloves and
goggles. Mind the warning labels on the chemicals used.
-Procure the needed supplies and arrange them on the counter in the way that seems most
appropriate for you to perform the procedure that follows.
-Allow the Glycine-Hydrazine Buffer wi NAD and Ammonium Sulfate Buffer to warm
to room temperature before use. Also make sure to use the magnetic stirrer to mix these
solutions thoroughly particularly the G-H B.
-To prepare the water bath, fill the rectangular container ~ halfway with warm water, add
a stir bar, and place on the hot plate.
-Position the ring stand and clamp such that it can hold the thermometer in the bath
container without it contacting the container's surface or the stir bar.
-Set the hot plate to between LOW and 2. The water temperature should be 37 degrees
Celsius. Add cold water to the bath ifit gets above this and tum off the hot plate.
-Turning on the stirrer will ensure even heating of the water.
-Label the test tubes and arrange them in the rack.
-To each test tube add 2 ml of the Glycine-Hydrazine Bufferw/NAD using the 1000 L
pipette.
If not already done, prepare the ADH solution.
-Add 50 microliters of ADH solution to each test tube using the 200 L pipette.
-Stopper the tube and invert to mix contents.
-Add 5 microliters of the appropriate dialysate to each test tube using the 20 L pipette and
stopper the tube. The alcohol content of the dialysate is extremely low so it is very
important the tubes be sealed to prevent the sample from evaporating. (Note: when using
such small volumes make sure to puncture the surface of the sample liquid and visually
confirm that a sample was obtained. Surface tension can keep you from drawing a
sample. Depress, submerge, release)
-Mix the contents by inverting the test tube several times.
-Place the test tubes, within the test tube rack, in the bath so that they remain vertical and
the solution is submerged in the water but the top of the test tubes are not. You may lay a
flat object of sufficient weight on top of the tubes w/in the rack, to prevent them from
floating
-Incubate the test tubes at 37 degrees Celsius for 25 minutes (25 degrees Celsius for 75
minutes also works) making sure to keep the temperature stable.
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-During this time label the cuvettes you will be using. It is also a good idea to wipe down
the outer surface of the cuvettes with an alcohol swab to remove fingerprints and any film
that may interfere with the fluorometry readings.
-It is important that you don't shake the tubes as air bubbles and shock affect the ADH.
-During this procedure the sample preparations may have to be staggered depending on
the number of samples and the measurement technique being used.
-Once the incubation period is over remove the test tubes and invert one last time.
-Pour the contents of each test tube into the appropriately labeled cuvette.
-Take the fluorometric or spectroscopic reading following the protocol appropriate for the
device used.
-If using fluorometry, use a 360 nm excitation filter & a 460 nm emission filter
-Using UV spectroscopy the absorbance ofNADH (a product of the break down of
. ethanol by ADH) at 340 nm will increase with increased alcohol concentration.
-For either fluorometry or spectroscopy, readings can be referenced to a standard curve
created based on known concentrations of ethanol
-Therefore, we have included mixing procedures for ethanol standards, used in creating a
standard curve, below. In addition, although we haven't used the calculations on the
following page, we have included them for your information.
Ethanol standard mixing procedures
o Ethanol stock solution: Mix 5.8 ilL 200 proof ethanol with 10 ml DI water for [10
mM] ethanol. This will serve as the highest point on the standard curve. Keep
covered to avoid evaporation of ethanol.
o Perform 2 subsequent IO-fold dilutions (e.g., mix 1 ml stock solution with 9 ml DI
water to obtain 1 mM solution) to attain the remaining ethanol concentrations for
standard curve:
o 1 mM
o 0.1 mM
Calculation methods:
To calculate the amount of ethanol in a given sample there are two methods which are
outlined in the instruction sheet for there NAD-ADH Reagent Multiple Test Vials.
o The first method uses a 0.08% standard to calculate the ethanol concentration of a
sample using the formula:
Alcohol (mgldl) = A340SamplJA340 Standard * Concentration of Ethanol Standard (mgldl)
So if a sample has an absorbance at 340 nm of 0.3492 and the 0.08% standard
(convert to mgldl by multiplying w/v by 1000) has an absorbance of 0.2136 then the
equation would be:
Alcohol (mgldl) = (0.3492 10.2136) * (0.08% w/v * 1000) = 130.79 mgldl
To convert the answer from mgldl to mmole/l multiply by 0.217 so:
130.79 mgldl * 0.217 = 28.4 mmole/l
o The other method uses the absorbance of the sample only and uses the following
formula:
Alcohol (mgldl) = A340 * [(A x B x C) 1(D x E x F x G)]
A = Total reaction volume (ml)
B =--= Molecular weight of ethanol (46.068)
C = Conversion of ml to dl (l00)
D = Millimolar absorbtivity ofNADH at 340 nm (6.22)
E = Volume of sample (ml)
F = Light path of cuvet (cm) (usually 1 cm)
G = Conversion ofml to liter (1000)
So for an A340 of 0.3492 using the above technique;
A = 1.052 ml
B = 46.068
C = 100
D = 6.22
E = 0.002 ml
F= 1 cm
G = 1000
So;
Alcohol (mgldl) = 0.3492 * [(1.052 x 46.068 x 100)/(6.22 x 0.002 x 1 x 1000)] =
136 mg/dl
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APPENDIXB
INFORMED CONSENT FORM - IRB# C2-116-08F
TITLE: Pilot study for microdialysis in skeletal muscle
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues
APPROVED BY INSTITUTIONAL REVIEW BOARD: November 8, 2007
This is an important form. Please read it carefully. It tells you what you need to
know about this study. If you agree to take part in this research study, you need to
sign the form. Your signature means that you have been told about the study and
what the risks are. Your signature on this form also means that you want to take
part in this study.
Why is this study being done?
We are perfonning this pilot study which involves use of an experimental procedure to
develop our ability to recover substances out of skeletal muscle. We have used this
technique in skin and we are now adapting this method to use in skeletal muscle.
What will happen in the study?
1. You will arrive at Dr. Halliwill's laboratory in room 166 in Esslinger Hall at the
University of Oregon for a one-day experiment. This experiment will take approximately
six hours. You will meet with one of the investigators of the study to discuss the project,
to see the laboratory, and to read this fonn. Your height and weight and resting blood
pressure will be measured, and you will be asked questions about your health history.
You will need to wear a t-shirt and refrain from eating for one hour prior to arrival. In
addition, you will need to refrain from consuming caffeine (for example, coffee, tea,
energy drinks like Red Bull, or soda like Coke, which contain caffeine) or medications
(except oral contraceptives) for 12 hours prior to the study and abstain from alcohol or
exercise for 24 hours prior to the study. If you use oral contraceptives, you should take
this when you nonnally do so.
2. During the study visit, your heart rate will be monitored by electrocardiogram
electrodes placed on your skin. Your blood pressure will be measured at periodic
intervals by the inflation of a blood pressure cuff around your ann.
3. You will have 4-5 small probes (these are called "microdialysis fibers") placed into
the vastus lateralus (outer thigh) muscle of your leg. First, the area of skin where the
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probes will enter and exit will be numbed with a local anesthetic. Then a small needle
will be placed through the skin and through the muscle, exiting back out about 2-3 inches
from where it entered your skin and muscle. The small probes will be passed through the
needle, and then the needle will be withdrawn, leaving the small probes passing through
your muscle. The two probes will be separated by about 1 inch. These will remain in
place throughout the rest of the study.
4. We will need to wait about 1-2 hours after the small probes are placed in your muscle
to let the insertion trauma (redness of your skin around the small probes) to go away.
During this time we will infuse a solution into the probes but you should not feel
anything with this infusion.
5. After the insertion trauma passes, we will put small doses of several drugs through
the small probes in your muscle. The drugs you may receive include the following:
a. Ethanol alcohol. This is used to determine how much blood flow muscle
receives. You should not feel anything when this drug infuses into your muscle.
b. Histamine. This substance is naturally produced by your body and will cause
blood vessels to open in the local area of muscles around the probe. You should not feel
anything when this drug infuses into your muscle. However, it is possible you may feel
an itching sensation combined with redness to your skin where the probe is located
approximately 30 minutes after the infusion starts.
c. Compound 48/80. This is a substance that releases histamine, which is naturally
produced by your body, which will cause blood vessels in that local area of muscles to
open. You should not feel anything when this drug infuses into your muscles. However,
it is possible you may feel an itching sensation combined with redness to your skin where
the probe is located approximately 30 minutes after the infusion starts.
d. Cromolyn (a common ingredient in over the counter allergy remedies). This drug
blocks the release of histamine. You should not feel anything when this drug infuses into
your muscle.
e. Pyrilamine (a common ingredient in over the counter cold remedies). This drug
blocks the effects of histamine and will prevent blood vessels in muscle from opening up
if histamine is present. You should not feel anything when this drug infuses into your
muscle.
f. Cimetidine (brand name Tagament). This drug blocks the effects of histamine
and will prevent blood vessels in muscle from opening up if histamine is present. You
should not feel anything when this drug infuses into your muscle.
g. Sodium nitroprusside. This drug will cause blood vessels in the local area of
muscle to open up. You should not feel anything when this drug infuses into your
muscle.
6. After the study, we will remove the flexible probes and a bandage will be placed over
that area of skin. You will then be sent home.
7. You should notify the investigator immediately if you feel any significant discomfort
or concern about your well-being at any time during the initial visit study. Some
examples of discomfort include shortness ofbreath, light-headedness, and nausea.
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How long will I be in the study?
You will be in the study for one day. The study will last six hours. You will need to
refrain from eating for one hour prior to the study.
What are the risks of the study?
1. Muscle Microdialysis: There may be some discomfort during the insertion of the
small probes into your muscle. We will use a local anesthetic to numb skin where the
probes will be inserted to minimize this discomfort, but you may feel pressure or a dull
ache in the muscle as the needle moves through the muscle. The infusions through the
fiber should not be painful, and there should only be minor swelling at the sites. At the
end of the study, the fibers will be withdrawn and a sterile dressing will be applied. Any
swelling or redness after the study should be gone a few hours after completion of the
study, but you may feel some muscle soreness for several days. You will be given some
ibuprofen (e.g. Advil or Motrin) to relieve some of the initial soreness. Although the
small probes are sterile, there is a slight risk of infection at the sites where the probes
were placed. You will be instructed on how to keep the area clean for a day or two
following the study and will need to inform the researchers immediately if you have any
redness or swelling in the area. The researchers will also ask you to return to the lab the
day after the study visit so they can see how the sites are healing.
2. Infusions: We will be infusing very small doses of each drug and only into a very
small area of your muscle. You will not have any systemic (whole body) effects of these
drugs in the doses given in this study. There is a minimal risk of an allergic reaction to
these drugs.
May I participate if I am pregnant or breast-feeding?
This study may be harmful to an unborn or breast-fed child. There is not enough medical
information to know what the risks might be to a breast-fed infant or to an unborn child
in a woman who takes part in this study. Breast-feeding mothers are not able to take part
in this study. Women who can still become pregnant must have a negative pregnancy test
no more than 24 hours before taking part in the protocol orientation trial on the initial
visit. If the pregnancy test is positive (meaning that you are pregnant), you will not be
able to take part in the study. There is no cost for the pregnancy test.
Are there benefits to taking part in this study?
This study will not make your health better. The muscle dialysate fluid samples are not
being collected for diagnostic purposes. The results will not be reviewed by a physician
and no action will be taken if a laboratory result falls outside of the normal range.
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What other choices do I have if I don't take part in this study?
This study is only being done to gather infonnation. You may choose not to take part in
this study.
What are the costs of tests and procedures?
You will not pay for any tests or procedures that are done just for this research study.
You will get $60 for participating in this study. This money is for the inconvenience and
time you spent in this study. If you start the study but stop before the study has ended,
the amount of money you receive will be pro-rated at a rate of $1 0 per hour of the study
you complete.
Who can answer my questions?
You may talk to Dr. John Halliwill at any time about any question you have on this study.
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541)
346-5425.
What are my rights if I take part in this study?
Taking part in this research study is your decision. You do not have to take part in this
study, but if you do, you can stop at any time. Your decision whether or not to participate
will not affect your relationship with The University of Oregon.
You do not waive any liability rights for personal injury by signing this fonn. All fonns
of medical diagnosis and treatment whether routine or experimental, involve some risk of
injury. In spite of all precautions, you might develop medical complications from
participating in this study.
The investigators may stop you from taking part in this study at any time if it is in your
best interest, if you do not follow the study rules, or if the study is stopped.
If you are physically injured because of the project, you and your insurance company will
have to pay your doctor bills. If you are a UO student or employee and are covered by a
UO medical plan, that plai1 might have tenns that apply to your injury.
If you experience hann because of the project, you can ask the State of Oregon to pay
you. If you have been hanned, there are two University representatives you need to
contact. Here are their addresses and phone numbers:
General Counsel
Office of the President
University of Oregon
Eugene, OR 97403
(541) 346-3082
Office for Protection of Human Subjects
University of Oregon
Eugene, OR 97403
(541) 346-2510
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A law called the Oregon Tort Claims Act limits the amount of money you can receive
from the State of Oregon if you are harmed. The most you could receive would be
$100,000, no matter how badly you are harmed. If other people are also harmed by the
project, all of you together could only receive $500,000.
What about confidentiality?
Any information that is obtained in connection with this study and that can be identified
with you will remain confidential and will be disclosed only with your permission.
Subject identities will be kept confidential by assigning you a "subject identification
number". The names associated with each subject identification number will be kept in a
locked file cabinet in Dr. Halliwill's office. The list of names will be destroyed when
study results are published or 24 months after your participation, whichever comes first.
All blood samples will be destroyed when study results are published or 24 months after
your participation, whichever comes first.
The Office for Responsible Conduct of Research and/or authorized representatives of the
Food and Drug Administration (FDA) or National Institute of Health may need to review
records of individual subjects. As a result, they may see your name; but they are bound
by rules of confidentiality not to reveal your identity to others.
I have had an opportunity to have my questions answered. I have been given a copy
of this form. I agree to take part in this study.
If you have questions regarding your rights as a research subject, contact the Office for
Protection of Human Subjects, 5237 University of Oregon, Eugene, OR 97403,541/346-
2510.
Your signature indicates that you have read and understand the information provided
above, that you willingly agree to participate, that you may withdraw your consent at any
time and discontinue participation without penalty, that you will receive a copy of this
form, and that you are not waiving any legal claims, rights or remedies.
(Date)
(Date)
(Signature of Participant)
(Signature of Individual Obtaining Consent)
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APPENDIXC
INFORMED CONSENT FORM - IRB# C2-294-08F-3
TITLE: Interstitial glucose concentrations following exercise
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues
APPROVED BY INSTITUTIONAL REVIEW BOARD: June 7, 2007
This is an important form. Please read it carefully. It tells you what you need to
know about this study. If you agree to take part in this research study, you need to
sign the form. Your signature means that you have been told about the study and
what the risks are. Your signature on this form also means that you want to take
part in this study.
Why is this research study being done?
When humans exercise, there is an increase in blood flow to the skeletal muscle. This
increase in blood flow lasts for several hours after exercise but we do not understand all
the mechanisms that cause this increase in blood flow or why it happens. The purpose of
this study is to provide more infonnation on what causes blood flow increases to occur
and to detennine whether or not this blood flow is involved in metabolism.
What will happen in the study?
Initial visit
1. You will arrive at Dr. Halliwill's laboratory in Esslinger Hall at the University of
Oregon for an initial visit. This initial visit will take approximately two hours. You will
meet with one of the investigators of the study to discuss the project, to see the
laboratory, and to read this fonn. Your height and weight and resting blood pressure will
be measured, and you will be asked questions about your health history. You will be
given a physical activity questionnaire, which will allow investigators to detennine your
activity level. The questionnaire will take approximately 15 minutes to complete. You
will need to wear a t-shirt and refi-ain fi-om eating for two hours prior to arrival. In
addition, you will need to refi-ain fi-om consuming caffeine (for example, coffee, tea, red
bull, coke, etc.) or medications (except oral contraceptives) for 12 hours prior to the study
and abstain from alcohol or exercise for 24 hours prior to the study. If you use oral
contraceptives, you should take this when you nonnally do so.
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2. If you are a woman who can still become pregnant, you will be asked to undergo a
pregnancy test during the initial visit (and again during the study visit). For this test, you
will be asked to collect a sample of urine in the women's restroom near the physiology
lab. If the test is "positive," indicating that you are pregnant, you will not be allowed to
participate and will be advised to see your physician or the University of Oregon Health
Center.
3. Graded Exercise Test: You will pedal on an exercise bicycle while wearing a mouth
piece, nose clip, and electrocardiogram electrodes (heart rhythm monitor). If you are a
woman, the adhesive patches used for this test will be placed on you by one of the
women in the lab. After a 5-minute warm-up, you will be asked to maintain a selected
pedaling rate as pedaling resistance (work) is increased every minute until you reach your
maximum exercise capacity. This is to measure your overall aerobic fitness level. It
normally takes 10 to 15 minutes for people to reach their maximum effort. The total time
for this test (including placement of ECG electrodes, warm-up, exercise, and cool-down)
is approximately one hour. This session will serve to familiarize you with the procedures
to be used on the study visit. It will also establish your maximal exercise tolerance on a
bike and therefore will be used to establish the appropriate workload for the exercise
session on the study visit.
4. You should notify the investigator immediately if you feel any significant discomfort
or concern about your well-being at any time during the initial visit study. Some
examples of discomfort include shortness of breath, light-headedness, and nausea.
5. This session will serve to familiarize you with the procedures to be used on the study
day. It will also establish your maximal exercise tolerance on a bike and therefore will be
used to establish the appropriate workload for the exercise session on the study day. At
this time you will be reminded not to donate blood or to participate in other research
studies where they will be drawing blood for 8 weeks.
Study visit
1. You will then return to Dr. Halliwill's laboratory to participate in the two study visits,
one of which will be between 7 and 10 days after the initial visit and the other will be
between 7 and 10 days after that. These two testing sessions will take approximately
five hours each. You will need to wear a t-shirt, shorts, and refrain from eating at
least two hours prior to arrival.
2. If you are a woman who can still become pregnant, you will be asked to undergo a
pregnancy test during the study visit.
3. During the study visit, your heart rate will be monitored by electrocardiogram
electrodes placed on your skin. If you are a woman, the adhesive patches used for
this test will be placed on you by one of the women in the lab. Your blood pressure
will be measured at periodic intervals by the inflation of a blood pressure cuff around
your arm.
4. During the study visit, you will periodically breathe small amounts of acetylene gas
mixed with air through a mouthpiece. Acetylene gas is an inert gas that is not
harmful in any way to people and it is not flammable in the concentrations that are
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used in the lab. This is used to study how much work the heart is perfom1ing.
Periodically, a small probe (ultrasound-Doppler probe) will be held over an artery at
your groin-hip intersection. The ultrasound-Doppler probe uses ultrasound waves to
measure blood flow in the artery.
5. Venous Catheter: You will have one small flexible needle ("intravenous catheter")
placed into a vein in the back of your hand. The skin will be sterilized before this
procedure. This catheter will remain in your skin throughout the five hour study.
During the study, this hand will be placed in a warming chamber to heat the skin of
your hand to about 108°F which will feel warm but should not cause discomfort.
Several blood samples will be collected from the catheter during the five hour study.
In total, 150 ml will be withdrawn during the visit. This is approximately five
ounces (a little more than half a cup) and about a third of the amount withdrawn when
you volunteer to "give blood" for Lane Memorial Blood Bank or similar blood
donation programs. After the study, we will remove the flexible needle in your vein
and a bandage will be placed over that area of skin.
6. Bicycle exercise session: You will be asked to pedal on a bicycle at a moderate rate
for one hour on one of the study visits. On the other study visit, you will not exercise
but will sit and rest for a few minutes.
7. Muscle Microdialysis: You will have 4-5 small probes (these are called
"microdialysis fibers") placed into the vastus lateralus (outer thigh) muscle of your
leg. This will be done after you have exercised (or rested). First, the area of skin
where the probes will enter and exit will be numbed with a local anesthetic
(lidocaine/xylocaine with epinephrine). Then a small needle will be placed through
the skin and through the muscle, exiting back out about 2-3 inches from where it
entered your skin and muscle. The small probes will be passed through the needle,
and then the needle will be withdrawn, leaving the small probes passing through your
muscle. This process of inserting a small needle through the skin and muscle to place
a probe will be repeated 4 or 5 times, once for each of the probes that is placed. The
probes will be separated by about 1 inch. These will remain in place throughout the
rest of the study. There may be some discomfort during the insertion of the small
probes into your muscle. We will use a local anesthetic to numb skin where the
probes will be inserted to minimize this discomfort, but you may feel pressure or a
dull ache in the muscle as the needle moves through the muscle. The infusions
through the fiber should not be painful, and there should only be minor swelling at the
sites.
8. Microdialysis infusions: We will put small doses of several drugs through the small
probes in your muscle. The drugs you may receive include the following:
a. Ethanol alcohol. This is used to determine how much blood flow muscle
receives. You should not feel anything when this drug infuses into your
muscle.
b. Pyrilamine (a common ingredient in over the counter cold remedies). This
drug blocks the effects of histamine and will prevent blood vessels in the
muscle from opening up if histamine is present. You should not feel
anything when this drug infuses into your muscle.
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c. Cimetidine (brand name Tagament). This drug blocks the effects of
histamine and will prevent blood vessels in the muscle from opening up if
histamine is present. You should not feel anything when this drug infuses
into your muscle.
d. Radioactive nuclide. Tritiated glucose is a radioactive labeled fonn of
glucose, a sugar. It is being used to help measure the levels of glucose in
your muscle. You should not feel anything when this drug infuses into
your muscle.
9. Oral Glucose Tolerance Test: You will be given a flavored concentrated sugar-water
beverage to drink. You will be asked to drink up to 10 ounces.
10. At the end of the study visit, the fibers will be withdrawn from your leg and a sterile
dressing will be applied. Any swelling or redness after the study should be gone a
few hours after completion of the study, but you may feel some muscle soreness for
several days. You will be given some ibuprofen (e.g. Advil or Motrin) to relieve
some of the initial soreness. Although the small probes are sterile, there is a slight
risk of infection at the sites where the probes were placed. You will be instructed on
how to keep the area clean for a day or two following the study and will need to
infonn the researchers immediately if you have any redness or swelling in the area.
The researchers will also ask you to return to the lab the day after the study visit so
they can see how the sites are healing.
11. You should notifY the investigator immediately if you feel any significant discomfort
or concern about your well-being at any time during the initial visit or the study visit.
Some examples of discomfort include shortness of breath, light-headedness, and
nausea.
How long will I be in the study?
You will be in the study for three days (initial visit and two study visits). The initial visit
will last two hours. The study visits will last five hours each. You will need to refrain
from eating for two hours prior to the study visits.
What are the risks of the study?
1. Graded exercise testing: There is some minor discomfort associated with exercise
testing, including temporary fatigue, shortness of breath, and muscle soreness. These
sensations resolve within minutes after the test is completed. There is the possibility
of some residual muscle soreness in the few days following the exercise test. There is
also the risk of a heart attack or death during an exercise test. The risk of a
complication requiring hospitalization is about 1 incident in 1000. The risk of a heart
attack during or immediately after an exercise test is less than 1 incident in 2500. The
risk of death during or immediately after an exercise test is less than 1 incident in
10,000. In the unlikely case of a life-threatening heart rhythm, the laboratory is
equipped with an Automatic Electronic Defibrillator that is located in the same room
where the study is taking place. Dr. Halliwill has up to date Advanced Cardiac Life
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Support (ACLS) training. In the event of an emergency, the Department of Public
Safety (6-6666) will be called in order to activate the emergency medical system (i.e.,
911) and will direct an ambulance to the conect location.
2. Intravenous catheters: There may be some discomfort during the insertion of the
small flexible needle into your vein. Once the needle is in place, the pain should
subside. Blood sampling through the needle should not be painful, and there should
only be minor swelling at the site. At the end of the study, the needle will be
withdrawn and a sterile dressing will be applied. Any swelling or redness after the
study should be gone a few hours after completion of the study. Although the needle
is sterile, there is a slight risk of infection at the site where the needle was placed in
your skin. You will be instructed how to keep the area clean for a day or two
following the study. The most common complications of inserting a small needle into
a vein are a small bruise and pain at the site of the needle location which may last
several days after removal of the catheter.
3. Blood withdrawal: In total, 150 ml will be withdrawn during the study visit. This is
approximately five ounces (a little more than half a cup) and about a third of the
amount withdrawn when you volunteer to "give blood" for Lane Memorial Blood
Bank or similar blood donation programs. You will not be allowed to donate blood
for 8 weeks before the study, or for 8 weeks after the study.
4. Muscle Microdialysis: There may be some discomfort during the insertion of the
small probes into your muscle. We will use a local anesthetic to numb skin where the
probes will be inserted to minimize this discomfort, but you may feel pressure or a
dull ache in the muscle as the needle moves through the muscle. The infusions
through the fiber should not be painful, and there should only be minor swelling at the
sites. At the end of the study, the fibers will be withdrawn and a sterile dressing will
be applied. Any swelling or redness after the study should be gone a few hours after
completion of the study, but you may feel some muscle soreness for several days.
You will be given some ibuprofen (e.g. Advil or Motrin) to relieve some of the initial
soreness. Although the small probes are sterile, there is a slight risk of infection at
the sites where the probes were placed. You will be instructed on how to keep the
area clean for a day or two following the study and will need to inform the
researchers immediately if you have any redness or swelling in the area. The
researchers will also ask you to return to the lab the day after the study visit so they
can see how the sites are healing.
5. Infusions: We will be infusing very small doses of each drug and only into a very
small area of your muscle. You will not have any systemic (whole body) effects of
these drugs in the doses given in this study. There is a minimal risk of an allergic
reaction to these drugs.
6. Radioactive nuclide: This research study involves exposure to radiation from tritiated
glucose, a radioactive labeled form of glucose. This radiation exposure is not
necessary for your medical care and is for research purposes only. The total amount
of radiation that you will receive in this study is equivalent to a uniform whole body
exposure ofless than 1 day of exposure to natural background radiation. For
comparison, the amount ofradiation you would receive from a chest X-ray is
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equivalent to 5 days of exposure and the amount of radiation you would receive from
a dental X-ray is equivalent to 11 days of exposure. This use involves minimal risk
and is necessary to obtain the research information desired.
7. Oral Glucose Tolerance Test: Drinking the concentrated sugar-water beverage can
lead to nausea, vomiting, diarrhea, or fainting in some individuals. You should notify
the investigator immediately if you feel any significant discomfort after drinking this
beverage.
May I participate if I am pregnant or breast-feeding?
This study may be harmful to an unborn or breast-fed child. There is not enough medical
information to know what the risks might be to a breast-fed infant or to an unborn child
in a woman who takes part in this study. Breast-feeding mothers are not able to take part
in this study. Women who can still become pregnant must have a negative pregnancy test
no more than 24 hours before taking part in the graded exercise test on the initial visit and
each of the two study visits. If the pregnancy test is positive (meaning that you are
pregnant), you will not be able to take part in the study. There is no cost for the
pregnancy test.
Are there benefits to taking part in this study?
This study will not make your health better. Blood and fluid samples collected from
microdialysis are not being collected for diagnostic purposes. The results will not be
reviewed by a physician and no action will be taken if a laboratory result falls outside of
the normal range.
What other choices do I have if I don't take part in this study?
This study is only being done to gather information. You may choose not to take part in
this study.
What are the costs of tests and procedures?
You will not need to pay for any tests or procedures that are done just for this research
study. You will get $120 for participating in this study. This money is for the
inconvenience and time you spent in this study. If you start the study but stop before the
study has ended, the amount of money you receive will be pro-rated at a rate of $1 0 per
hour of the study you complete.
Who can answer my questions?
You may talk to Dr. John Halliwill at any time about any question you have on this study.
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541)
346-5425.
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What are my rights if I take part in this study?
Taking pmi in this research study is your decision. You do not have to take part in this
study, but if you do, you can stop at any time. Your decision whether or not to participate
will not affect your relationship with the University of Oregon.
You do not waive any liability rights for personal injury by signing this form. All forms
of medical diagnosis and treatment whether routine or experimental, involve some risk of
injury. In spite of all precautions, you might develop medical complications from
participating in this study.
The investigators may stop you from taking part in this study at any time if it is in your
best interest, if you do not follow the study rules, or if the study is stopped.
If you are physically injured because of the project, you and your insurance company will
have to pay your doctor bills. If you are a UO student or employee and are covered by a
UO medical plan, that plan might have terms that apply to your injury.
If you experience hann because of the proj ect, you can ask the State of Oregon to pay
you. If you have been harmed, there are two University representatives you need to
contact. Here are their addresses and phone numbers:
General Counsel
Office of the President
University of Oregon
Eugene, OR 97403
(541) 346-3082
Office of Human Subjects Compliance
University of Oregon
Eugene, OR 97403
(541) 346-2510
A law called the Oregon Tort Claims Act limits the al110unt ofmoney you can receive
from the State of Oregon if you are harmed. The most you could receive would be
$100,000, no matter how badly you are harmed. If other people are also harmed by the
project, all of you together could only receive $500,000.
What about confidentiality?
Any information that is obtained in connection with this study and that can be identified
with you will remain confidential and will be disclosed only with your permission.
Subject identities will be kept confidential by assigning you a "subject identification
number". The nal11es associated with each subject identification number will be kept in a
locked file cabinet in Dr. Halliwill's office area.
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The Office for Responsible Conduct of Research and/or authorized representatives of the
Food and Drug Administration (FDA) or National Institute of Health (NIH) may need to
review records of individual subjects. As a result, they may see your name, but they are
bound by rules of confidentiality not to reveal your identity to others.
The list of names will be destroyed when study results are published or 24 months after
your participation, whichever comes first. All blood and muscle dialysate fluid samples
will be destroyed when study results are published or 24 months after your participation,
whichever comes first. Other information may be stored by the researchers indefinitely.
I have had an opportunity to have my questions answered. I have been given a copy
of this form. I agree to take part in this study.
If you have questions regarding your rights as a research subject, contact Office for
Protection of Human Subjects, 5237 University of Oregon, Eugene, OR 97403, (541)
346-2510.
Your signature indicates that you have read and understand the information provided
above, that you willingly agree to participate, that you may withdraw your consent at any
time and discontinue participation without penalty, that you will receive a copy of this
form, and that you are not waiving any legal claims, rights or remedies.
(Date)
(Date)
(Signature of Participant)
(Signature ofIndividual Obtaining Consent)
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APPENDIXD
INFORMED CONSENT FORM - IRB# A548-07F
TITLE: Short-term benefits of exercise on cardiovascular-metabolic integration in
humans (Protocol 3)
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues
APPROVED BY INSTITUTIONAL REVIEW BOARD: February 6, 2008
This is an important form. Please read it carefully. It tells you what you need to
know about this study. If you agree to take part in this research study, you need to
sign the form. Your signature means that you have been told about the study and
what the risks are. Your signature on this form also means that you want to take
part in this study.
Why is this research study being done?
When humans exercise, there is an increase in blood flow to the skeletal muscle. This
increase in blood flow lasts for several hours after exercise but we do not understand all
the mechanisms that cause this increase in blood flow or why it happens. The purpose of
this study is to provide more information on what causes blood flow increases to occur
and to determine whether or not this blood flow is involved in metabolism.
What will happen in the study?
Initial visit
1. You will arrive at Dr. Halliwill's laboratory in Esslinger Hall at the University of
Oregon for an initial visit. This initial visit will take approximately two hours. You
will meet with one of the investigators of the study to discuss the project, to see the
laboratory, and to read this form. Your height and weight and resting blood pressure
will be measured, and you will be asked questions about your health history. You
will be given a physical activity questionnaire, which will allow investigators to
determine your activity level. The questionnaire will take approximately 15 minutes
to complete. You will need to wear a t-shirt and refrain from eating for one hour
prior to arrival. In addition, you will need to refrain from consuming caffeine (for
example, coffee, tea, red bull, coke, etc.) or medications (except oral contraceptives)
for 12 hours prior to the study and abstain from alcohol or exercise for 24 hours prior
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to the study. If you use oral contraceptives, you should take this when you nonnally
do so.
2. If you are a woman who can still become pregnant, you will be asked to undergo a
pregnancy test during the initial visit (and again during the study visits). For this test,
you will be asked to collect a sample of urine in the women's restroom near the
physiology lab. If the test is "positive," indicating that you are pregnant, you will not
be allowed to participate and will be advised to see your physician or the University
of Oregon Health Center.
3. Graded Exercise Test: You will pedal on an exercise bicycle while wearing a mouth
piece, nose clip, and electrocardiogram electrodes (heart rhythm monitor). If you are
a woman, the adhesive patches used for this test will be placed on you by one of the
women in the lab. After a 5-minute wann-up, you will be asked to maintain a
selected pedaling rate as pedaling resistance (work) is increased every minute until
you reach your maximum exercise capacity. This is to measure your overall aerobic
fitness level. It nonnally takes 10 to 15 minutes for people to reach their maximum
effort. The total time for this test (including placement of ECG electrodes, wann-up,
exercise, and cool-down) is approximately one hour. This session will serve to
familiarize you with the procedures to be used on the study visits. It will also
establish your maximal exercise tolerance on a bike and therefore will be used to
establish the appropriate workload for the exercise session on the study visits.
4. You should notify the investigator immediately if you feel any significant discomfort
or concern about your well-being at any time during the initial visit study. Some
examples of discomfort include shortness of breath, light-headedness, and nausea.
5. This session will serve to familiarize you with the procedures to be used on the study
day. It will also establish your maximal exercise tolerance on a bike and therefore
will be used to establish the appropriate workload for the exercise session on the
study day. At this time you will be reminded not to donate blood or to participate in
other research studies where they will be drawing blood for 8 weeks.
Study visits
1. You will then return to Dr. Halliwill's laboratory to participate in the two study visits,
one of which will be between 7 and 10 days after the initial visit and the other will be
between 7 and 10 days after that. These two testing session will take approximately
six hours each. You will need to wear at-shirt, shorts, and refrain from eating at least
three hours prior to arrival.
2. If you are a woman who can still become pregnant, you will be asked to undergo a
pregnancy test during the study visits.
3. On one of the study visits you will be given a 540 mg dose offexofenadine
hydrochloride (brand name Allegra) and a 300 mg dose of ranitidine hydrochloride
(brand name Zantac).
4. During the study visits, your heart rate will be monitored by electrocardiogram
electrodes placed on your skin. If you are a woman, the adhesive patches used for
this test will be placed on you by one of the women in the lab. Your blood pressure
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will be measured at peliodic intervals by the inflation of a blood pressure cuff around
your ann.
5. During the study visits, you will periodically breathe small amounts of acetylene gas
mixed with air through a mouthpiece. Acetylene gas is an inert gas that is not
hannful in any way to people and it is not flammable in the concentrations that are
used in the lab. This is used to study how much work the heart is perfonning. A
small probe (laser-Doppler probe) will be placed over an area of skin on your foreann
and another on your thigh. The laser-Doppler probe uses light to measure skin blood
flow in these areas, and is taped in place. Periodically, a small probe (ultrasound-
Doppler probe) will be held over an artery at your elbow and an artery at your groin-
hip intersection. The ultrasound-Doppler probe uses ultrasound waves to measure
blood flow in these arteries.
6. Venous Catheter: You will have one small flexible needle ("intravenous catheter")
placed into a vein in the back of your hand. The skin will be sterilized before this
procedure. This catheter will remain in your skin throughout the six hour study.
During the study, this hand will be placed in a wanning chamber to heat the skin of
your hand to about 108°F which will feel wann but should not cause discomfort.
Several blood samples will be collected from the catheter during the six hour study.
In total, 300 ml will be withdrawn during over the two visits. This is approximately
ten ounces (a little more than a cup) and about two-thirds of the amount withdrawn
when you volunteer to "give blood" for Lane Memorial Blood Bank or similar blood
donation programs. After the study, we will remove the flexible needle in your vein
and a bandage will be placed over that area of skin.
7. Bicycle exercise session: DUling the study visits, you will pedal on a bicycle at a
moderate rate for 1 hour.
8. Glucose Tolerance Tests: To see how your body handles glucose (sugar), you will be
given a "glucose tolerance test." The test will be given either orally or intravenously.
For an oral test, you will be given a flavored concentrated sugar-water beverage to
drink. You will be asked to drink up to 10 ounces. For an intravenous test, the
researchers will inject a similar amount of sterile concentrated sugar-water into a
catheter in a vein in your ann over the course of 2-4 minutes. The researches will
decide which type oftest you will receive.
9. Local heating: Towards the end of the study visit, we will wann the skin around the
laser-Doppler probes with small heating devices. We will heat the skin in these areas
to about 108°F for a period of 40 minutes. This will feel wann but should not cause
discomfort.
10. After the study, we will remove the flexible needle in your vein and a bandage will be
placed over that area of skin as well. You will then be sent home.
11. You should notify the investigator immediately if you feel any significant discomfort
or concern about your well-being at any time during the initial visit or the study visit.
Some examples of discomfort include shortness of breath, light-headedness, and
nausea.
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How long will I be in the study?
You will be in the study for three days (initial visit and two study visits). The initial visit
will last two hours. The study visits will last six hours. You will need to refrain from
eating for three hours prior to the study visits.
What are the risks of the study?
1. Graded exercise testing: There is some minor discomfort associated with exercise
testing, including temporary fatigue, shortness of breath, and muscle soreness. These
sensations resolve within minutes after the test is completed. There is the possibility
of some residual muscle soreness in the few days following the exercise test. There is
also the risk of a heart attack or death during an exercise test. The risk of a
complication requiring hospitalization is about 1 incident in 1000. The risk of a heart
attack during or immediately after an exercise test is less than 1 incident in 2500. The
risk of death during or immediately after an exercise test is less than 1 incident in
10,000. In the unlikely case of a life-threatening heart rhythm, the laboratory is
equipped with an Automatic Electronic Defibrillator that is located in the same room
where the study is taking place. Dr. Halliwill has up to date Advanced Cardiac Life
Support (ACLS) training. In the event of an emergency, the Department of Public
Safety (6-6666) will be called in order to activate the emergency medical system (i.e.,
911) and will direct an ambulance to the correct location.
2. Intravenous catheters: There may be some discomfort during the insertion of the
small flexible needle into your vein. Once the needle is in place, the pain should
subside. Blood sampling through the needle should not be painful, and there should
only be minor swelling at the site. At the end of the study, the needle will be
withdrawn and a sterile dressing will be applied. Any swelling or redness after the
study should be gone a few hours after completion of the study. Although the needle
is sterile, there is a slight risk of infection at the site where the needle was placed in
your skin. You will be instructed how to keep the area clean for a day or two
following the study. The most common complications of inserting a small needle into
a vein are a small bruise and pain at the site of the needle location which may last
several days after removal of the catheter. There is a possibility of a blood clot
forming in the vein used for the infusion and this could make the vein painful and
swollen; however, it is extremely unlikely that this would result in a serious health
risk to you.
3. Fexofenadine Hydrochloride: If you are allergic to fexofenadine hydrochloride (brand
name Allegra) you will not be allowed to participate in the study. On one ofthe
study visits you will be given a 540 mg dose of fexofenadine hydrochloride. A dose
of 180 mg fexofenadine hydrochloride is commonly prescribed. Doses up to 690 mg
twice daily for a month showed no adverse effects in experimental studies.
4. Ranitidine Hydrochloride: If you are allergic to ranitidine hydrochloride (brand name
Zantac) you will not be allowed to participate in the study. On one of the study visits
you will be given a 300 mg dose ofranitidine hydrochloride. A dose of300 mg
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ranitidine hydrochloride is commonly prescribed. Studies have shown that doses as
high as 400 mg in a single day have no adverse effects.
5. Blood withdrawal: In total, 300 ml will be withdrawn during over the two visits.
This is approximately ten ounces (a little more than a cup) and about two-thirds of the
amount withdrawn when you volunteer to "give blood" for Lane Memorial Blood
Bank or similar blood donation programs. You will not be allowed to donate blood
for 8 weeks before the study, or for 8 weeks after the study.
6. Oral Glucose Tolerance Test: This test transiently raises blood sugar levels.
Drinking the concentrated sugar-water beverage can lead to nausea, vomiting,
diarrhea, or fainting in some individuals. You should notify the investigator
immediately if you feel any significant discomfort after drinking this beverage.
7. Intravenous Glucose Tolerance Test: This test transiently raises blood sugar levels.
Having an injection of concentrated sugar-water can lead to generalized flushing,
mild shoulder pain, or whole body warming. These symptoms generally subside
within 10 minutes. The test can also produce mild swelling at the site of injection.
You should notify the investigator immediately if you feel any significant discomfort
after the injection.
May I participate if I am pregnant or breast-feeding?
This study may be harmful to an unborn or breast-fed child. There is not enough medical
information to know what the risks might be to a breast-fed infant or to an unborn child
in a woman who takes part in this study. Breast-feeding mothers are not able to take part
in this study. Women who can still become pregnant must have a negative pregnancy test
no more than 24 hours before taking part in the graded exercise test on the initial visit. If
the pregnancy test is positive (meaning that you are pregnant), you will not be able to
take part in the study. There is no cost for the pregnancy test.
Are there benefits to taking part in this study?
This study will not make your health better. Blood samples are not being collected for
diagnostic purposes. The results will not be reviewed by a physician and no action will
be taken if a laboratory result falls outside of the normal range.
What other choices do I have if I don't take part in this study?
This study is only being done to gather information. You may choose not to take part in
this study.
What are the costs of tests and procedures?
You will not need to pay for any tests or procedures that are done just for this research
study. You will get $140 for participating in this study. This money is for the
inconvenience and time you spent in this study. If you start the study but stop before the
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study has ended, the amount of money you receive will be pro-rated at a rate of $1 0 per
hour of the study you complete.
Who can answer my questions?
You may talk to Dr. John Halliwill at any time about any question you have on this study.
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541)
346-5425.
What are my rights if I take part in this study?
Taking part in this research study is your decision. You do not have to take part in this
study, but if you do, you can stop at any time. Your decision whether or not to participate
will not affect your relationship with the University of Oregon.
You do not waive any liability rights for personal injury by signing this form. All forms
of medical diagnosis and treatment whether routine or experimental, involve some risk of
injury. In spite of all precautions, you might develop medical complications from
participating in this study.
The investigators may stop you from taking part in this study at any time if it is in your
best interest, if you do not follow the study rules, or ifthe study is stopped.
If you are physically injured because of the project, you and your insurance company will
have to pay your doctor bills. If you are a UO student or employee and are covered by a
UO medical plan, that plan might have terms that apply to your injury.
If you experience harm because of the project, you can ask the State of Oregon to pay
you. If you have been harmed, there are two University representatives you need to
contact. Here are their addresses and phone numbers:
General Counsel
Office of the President
University of Oregon
Eugene, OR 97403
(541) 346-3082
Office of Human Subjects Compliance
University of Oregon
Eugene, OR 97403
(541) 346-2510
A law called the Oregon Tort Claims Act limits the amount of money you can receive
from the State of Oregon if you are harmed. The most you could receive would be
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$100,000, no matter how badly you are harmed. If other people are also harmed by the
project, all of you together could only receive $500,000.
What about confidentiality?
Any information that is obtained in connection with this study and that can be identified
with you will remain confidential and will be disclosed only with your permission.
Subject identities will be kept confidential by assigning you a "subject identification
number". The names associated with each subject identification number will be kept in a
locked file cabinet in Dr. Halliwill's office area.
The Office for Responsible Conduct of Research and/or authorized representatives of the
Food and Drug Administration (FDA) or National Institute of Health (NIH) may need to
review records of individual subjects. As a result, they may see your name, but they are
bound by rules of confidentiality not to reveal your identity to others.
The list of names will be destroyed when study results are published or 24 months after
your participation, whichever comes first. All blood and muscle dialysate fluid samples
will be destroyed when study results are published or 24 months after your participation,
whichever comes first. Other information may be stored by the researchers indefinitely.
I have had an opportunity to have my questions answered. I have been given a copy
of this form. I agree to take part in this study.
If you have questions regarding your rights as a research subject, contact Office for
Protection of Human Subjects, 5237 University of Oregon, Eugene, OR 97403, (541)
346-2510.
Your signature indicates that you have read and understand the information provided
above, that you willingly agree to participate, that you may withdraw your consent at any
time and discontinue participation without penalty, that you will receive a copy of this
form, and that you are not waiving any legal claims, rights or remedies.
(Date)
(Date)
(Signature of Participant)
(Signature of Individual Obtaining Consent)
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